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Despite the high incidence and economic cost of UBC, the molecular landscape of this tumor type 
remains relatively understudied. In this dissertation I describe the identification of novel genes 
involved in the development of UBC, using whole exome sequencing and a combination of 
targeted resequencing strategies. Our findings confirm previous studies pinpointing the chromatin 
remodeling pathway as frequently altered in UBC, including mutations in ARID1A, KDM6A, 
CREBBP, EP300, MLL, and MLL3. Moreover, we identified mutations in previously unreported 
genes belonging to this pathway (MLL2, ASXL2, and BPTF). Additionally, for the first time we 
found frequent mutations in DNA repair genes (ATM, ERCC2, and FANCA), as well as in subunits of 
the cohesin complex (STAG1, STAG2, SMC1A, and SMC1β). We did not identify significant 
differences in number or type of mutations according to tumor aggressiveness, patient age or 
smoking status. We analyzed mutations and loss of ARID1A expression to place them in the 
context of current bladder cancer molecular knowledge, finding they preferentially associated 
with the aggressive pathway of genetic progression. Regarding cohesin, we assessed the 
expression of its components in a cohort of 91 UBCs, finding low-frequency losses of SMC1, SMC3, 
RAD21, and PDS5B, as well as much more frequent losses of STAG2 expression. Intriguingly, we 
found that meiotic cohesin components SMC1β, REC8, and STAG3 are also expressed in UBC. We 
then focused on STAG2: mutations, predominantly truncating, were distributed all along the gene 
with a pattern characteristic of tumors suppressors, and were more frequent in non-aggressive 
UBCs. We also found evidence of genomic losses as a cause of STAG2 inactivation in a small 
subset of tumors. Loss of STAG2 was more common in non-aggressive tumors and associated with 
low proliferative index, mutations in FGFR3, and normal p53 expression. Importantly, STAG2 
negative tumors frequently retained STAG1 expression, suggesting the competence of the cohesin 
complex. Contrary to what has been reported in other tumor types, STAG2 loss was not 
associated with aneuploidy in UBC tumors. Moreover, downregulating STAG2 in vitro did not 
cause significant changes in chromosome number or centromeric cohesion defects. As expected 
for a tumor suppressor, STAG2 overexpression impaired colony formation in vitro. Surprisingly, 
the same effect was seen upon STAG2 knockdown. RNA-sequencing of STAG2 knockdown cells did 
not reveal consistent transcriptional changes. Lastly, we found that loss of STAG2 associated with 
improved outcome in both NMIUBC and in MIUBC. However, it was an independent predictor of 
outcome only in the latter. Altogether, this work supports an important role of chromatin 
remodeling and cohesin components in UBC and contributes to refine the genetic events involved 
in UBC development/progression. Further studies are needed to unveil the mechanisms through 
which ARID1A and STAG2 alterations contribute to UBC and to determine whether they can 
improve the molecular taxonomy of this tumor and can be used in patient management.
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Pese a la alta incidencia y coste económico del cáncer de vejiga (CV), el panorama molecular de 
este tipo de tumor permanece relativamente poco estudiado. En este trabajo describo la 
identificación de nuevos genes involucrados en el desarrollo de CV usando secuenciación de 
exomas y una combinación de estrategias de resecuenciación dirigida. Nuestros hallazgos 
confirman estudios previos que apuntaban a que las vías de remodelación de la cromatina sufre 
alteraciones frecuentes en CV, incluyendo mutaciones en ARID1A, KDM6A, CREBBP, EP300, MLL, y 
MLL3  (Gui 2011). Además, hemos identificado alteraciones en genes no descritos que pertenecen 
a esta vía (MLL2, ASXL2, y BPTF). Por primera vez, hemos encontrado alteraciones frecuentes en 
genes involucrados en la reparación del ADN (ATM, ERCC2, y FANCA), así como en subunidades 
del complejo cohesina (STAG1, STAG2, SMC1A, y SMC1β). No hemos identificado diferencias 
significativas en el número o tipo de alteraciones de acuerdo a la agresividad del tumor o a la 
edad o exposición al tabaco del paciente. Hemos analizado más a fondo las mutaciones y pérdida 
de expresión de STAG2 para colocarlas en el contexto de las vías moleculares del CV conocidas, 
encontrando que se asocian preferentemente con la vía más agresiva de progresión genética. 
Para caracterizar en detalle el papel del complejo cohesina en CV, valoramos la expresión de los 
componentes del complejo en una población de 91 CV, hallando pérdidas poco frecuentes de 
SMC1, SMC3, RAD21, y PDS5B, así como pérdidas mucho más frecuentes de la expresión de 
STAG2. Curiosamente, hemos observado que SMC1β, REC8 y STAG3, componentes de la cohesina 
meiótica, también se expresan en CV. Hemos analizado las alteraciones y pérdida de expresión de 
STAG2 en una población más numerosa de CV, hallando tanto mutaciones como pérdidas 
genómicas que son responsables de la pérdida de expresión de STAG2 en CV. La mayoría de las 
mutaciones en STAG2 son truncantes, se distribuyen a lo largo de la secuencia de la proteína en 
un patrón característico de los supresores tumorales y son más frecuentes en los CV no agresivos. 
La pérdida de STAG2 es más común en los tumores no agresivos y se asocia a mutaciones en 
FGFR3, expresión normal de p53 y un índice proliferativo bajo. Los tumores que no expresan 
STAG2 suelen retener la expresión de STAG1, lo que sugiere que en este contexto el complejo 
cohesina permanece activo. La pérdida de STAG2 no se correlaciona con la diferenciación de las 
células uroteliales. Al contrario de lo que se ha reseñado en otros tipos de tumores, la pérdida de 
STAG2 no causa aenuploidía o defectos en la cohesión centromérica en líneas celulares o tumores 
de CV. Como se esperaría de un supresor tumoral, la sobreexpresión de STAG2 impide la 
formación de colonias in vitro. Sorprendentemente, al silenciar la expresión de STAG2 se observa 
el mismo efecto. Sin embargo, la secuenciación de RNA de células en las que se había silenciado 
STAG2 no reveló cambios transcripcionales consistentes. Por último, hemos descrito que la 
pérdida de STAG2 también se asocia con un mejor resultado en el CV invasivo. En conjunto, este 
Resumen 
14 
 
trabajo apoya la importancia del papel de los remodeladores de cromatina y de los componentes 
de la cohesina en CV y contribuye a refinar los eventos genéticos involucrados en el 
desarrollo/progresión del CV. Hay que realizar más estudios para determinar si las alteraciones en 
ARID1A y STAG2 contribuyen a la taxonomía molecular del CV y para mejorar el manejo de los 
pacientes. 
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ESCO1 Establishment of sister chromatid cohesion N-acetyltransferase 1  
ESCO2 Establishment of sister chromatid cohesion N-acetyltransferase 2 
ESPL1 Extra spindle pole bodies homolog 1 
FANCA Fanconi anemia, complementation group A  
FBS Fetal Bovine Serum 
FDR False discovery rate 
FGFR Fibroblast growth factor receptor 
FPKM Fragments per kilobase of exon per million fragments mapped 
FRP1 Free running period 1 
FYN Tyrosine-protein kinase Fyn 
G Grade 
G1 Gap 1 phase of the cell cycle 
GEO Gene Expression Omnibus  
GLI2 GLI family zinc finger 2  
GO Gene Ontology 
GSTM1 Glutathione S-transferase mu 1  
GTP Guanosine 5'-triphosphate 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPRT Hypoxanthine phosphoribosyltransferase 1  
HPV Human papiloma virus 
HRAS v-Ha-ras harvey rat sarcoma viral oncogene homolog 
HRP Horseradish peroxidase 
IFI6 Interferon, alpha-inducible protein 6  
IGF1R Insulin-like growth factor 1 receptor  
IHC Immunohistochemistry 
INI1 Integrase Interactor 1 
ISBLAC Integrated Study on Bladder Cancer  
KDM6 Lysine (K)-specific demethylase 6 
KEGG Kyoto Encyclopedia of Genes and Genomes 
Ki67 Marker of proliferation Ki-67  
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KO Knock out 
KRAS Kirsten rat sarcoma viral oncogene homolog  
KRT10 Keratin 10 
KRT14 Keratin 14 
KRT18 Keratin 18 
KRT20 Keratin 20 
KRT5 Keratin 5 
KW Kruskal Wallis test 
LOH Loss of heterozygosity 
MAPK Mitogen-activated protein kinase 
MAPK15 Mitogen-activated protein kinase 15  
MAU2 MAU2 chromatid cohesion factor homolog 
MEF Mouse embrionic fibroblast 
MET Met proto-oncogene  
MFGE8 Milk fat globule-EGF factor 8 protein  
MI Muscle-invasive 
MIUBC Muscle-invasive urothelial bladder cancer 
MLL Myeloid/lymphoid or mixed-lineage leukemia 
MLL2 Myeloid/lymphoid or mixed-lineage leukemia 2 
MLL3 Myeloid/lymphoid or mixed-lineage leukemia 3 
mRNA Messenger RNA 
MTMR3 Myotubularin related protein 3  
mTOR Mammalian target of rapamycin 
MVAC Mehtrotrexate, vinblastine, doxorubicin, and cisplatin 
MW Mann-Whitney U test 
NAT2 N-acetyltransferase 2  
NFDM Non-fat dried milk 
NIPBL Nipped-B homolog  
NMI Non muscle-invasive 
NMIUBC Non muscle-invasive urothelial bladder cancer 
NPR2 Natriuretic peptide receptor 2  
NRAS Neuroblastoma RAS viral (v-ras) oncogene homolog  
NS:S nonsynonymous:synonymous ratio 
NU Normal urothelium 
OR Odds ratio 
P Probability values 
p110 Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha protein 
p16 Cyclin-dependent kinase inhibitor 2A protein 
p21 Cyclin-dependent kinase inhibitor 1 protein 
P33ING1 p33 inhibiton of growth 1 
p53 Tumor protein 53 
p63 Tumor protein 63 
p85 Phosphatidylinositol 3-kinase regulatory subunit protein 
PARP Poly (ADP-ribose) polymerase  
PARP1 Poly (ADP-ribose) polymerase 1  
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PBAF SWI/SNF-B chromatin-remodeling complex 
PBS Phosphate-Buffered Saline 
PCA Principal Component Analysis 
P-CAD Cadherin 3, type 1 
PCR Polymerase chain reaction 
PDK1 Pyruvate dehydrogenase kinase, isozyme 1  
PDS5A PDS5, regulator of cohesion maintenance, homolog A 
PDS5B PDS5, regulator of cohesion maintenance, homolog B 
PI3K Phosphoinositide-3 kinase 
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha  
PIM1 Proto-oncogene serine/threonine-protein kinase Pim-1 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PKC Protein kinase C 
PLK1 Polo-like kinase 1  
PP2A Protein phosphatase 2A 
pRB Retinoblastoma protein 
PTCH Patched 
PTEN Phosphatase and tensin homolog 
PTPRD Protein tyrosine phosphatase, receptor type, D  
RAD21  RAD21 homolog  
RAD51 RAD51 recombinase 
RB Retinoblastoma 
RB1 Retinoblastoma 1 
REC8 REC8 meiotic recombination protein  
RHOBTB3 Rho-related BTB domain containing 3  
RNA Ribonucleic acid 
RT-qPCR Real-time reverse transcription polymerase chain reaction 
S Synthesis phase of the cell cycle 
S6K S6 kinase 
SCC  Squamous cell carcinoma 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SGO1 Shugoshin 1 
shNT Non-targeting shRNA control 
shRNA Short hairpin RNA 
SLC14A Solute carrier family 14 A 
SMC1A Structural maintenance of chromosomes 1A  
SMC1β Structural maintenance of chromosomes 1β  
SMC3 Structural maintenance of chromosomes 3 
SNF5 Sucrose nonfermenting protein 5 
SNP Single nucleotide polymorphism 
SNV Single nucleotide variant 
STAG1 Stromal antigen 1  
STAG2 Stromal antigen 2  
STAG3 Stromal antigen 3  
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SWI/SNF Switch/Sucrose NonFermentable 
T Stage 
TACC3 Transforming, acidic coiled-coil containing protein 3 
TBS-T Tris buffered-saline - tween 
TERT Telomerase reverse transcriptase 
TFEB Transcription factor EB  
TMA Tissue microarray 
TOP2A Topoisomerase II alpha 
TP53 Tumor protein 53 
TRIO Trio Rho guanine nucleotide exchange factor 
TSC1 Tuberous sclerosis 1  
TSC22D2 TSC22 domain family, member 2  
TSC22D3 TSC22 domain family, member 3  
TUR Transurethral resection 
UBC Urothelial bladder cancer 
UCSF University of California San Francisco 
UPK3B Uroplakin 3B  
US United States 
WAPL Wings apart-like homolog  
WES Whole Exome Sequencing 
WHO World Health Organization 
WNT6 Wngless-type MMTV integration site family, member 6  
WNT7A Wngless-type MMTV integration site family, member 7A  
WNT9A Wngless-type MMTV integration site family, member 9A  
WT Wild type 
 
 
 24 
 
 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              Introduction 
 
 26 
 
Introduction 
27 
 
1. URINARY BLADDER BIOLOGY 
The urinary bladder, located above and behind the pelvic pubic bone, is a distensible organ 
responsible for the collection and storage of the urine produced at the kidneys, as well as its 
subsequent disposal through the urethra.  Bladder architecture is adapted to allow the fulfillment 
of these functions, with a hollow space surrounded by a layer of muscle. It is organized in four 
distinct layers: the urothelium, the lamina propria, the detrusor muscle, and the perivesical fat 
(Figure 1a).  
 
Figure 1. Anatomy and histology of the urinary bladder. (a) Anterior anatomy of the male (top) 
and female (bottom) urinary bladder. Adapted from Tank et al. 2009. (b) Schematic 
representation of the urothelium. Modified from Laguna et al. 2006. (c) Hematoxylin-eosin 
staining of normal urothelium. Adapted from Krueger et al. 2012. 
 
1.1. The urothelium 
The urothelium, a multilayered epithelium, is comprised of 3-6 cell layers depending on the 
degree of distension of the organ (Jost et al. 1989). It lines the whole urogenital tract, starting at 
the renal pelvis and reaching as far as the urethra. There are three types of cells in the urothelium 
(Figure 1b, c). The most superficial and differentiated ones are called umbrella cells, which have a 
diameter of 50-120 μm, are often multinucleate, form a single layer, and are characterized by the 
expression of four highly-conserved uroplakin proteins and low molecular weight cytokeratins 
(CK18, CK20) (Moll et al. 1990; Schaafsma et al. 1990; Apodaca 2004). Each umbrella cell covers 
several underlying intermediate cells, which measure 20 μm across. Lastly, basal cells, which form 
a single layer, have a diameter of 5-10 μm (Lewis 2000). Both basal and intermediate cells express 
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p63 and high molecular weight cytokeratins (KRT5, KRT10, KRT14) (Moll et al. 1982; Yang et al. 
1998; Castillo-Martin et al. 2010). Originally, morphological observations and labeling experiments 
suggested that basal cells migrate towards the bladder lumen and fuse to give rise to 
multinucleated umbrella cells (Martin 1972). However, more recent studies suggest that umbrella 
and basal cells have different origins (Signoretti et al. 2005; Dancik et al. 2013). 
1.2. Other bladder structures 
Beneath the urothelium lies the lamina propria, which is composed of stromal connective 
tissue of varying densities, as well as some discontinuous stretches of smooth muscle usually 
associated with blood vessels. Underneath the lamina propria lies the detrusor muscle of the 
bladder, which combines circular and longitudinal layers of smooth muscle bundles without 
concrete orientation. Finally, there is a layer of adipocytes, fibrous tissue, and blood vessels 
surrounding the bladder that are known as the perivesical tissue.  
2. BLADDER CANCER INCIDENCE AND MORTALITY 
Bladder cancer is the second most frequent urogenital tract tumor in men (Sieguel et al. 2014). 
It is estimated that over 386,000 patients are diagnosed and 150,000 die from bladder tumors 
every year worldwide (Jemal et al. 2011). The difference between incidence and mortality is 
indicative of a prolonged progression interval. Indeed, the average 5-year survival rate in Europe 
is around 70% (Sant et al. 2003). 
 The incidence of bladder cancer is higher in males than females: the 2012 age-standardized 
incidence estimated rates per 100,000 European individuals were 26.9 in males and 5.3 in females 
(Ferlay et al. 2013). The areas with the highest incidences are North Africa, Europe and North 
America (Jemal et al. 2011). However, the likelihood of detecting low-grade tumors varies across 
world regions, so studying global mortality rather than diagnosis rates is usually more informative.  
Examining worldwide male mortality rates, the highest values are found in Egypt (16.3 per 
100,000), followed by several European countries (Jemal et al. 2011). Within Europe, Spain has 
one of the highest male incidence rates: 32.71 cases per 100,000 inhabitants, as opposed to the 
European average of 26.9 (Miñana et al. 2014).  
Interestingly, even though women are less likely to develop bladder tumors, they exhibit 
higher UBC-related mortality rates than men even after adjusting for tumor stage and grade (Cook 
et al. 2011). A later diagnosis, physiological differences in bladder muscle strength, and other 
sociological, hormonal and environmental factors have been suggested to play a role (Fajkovic et 
al. 2011).  
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3. BLADDER CANCER ETIOLOGY 
About half of all bladder cancer cases in Africa and the Middle East can be attributed to 
chronic Schistosoma haematobium infection (Parkin 2006). Recurrent Schistosoma infection 
causes chronic cystitis, favoring the development of bladder tumors. Tobacco smoking, exposure 
to high arsenic concentrations in drinking water, and aromatic amine work-related exposure are 
the major risk factors in Western countries (Letašiová et al. 2012). Smoking accounts for 50% of 
bladder cancer cases in men (Zeegers et al. 2000), while occupational exposures are responsible 
for fewer than 10% of the cases in Western Europe males (Kogevinas et al. 2003).  
There is a positive correlation between daily number of cigarettes smoked or number of 
smoking years and the risk of developing bladder cancer (Silverman et al. 2006). Although the risk 
is significantly reduced as soon as one year after quitting, it does not reach the levels of 
individuals who have never smoked; only a 60% reduction in risk is observed even 25 years after 
quitting (Brennan et al. 2000). Unfiltered cigarettes pose about twice as much risk as filtered ones 
(Wynder et al. 1988) and so does black as opposed to blond tobacco (De Stefani et al. 1991). A 
more recent study in Spain found that although risk is 40% higher for smokers of black tobacco 
than for those using blonde varieties, this tendency is not significant (Samanic et al. 2006).  
Aromatic amines have been shown to play a major role in the development of UBC (reviewed 
in Vineis and Pirastu 1997). Aromatic amines are present at low levels in tobacco smoke and are 
transformed into metabolic intermediates that form DNA adducts (Talaska et al. 1991). Since 
aromatic amines are metabolized by the kidney, they become potential carcinogens in the upper 
and lower urinary tracts (reviewed in Jung and Messing 2000). Occupational exposure to aromatic 
amines, polycyclic aromatic or chlorinated hydrocarbons, mainly affect workers in the paint, dye, 
metal and petroleum processing jobs (reviewed in Burger et al. 2013). Other less characterized 
factors that might affect the risk of developing UBC include diet and fluid intake. The intake of 
liquids might decrease said risk by further diluting carcinogens in urine but chlorinated water 
negatively affects such risk and both factors have never been studied simultaneously. On the 
other hand, the presence of arsenic in drinking water has been proven to cause UBC in regions 
subjected to elevated exposure, such as Bangladesh and Chile (Fernandez et al. 2012). 
There are also genetic factors associated with the development of UBC. Highly prevalent 
polymorphisms decreasing NAT2 and GSTM1 activity have been associated to a ca. 30% increase 
in risk of developing bladder cancer (García-Closas et al. 2005). NAT2 and GSTM1 detoxify 
aromatic amines, decreasing carcinogenic DNA adduct formation. Additionally, recent genome-
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wide association studies have identified other sequence variants linked to genetic predisposition 
to developing UBC (Kiemeney et al. 2008, 2010; Rafnar et al. 2009; Wu et al. 2009; Rothman et al. 
2010; Garcia-Closas et al. 2011). One of the responsible genes accounting for such susceptibility 
was subsequently identified: SLC14A, which encodes a urea transporter that controls urine 
concentration, affecting bladder exposure to carcinogens (Rafnar et al. 2011). 
4. BLADDER TUMOR CLASSIFICATION 
The majority of bladder tumors arise in the urothelium, being designated as urothelial bladder 
cancer (UBC). Bladder squamous cell carcinomas (SCC) and adenocarcinomas (ADC) are less 
frequent tumors with features of squamous epithelial cells and bladder mucosa lining cells 
respectively. Most bladder tumors associated with tobacco are UBCs although urothelial tumors 
can present focally variable degrees of squamous differentiation; the majority of worldwide cases 
related to Schistosoma infection are SCCs (Sliverman et al. 2006). This is why in Egypt 75% of 
bladder tumors are SCCs. In the Western world, more than 90% of newly diagnosed cases are 
UBCs and pure SCCs represent 5-7% of the cases. Bladder ADCs are the least frequent tumors, 
representing 2% of all cases (Silverman et al. 2006). Other extremely rare non-urothelial bladder 
carcinomas include small cell carcinomas, lymphomas, and sarcomas. Morphologically, three 
categories of UBCs can be distinguished. Papillary tumors are the most frequent type; they 
develop projections towards the bladder lumen and tend to grow slowly. Solid tumors, which are 
less common but more aggressive, tend to grow into deeper bladder layers. The last type are in 
situ carcinomas (CIS) which are flat and only involve the most superficial fraction of the 
urothelium, but are nonetheless very aggressive. 
4.1. Staging and grading of bladder tumors 
The classification of bladder tumors is somewhat controversial and has been revised several 
times over the last 25 years by pathologists, clinicians and researchers. Usually, the main factors 
taken into account for bladder tumor categorization are stage and grade. Staging of UBCs is 
performed according to the degree of tissue invasion, whereas grading takes into consideration 
the morphology and degree of differentiation of tumor cells. 
The following stages can be distinguished in UBC (reviewed in Edge et al. 2010, see Fig. 2): 
-Tis: This stage corresponds to CIS, flat carcinomas restricted to the urothelium. 
-Ta: These are papillary tumors restricted to the most superficial layer of the bladder lining. 
-T1: These solid tumors have surpassed the lamina propria, invading the connective tissue 
beneath the urothelium. 
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-T2: The solid tumor has reached and grown into the surface of the bladder muscle. 
-T3: This stage designates solid tumors that have invaded the bladder perivesical fat. 
-T4: These solid tumors have grown until reaching neighboring organs within the pelvis, such 
as the prostate or the uterus. 
 
According to this classification, we can classify tumors as non-muscle invasive (NMI), including 
Tis, Ta, and T1, and muscle invasive (MI) comprising T2, T3 and T4 (Cheng et al. 2009). 
 
 
Figure 2. Staging of 
UBC. (a) Diagramatic 
representation of UBC 
staging, modified 
from Action on 
Bladder Cancer 
(www.actionon 
bladdercancer.org).       
(b) Hematoxylin-eosin 
staining of UBC of 
different stages. CIS 
and Ta adapted from 
Reis 2011, T1-T4 
modified from Cheng 
et al. 2009. 
 
Over time, many different grading classifications have been developed, differing mainly in the 
nomenclature ascribed to preneoplastic lesions and the number of categories used to sort UBCs. 
The most recent grading is the 2004 
World Health Organization (WHO) 
classification, which differentiates 
between NMI and MI urothelial tumors 
(Table 1) (Montironi and López-Beltrán 
2005). However, it has been 
recommended to use it together with the 
1973 WHO classification until it is clinically 
validated (Montironi and López-Beltrán 
2005). The 1973 WHO classification uses 
three grades: G1 and G2 are generally 
considered low grade, and refer to cells 
Table 1. 1973 and 2004 WHO Classifications of UBC. 
Extracted from Babjuk et al. 2011. 
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that are well differentiated and exhibit few mitoses, and G3 are of high grade with poorly 
differentiated cells harboring aberrant nuclei and frequent mitoses (Mostofi et al. 1973).  
 Most clinicians and researchers use a combination of grading and staging to describe the 
cases they study according to how life-threatening the tumors are: low risk (LR) (TaG1, TaG2, and 
T1G2) and high risk (HR) (TaG3, T1G3, and all >T2 tumors regardless of grade). Throughout this 
thesis, the terms non-aggressive (tumor of Ta stage and low grade) and aggressive (tumor of high 
grade regardless of stage) will also be used. 
5. BLADDER CANCER DIAGNOSIS AND CLINICAL MANAGEMENT  
 The most common symptom of bladder cancer is painless hematuria. Approximately 20% 
of patients with gross hematuria and 5% of those with microscopic hematuria have a bladder 
tumor (reviewed in Chou and Dana 2010). At diagnosis, 75-85% of UBC cases present NMI tumors, 
of which 31-78% will progress and 1-45% will recur within 5 years from initial diagnosis (Babjuk et 
al. 2011; Sylvester et al. 2006). Approximately half of MI tumors metastasize, frequently leading 
to death. Upon detection, bladder tumors are usually removed using transurethral resection 
(TUR), and diagnostic biopsies are taken if CIS is suspected (Kamat et al. 2013).  
5.1. Management of NMIUBC 
In NMIUBC, current clinical practice advises that a complete TUR is performed in patients with 
papillary tumors and, if the tumor is of T1 stage and/or high grade, a second TUR  is 
recommended 2-6 weeks after the initial one (Babjuk et al. 2011). This is due to the fact that 
these tumors might present several locations, resulting in TUR leaving behind residual cancerous 
cells. It is recommended to administer one dose of intravesical chemotherapy immediately after 
resection. The most commonly used drug for this purpose is mitomycin-C, although epirubicin or 
doxorubicin are also frequently administered with comparable results (Babjuk et al. 2011). This 
should be followed by either further chemotherapy instillations (to prevent recurrence) or at least 
12 months of bacillus Calmette-Guerin (BCG) intravesical therapy if there is intermediate or high 
risk of progression (Babjuk et al. 2011). The same treatment is suggested in the presence of CIS.  
BCG attaches to integrin and fibronectin receptors in bladder tumoral cells, stimulating local 
cytokine release that triggers non-specific defense mechanisms. This results in the elimination of 
malignant cells and thus a delay or even completely prevention of tumor progression (Babjuk et 
al. 2011). BCG induction is performed for 6 consecutive weeks and periodical maintenance 
instillations lasting from 1-3 years are recommended (Babjuk et al. 2011). BCG instillation causes 
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frequent side effects that often lead to treatment withholding during the 6 initial months; the 
main serious complications are cystitis and sepsis and occur in about 5% of the cases (van der 
Meijden et al. 2003). Therefore, each patient should be carefully assessed for concurrent 
pathologies (such as post-TUR infections), recurrence and progression risks before prescribing 
BCG instillations. 
If BCG treatment fails in patients with NMIUBC who present a very high risk of progression, 
cystectomy might be considered (Babjuk et al. 2011). This procedure has important morbidities: 
patients develop urinary tract infection or septicemia that required hospitalization in 30% of cases 
(van Hemelrijck et al. 2013), so it should only be prescribed to patients who would truly benefit 
from it. Factors leading to a recommended cystectomy in patients with T1 tumors include the 
presence of multiple or extensive tumor foci that prevent complete resection, recurrent disease 
after intravesical therapy or upon a second TUR, deep penetration into the lamina propria, 
invasion of the lymphatic space or the prostate, development of CIS, and patient failure to 
adequately follow the prescribed treatment (Shariat 2007). 
About 20% of patients with NMI tumors are cured after the first TUR, but 50-60% undergo 
recurrence and 10-15% progress to develop MI tumors, which results in death in 50% of the cases 
(Sylvester et al. 2006). Such a heterogeneous prognostic landscape translates into a need for 
lifelong surveillance of the patients. This, together with potential complications, raises the costs 
derived from bladder cancer (reviewed in Svatek et al. 2014). A study performed in the United 
States demonstrated that the medical care of a bladder cancer patient can cost between $US 
65,158 and $US 120,684 (Avritscher et al. 2006). The most cost-effective technique to assess 
recurrence is cystoscopy, which allows easy determination of number, location, and size of 
tumors, but also entails significant discomfort for the patients (Kamat et al. 2013). A downside of 
this technique lies in its failure to detect CIS, which has an appearance that is very similar to that 
of normal urothelium (Witjes 2004). To detect this type of tumor, photosensitising agents such as 
5-aminolevulinic acid or hexyl aminolevulinate are used in combination with fluorescence 
microscopy (reviewed in Rink et al. 2013). These drugs work by stimulating tumor-cell selective 
accumulation of porphyrins, which emit in red wavelengths upon excitation with blue light 
(Kausch et al. 2009). This technique raises the cost of the procedure but it also results in fewer 
recurrences, with the associated savings, making it at least cost-neutral (Rink et al. 2013). There is 
still some debate as to whether photodynamic diagnostic cystoscopies should be the standard of 
care for NMIUBC patients. 
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5.2. Management of MIUBC 
The treatment of MI tumors differs depending on whether the disease is localized or 
metastatic. For localized disease, radical cystectomy is the most common treatment (Stenzl et al. 
2011). Whenever possible, a fraction of functioning urethra and its associated nerves should be 
preserved to allow for urinary diversion.  The most common type of urinary diversion is the 
orthotopic neobladder substitution, which does not compromise patient prognosis and 
contributes to an improved life quality after cystectomy (Stenzl et al. 2010). Even though 
radiotherapy is sometimes administered before surgery, it has not been shown to increase 
survival and therefore is not currently advised for fit patients (Stenzl et al. 2011). However, a 
recent report argues that sensitizing tumors to radiation with fluorouracil or mitomycin C 
chemotherapy reduces the need for radical cystectomy, although their findings do not reach 
statistic significance (James et al. 2012). This strategy might prove adequate in cases where a 
cystectomy is not advised, such as elderly or frail patients.  
There is some evidence that patient outcome can improve if radical cystectomy is preceeded 
by neoadjuvant containing chemotherapy, except for patients suffering from impaired kidney 
function or a weakened physical state (Stenzl et al. 2011). This reduces the risk of progression of 
undetectable micrometastasis in local MIUBC and increases the survival of patients with 
metastatic MIUBC. The first-line treatment for both patient groups is combination chemotherapy 
containing cisplatin. Cisplatin is administered together with gemcitabine or with methotrexate, 
vinblastine, and adriamycin (MVAC); the latter combination results in a slightly longer overall 
survival (15.2 months vs. 14.0 months) but the administration with gemcitabine is less toxic, so it 
is becoming the new treatment standard (von der Maase et al. 2005).  
Lymphadenectomy should be performed for pelvic nodes upon cystectomy, both to optimize 
the staging of the tumor, and to improve survival (reviewed in Tilki et al. 2013). Some studies 
suggest that lymphadenectomy might improve survival regardless of tumor stage. However, the 
available evidence is mainly retrospective and of low quality, and there are no guidelines to 
standardize the procedure, so further trials are needed to determine the extent of the surgery 
and the optimal number of nodes to be removed. 
When a patient with metastatic UBC is considered ineligible for cisplatin treatment, the 
combination of carboplatin and gemcitabine is advised. Upon progression after receiving first-line 
treatment, the recently approved second-line drug (vinfluvine) or inclusion in approved clinical 
trials for other drugs are recommended (Stenzl et al. 2011). Such clinical trials are starting to 
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include drugs targeting some of the underlying genetic alterations, such as those affecting FGFR3 
or mTOR (Bellmunt et al. 2013; Gust et al. 2013; Seront et al. 2013).  
6. A MORPHOGENETIC VIEW OF UBC TUMOR PROGRESSION 
The current paradigm is that there are two genetic pathways of tumor progression from 
normal urothelium (reviewed in Castillo-Martin et al. 2010; McConkey et al. 2010). In short, the 
non-aggressive pathway involves mainly oncogenes, with activating mutations in FGFR3 and 
PIK3CA being the most common alterations. These mutations are associated with the 
development of tumors of low stage, which are usually papillary, and present a low likelihood of 
progression. A small proportion of them acquires genetic alterations such as CDKN2A losses and 
mutations in TP53, resulting in the development of invasive, high stage tumors. The aggressive 
pathway involves predominantly tumor suppressors: mutations in TP53, PTEN, and inactivation of 
the RB pathway are frequent. These tumors are aggressive, likely to progress, and are commonly 
detected after having invaded muscle, although it is thought that CIS can be a precursor of tumors 
belonging to this pathway. Both pathways share early losses of chromosome 9 and mutations in 
the TERT promoter. Additionally, there is extensive evidence proving that non-aggressive tumors 
are genomically stable, as opposed to aggressive tumors.  
6.1. Alterations common to both pathways 
The most common genomic alterations in all subtypes of UBC affect chromosome 9, which has 
been found to be totally or partially lost in tumors of all stages and grades (Spruck et al. 1994; 
Hartmann et al. 2002; Mhawech-Fauceglia et al. 2006). The frequently deleted regions include 
9p22–23 in the short arm, and 9q11–13, 9q12–13, 9q21–22, and 9q34 in the long arm of the 
chromosome. They encompass at least 7 known tumor suppressor genes, namely BNC2, DAPK1, 
DBC1, CDKN2A/B, PTPRD, and TSC1, which could be responsible for the initial transformation of 
urothelial cells (Beothe et al. 2012). Consistently, bioinformatic analysis has suggested that loss of 
heterozygosity in chromosome 9 is one of the earliest genetic alterations in UBC pathogenesis 
(Bulashevska et al. 2004).  
Mutations in the promoter of TERT have recently been reported to occur in 70% of UBC 
tumors (Kinde et al. 2013; Liu et al. 2013; Rachakonda et al. 2013; Allory et al. 2014; Hurst et al. 
2014). A low proportion of control subjects without UBC may also present with TERT mutations. 
Altogether, these findings suggest that TERT promoter mutations are also a very early event in 
UBC shared by tumors belonging to both molecular pathways. Mutations have been detected in 
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exfoliated urine cells, making TERT promoter mutations a potential non-invasive diagnostic 
marker. In melanoma, mutations have been proposed to create novel transcription factor binding 
sites that could upregulate TERT expression (Horn et al. 2013; Huang et al. 2013) but no 
relationship was found between the presence of mutations and increased mRNA levels in UBC 
(Allory et al. 2014). Still, the functional significance of these mutations is not fully characterized.  
6.2. The non-aggressive pathway 
6.2.1. FGFR3 
Fibroblast Growth Factor receptors (FGFRs) are tyrosine kinases consisting of three 
immunoglobulin-like domains, a transmembrane domain, and a cytoplasmic domain with tyrosine 
kinase activity (Schlessinger 2000). There are four FGFR family members, namely FGFR1-4. Ligand 
binding induces receptor dimerization, resulting in several phosphorylation events that lead to 
receptor activation (Haughsten et al. 2010) and downstream signaling through the FRS2 adaptor 
protein. FGFR3 is the most predominantly expressed member of the FGFR family in the 
urothelium. FGFR3 is subjected to alternative splicing of its immunoglobulin-like domain III, 
producing the IIIb or IIIc isoforms, which have different tissue-specific expression and ligand 
specificities (reviewed in Knowles 2007).  The IIIb isoform of FGFR3 is expressed in epithelial cells. 
Activating mutations of FGFR3 in UBC were first identified in the late 90s (Cappellen et al. 
1999). Between 60-65% of UBCs harbor activating, oncogenic point mutations in FGFR3. The 
absence of FGFR3 mutations in normal urothelium from UBC patients suggests that they occur 
after chromosome 9 losses and TERT promoter mutations (Otto et al. 2009). FGFR3 mutations are 
clustered in three hotspots and commonly involve the substitution of certain residues with Cys 
(van Rhijn et al. 2004; Kompier et al. 2011). In the extracellular domain, exon 7 harbors frequent 
R248C (6%) and S249C (44%) alterations. Exon 10, which maps to the transmembrane domain, 
commonly exhibits G372C (3%), Y375C (11%), and A393E (0.4%) substitutions. Finally, in the 
tyrosine kinase domain, exon 15 frequently presents K652M (0.8%) mutations. Additional 
alterations mapping to the same hotspots occur at lower frequencies (Knowles 2007). Mutations 
in the extracellular or transmembrane domains of FGFR3 (exons 7 and 10) often result in 
spontaneous dimerization, while mutations in the kinase domain (exon 15) lead to constitutive 
receptor activation (Cappellen et al. 1999; Adar et al. 2002). Mutations are associated with FGFR3 
mRNA and protein overexpression. (Tomlison et al. 2007). Signaling downstream of FGFR3 
includes the PI3K/AKT, the RAS/MAPK, and the PKC pathways (Haughsten et al. 2010). Out of all 
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mutated tumors, 1/3 present concomitant mutations in other frequently altered genes in bladder 
cancer, while the remaining 2/3 harbor FGFR3 mutations exclusively (Kompier et al. 2011).  
Mutations in FGFR3 are more common in non-aggressive tumors, particularly in those of lower 
stage and grade, as described in two large studies including cases representative of the full UBC 
spectrum (Hernandez et al. 2006; Kompier et al. 2011). Moreover, FGFR3 alterations associate 
with a decreased risk of progression and longer survival (Hernandez et al. 2006; Kompier et al. 
2011). Interestingly, overexpression of wild-type FGFR3 occurs in about 40% of tumors, usually 
associated with aggressive features (Tomlinson et al. 2007).  
FGFR3 amplifications have been reported in 3% of UBCs (Fischbach et al. 2014). Additional 
FGFR3-related alterations in UBC involve gene fusions. FGFR3-TACC3 and FGFR3-BAIAP2L1 fusions 
have been identified in UBC cell lines, and 1/32 tumors without FGFR3 mutations that over 
expressed the protein by IHC was shown to harbor a FGFR3-TACC3 fusion (Williams et al. 2013). 
Subsequently, 2/42 tumors (1 NMI and 1 MI) have been show to harbor FGFR3-TACC3 fusion 
transcripts (Guo et al. 2013). This results in increased expression of TACC3, a protein involved in 
spindle stabilization during chromosome segregation.  
6.2.2. PIK3CA 
The PI3K pathway is crucial for regulation of cell survival and growth (Engelman 2009). There 
are three classes of PI3K enzymes. Class I PI3Ks form heterodimers, which are composed of a 
catalytic and a regulatory subunit. Class IA PI3Ks are characterized by being activated by receptor 
tyrosine kinases (García et al. 2006). In Class IA PI3Ks, the regulatory subunit is p85, whereas the 
catalytic protein is p110 (Bader et al. 2005). p110-α, encoded by PIK3CA, has been found to be 
mutated in 13-25%% of UBC (López-Knowles et al. 2006; Platt et al. 2009; Kompier et al. 2011). 
The discrepancies among studies most likely are due to the different methods employed for 
mutation detection. The most commonly mutations are E542K, E545K (both in exon 9), and 
H1047R (exon 20). Exon 9 encodes the helicase domain, where 80% of the mutations occur in 
UBC, whereas exon 20 corresponds to the kinase domain. The effect of the mutations is an 
oncogenic increase in PI3K activity (Bader et al. 2006; Zhao and Vogt 2008). Additionally, several 
studies have reported amplifications of 3q, the chromosomal arm where PIK3CA localizes (Koo et 
al. 1999; Cazier et al. 2014). Upon activation by membrane receptors, class I PI3Ks catalyze the 
generation of phosphatidylinositol-3,4,5-triphosphate (PIP3) from phosphatidylinositol-4,5-
bisphosphate (PIP2) (Bader et al. 2005). PIP3 binds to PDK1 and AKT, and AKT is activated by 
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PDK1-mediated phosphorylation. A phosphorylation cascade involving mTOR, S6K, and 4EBP1 
results in the activation of protein translation (Bader et al. 2005).  
Mutations in PIK3CA frequently co-occur with FGFR3 mutations, suggesting that PIK3CA 
alterations are also an early event in UBC development (López-Knowles et al. 2006; Kompier et al. 
2011). Additionally, this might imply that the oncogenic effect of mutations in FGFR3 and PIK3CA 
cooperate in the non-aggressive pathway of UBC development. PIK3CA alterations are more 
common in low grade tumors, but they are not significant predictors of outcome among NMIUBC 
(Kompier et al. 2011). 
6.2.3. RAS genes 
Mutations in HRAS, KRAS, or NRAS occur with an overall 11% prevalence in UBC (Jebar et al. 
2005; Kompier et al. 2011). The RAS proteins are small GTPases that transduce signals within the 
MAPK/ERK pathway, essential for cell proliferation and survival. Oncogenic mutations in codons 
12, 13 or 61 stabilize the Ras-GTP complex, resulting in a gain of function (reviewed in Prior et al. 
2012). Despite the high degree of homology between the three genes, KRAS mutations are more 
common in human cancers in general. In UBC, HRAS is mutated in 5.5% of tumors, KRAS in 5.5%, 
and NRAS mutations are rare (Fernández-Medarde and Santos 2011; Kompier et al. 2011). 
Interestingly, HRAS has been shown to have a stronger effect on PI3K pathway activation than 
KRAS and NRAS (Yan et al. 1998; Li et al. 2004), suggesting that HRAS and PIK3CA mutations might 
fulfill the same function in the non-aggressive pathway leading to bladder tumor formation. 
 
 
 
 
 
 
 
 
      
 
Figure 3. Molecular pathways of UBC development and progression. The non-aggressive pathway (upper) 
exhibits mutations in oncogenes and is genomically stable, whereas the aggressive pathway (lower) displays 
alterations in tumor supressors and is unstable. TERT promoter mutations and chromosome 9 losses are 
common to both pathways. 
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RAS and FGFR3 mutations are mutually exclusive (Jebar et al. 2005; Platt et al. 2009; Kompier 
et al. 2011), in agreement with the fact that both proteins effect on ERK1/2 signaling (di Martino 
et al. 2009). Overall, mutations in RAS genes do not associate with grade or stage (Kompier et al. 
2011) but a study reported a robust association between low HRAS mRNA expression and higher 
risk of progression in Ta UBC (Birkhahn et al. 2010). Further studies are needed in order to clarify 
the prognostic potential of mutations and expression levels of RAS genes. 
6.3. The G1-S cell cycle checkpoint and progression to aggressive tumors 
The G1-S checkpoint of the cell cycle is of particular importance for bladder cancer, through 
frequent alterations of CDKN2A, TP53, and RB. Cell cycle progression is controlled by cyclin-
dependent kinases (CDKs) and cyclins, which interact with CDKs, regulating their activity. Cyclin-
CDK complexes are formed and dissociated as the cell cycle advances, phosphorylating target 
proteins that permit cell cycle progression (reviewed in Malumbres and Barbacid 2009). Cyclin D1-
3 bind to CDK4 and CDK6 for entry into G1, a stage of the cycle which also requires cyclin E 
binding CDK2 in order to progress into S phase (Malumbres and Barbacid 2009).  
In G1, the retinoblastoma protein (Rb) is bound to the transcription factor E2F; this binding 
represses E2F activity which is essential for the G1-S transition to take place. Cyclin D-CDK4/6 
complexes phosphorylate Rb, releasing E2F and allowing cell cycle progression into S phase. CDK 
activity is also regulated by the CDK inhibitors (CDKis). The CDKi p16 (encoded by CDKN2A) blocks 
cyclin D-CDK4/6 binding; this prevents Rb phosphorylation and inhibiting progression into S 
phase. P53 also acts as a tumor suppressor at the G1-S checkpoint, inducing G1 arrest. In normal 
cells, p53 is expressed at low levels. Upon sensing DNA damage or other types of stress, p53 is 
stabilized and activated leading to p21 (encoded by CDKN1A) upregulation, which prevents the 
formation of cyclin-CDK complexes by binding to cyclins (Malumbres 2001; Malumbres and 
Barbacid 2009). Additionally, p53 represses c-Myc expression in a p21-independent manner (Ho 
et al. 2005). Both p21 upregulation and c-Myc repression are required for p53-dependent arrest 
of cells in G1, allowing DNA repair to occur. Therefore, Rb, p16, p21, and p53 are all negative 
regulators of G1-S transition, and thus loss of their normal function results in deregulated cell 
cycle progression. Alterations in all these tumor suppressors have been linked to UBC progression.  
6.3.1. CDKN2A/p16 
CDKN2A mRNA is undetectable in normal urothelium but is overexpressed in a subset of UBC, 
with levels increasing in tumors of higher stages and grades (Le Frere-Belda et al. 2004). Stage T1 
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tumors exhibit loss of p16 protein expression in 54% of the cases, and this loss is associated with 
an increased likelihood of tumor progression (Krüger et al. 2005). Losses of 9p21, where CDKN2A 
maps, are common in UBC (Williamson et al. 1995). Moreover, a recent report showed that 
CDKN2A homozygous deletions are more common in FGFR3-mutant tumors, regardless of their 
degree of muscle invasion (Rebouissou et al. 2012). Additionally, NMI tumors mutant for FGFR3 
that have lost one or both copies of CDKN2A were associated with an increased risk of 
progression (Rebouissou et al. 2012). These findings strengthen the hypothesis that CDKN2A loss 
is involved in the progression of NMI bladder tumors arising through the non-aggressive pathway. 
Figure 4. The G1-S checkpoint of 
the cell cycle. P16 represses cyclin 
D-CDK4/6 complex formation; this 
prevents Rb phosphorylation, so 
E2F is not released and cannot 
transcribe its target genes. 
Additionally, DNA damage induces 
p53 expression, which represses c-
Myc dependent transcription and 
upregulates p21; p21 impedes 
cyclin-CDK complex formation by 
binding to cyclins. These concerted 
processes arrest cells in G1. Upon 
alterations in any of the 
components, the G1-S checkpoint is 
bypassed. 
6.3.2. TP53 
Missense mutations in the TP53 tumor suppressor gene are the most frequent alterations in 
human cancers (Olivier et al. 2010). Mutations in TP53 have also been suggested to lead NMIUBC 
to progress and invade muscle. TP53 mutations occur more frequently in the highly conserved 
DNA-binding domain (codons 125-300), abrogating its transcriptional activity (Olivier et al. 2010). 
The majority of alterations in this domain are point mutations, most of which confer the altered 
protein a longer half-life, causing its nuclear accumulation (reviewed in Lane 2004). Therefore, 
immunohistochemical staining is frequently used as a surrogate for TP53 mutations. More than 
1/4 of NMI tumors exhibit abnormal nuclear staining of p53; these patients are at a higher risk of 
recurrence than those with normal staining (Chatterjee et al. 2004a). Overexpression of p53 in T1 
tumors is associated with a higher risk of progression (Sarkis et al. 1992; Grossman et al. 1998). 
Concurrent alteration of p16 and p53 expression in Ta and T1 tumors results in a significantly 
increased stage and grade-adjusted risk of progression of NMIUBC (Hitchings et al. 2004).  
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6.4. The aggressive pathway 
Although CIS are flat lesions, they exhibit aggressive features and often progress to MI bladder 
tumors (Cheng et al. 1999). CIS present frequent mutations in the tumor suppressor genes that 
control G1-S progression, making these alterations characteristic of the aggressive proposed 
mechanism of bladder tumor development. The genetic instability resulting from those mutations 
results in the accumulation of numerous genetic abnormalities in MIUBC.  
6.4.1. TP53 
Overall, mutations in TP53 have been detected in about 30% of high-grade UBC (Spruck et al. 
1994; Malats et al. 2005). In mouse models, loss of p53 in combination with either Rb or Pten 
deletions has been shown to induce CIS and favor progression into MI tumors (Zhang et al. 1999; 
Puzio-Kuter et al. 2009). In agreement with this observation, CIS exhibit common TP53 alterations 
(Hartmann et al. 2002).  Independently of the stage and grade of lesions, mutations in TP53 have 
been related to a poor prognosis (Esrig et al. 1994). However, a systematic meta-analysis 
highlights the fact that limitations associated with testing for p53 overexpression is not a robust 
independent marker to predict outcome in the clinical practice (Malats et al. 2005). 
6.4.2. RB  
Genetic alterations in the RB1 locus occur in approximately 30% of MI tumors (Miyamoto et al. 
1995), and RB1 LOH has been shown to mainly associated with MI tumors (Cairns et al. 1991). 
Both mutations and LOH in RB1 result in loss of protein expression. However, overexpression of 
Rb has also been detected in UBC (Cote et al. 1998) due to the increased expression of a 
hyperphosphorylated form of pRB, thought to be caused by p16 loss and/or cyclin D1 
overexpression (Chaterjee et al. 2004b). This hyperphosphorylation inactivates the RB tumor 
suppressor pathway. Therefore, inactivation of the RB pathway in MIUBC occurs through LOH or 
mutations of the RB gene, or by RB protein hyperphosphorylation. As mentioned above, in 
preclinical models this inactivation cooperates with p53 in the development of MIUBC. 
6.4.3. PTEN  
LOH or homozygous mutations leading to PTEN loss of function or decreased protein 
expression have been detected in 14% of aggressive UBCs (Cairns et al. 1998). PTEN is a lipid 
phosphatase that negatively regulates the PI3K pathway through dephosphorylation of PIP3, 
producing PIP2 (reviewed in Knowles 2006). Therefore, decreased PTEN expression leads to 
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higher proliferation and lower apoptosis by overactivation of PI3K signaling. Alterations of PTEN in 
UBC include point mutations and, more frequently, LOH. An inverse relationship between FGFR3 
mutations and PTEN loss has been observed (Platt et al. 2009). This pattern can be explained by 
the fact that both PTEN loss and PIK3CA activating mutations lead to PI3K pathway activation. The 
mechanisms by which PTEN and PIK3CA alterations happen specifically in one of the pathways are 
not understood, although they could be related to the higher frequency of genomic instability in  
Table 2. Summary of genetic changes found in UBC. The main genes implicated in cancer 
described in each region appear in brackets. Extensively modified from Knowles 2008. 
Deletions Amplifications Gains 
Cytogenetic 
location 
Tumor 
stage 
Frequency 
(%) 
Cytogenetic 
location 
Tumor 
stage 
Frequency 
(%) 
Cytogenetic 
location 
Tumor 
stage 
Frequency 
(%) 
2q Ta, >T2 10, 12 1q22 >T2 <5 1q 
Ta, 
>T2 
11-14, 17-
33 
5q >T2 15-24 3p24 >T2 <5 3q (PIK3CA) >T2 18 
6q >T2 15-28 
6p22     
(E2F3) 
>T2 5 - 10 5p (TRIO) >T2 24-37 
8p (FRP1) Ta, >T2 16, 29-34 8p12 
Ta, 
>T2 
occasional, 
<5 
7p (EGFR1) >T2 20 
9p (BNC2, 
CDKN2A/B, 
PTPRD) 
Ta, >T2 
36-47, 21-
30 
8q21-22 
and        q24 
(MYC) 
>T2 <5 8q (MYC) >T2 23-34 
9q (DAPK1, 
DBC1, PTCH, 
TSC1) 
Ta, >T2 44-66, 17 10p13-14 >T2 <5 10p >T2 12 
10p Ta 20 
11q13 
(CCND1) 
Ta occasional 
17q (ERBB2, 
TOP2A) 
Ta, 
>T2 
14, 30 
10q (PTEN) Ta, >T2 20, 16-21 12q15 >T2 <5 20p >T2 21 
11p   (KRAS; 
KAI) 
Ta, >T2 
10-24, 18-
24 
17q21 
(ERBB2, 
TOP2A) 
>T2 <5 
20q 
(AURKA) 
Ta, 
>T2 
13-17, 26-
28 
11q >T2 22 
20q13 
(AURKA) 
>T2 <5    
13q (RB1, 
P33ING1) 
Ta, >T2 17, 19       
15q (RAD51) >T2 13       
16q           (E-
CAD) 
>T2 15       
17p (TP53) Ta, >T2 15, 17-24       
18q Ta, >T2 13, 16-17       
Y Ta, >T2 24-28, 21       
 
the aggressive pathway. In fact, LOH of 10q23, where PTEN maps, is more common in aggressive 
than in non-aggressive bladder tumors (Aveyard et al. 1999; Wang et al. 2000; Harris et al. 2008). 
Moreover, the expression signature associated to loss of PTEN is a significant predictor of poor 
outcome in UBC (Saal et al. 2007). The collaboration between Pten and p53 in MIUBC formation 
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observed in mice (Puzio-Kuter et al. 2009) could be explained by wild type Pten’s role in inhibiting 
invasion in UBC (Gildea et al. 2004). 
6.4.4. MIUBC and genomic instability 
There is extensive evidence indicating that non-aggressive UBCs are genomically stable 
whereas aggressive UBCs are unstable. Array CGH showed that the higher the grade and stage of 
tumors, the greater the number of chromosome alterations (Blaveri et al. 2005). More than half 
of MI tumors present concurrent alterations in TP53 and RB (Cote et al. 1998; Grossman et al. 
1998). Tumors with defects in both genes present worse outcome than tumors harboring 
mutations in one of them only. Moreover, alterations in either or both of these genes were 
recently found to correlate with increased copy number changes in high-grade bladder tumors 
(Iyer et al. 2013). TP53 mutations have been proposed to contribute to the escape of apoptosis in 
aneuploid tumors (Li et al. 2010).  MI tumors with alterations in TP53 exhibit greater chromosome 
instability (Lindgren et al. 2010). Combined analysis of gene expression and genomic profiling has 
shown that Ta tumors constitute a different group than MI and NMI T1 tumors, supporting the 
classification of UBC into non-aggressive and aggressive cases (Lindgren et al. 2010). A summary 
of the most common genetic alterations in UBC detected by CGH can be found in Table 2. 
7. UBC AND EPIGENETIC ALTERATIONS 
Aberrant methylation is common in many tumor types, including UBC. Promoter 
hypermethylation at CpG islands has been shown to silence gene expression in cancer (reviewed 
in Baylin and Jones 2011). Aberrant methylation is observed both in loci presenting genetic 
alterations, such as CDKN2A, and in otherwise unaffected genes like DAPK (Chan et al. 2002). 
These abnormal methylation patterns have also been shown to correlate with grade, stage, and 
prognosis (Maruyama et al. 2001). A recent study described the existence of 7 chromosomal 
regions concurrently silenced by methylation of H3K9 and H3K27 and/or H3K9 hypoacetylation, 
mainly in CIS and MI tumors (Vallot et al. 2011), suggesting a common mechanism of epigenetic 
regulation affecting multiple genomic regions in a coordinated manner. There is some debate as 
to whether this mechanism involves only histone modifications or also implies cytosine 
methylation (Frigola et al. 2006; Vallot et al. 2011). The histone modifiers or the chromatin 
remodelers responsible for the epigenetic alterations in UBC have not been identified yet. Of 
note, altered DNA methylation in leukocyte DNA has also been found in patients with UBC, the 
relationship with tumor methylation being unknown (Moore et al. 2008). 
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8. EXOME SEQUENCING OF UBC 
Even though our knowledge about the events underlying UBC development, and progression 
has improved greatly over the last decade, the genetic alterations responsible for this tumor are 
incompletely defined. In the last few years, the advent of next generation sequencing (NGS) has 
led to a quantum leap in the knowledge of the genetic landscape of human cancer (Alexandrov et 
al. 2013; CGARN et al. 2013; Puente and López-Otín 2013). Whole exome sequencing (WES) is a 
less expensive, informative, alternative to whole genome sequencing studies for the purpose of 
gene discovery in complex diseases such as cancer (Stratton et al. 2009). The first 9 UBC exomes 
were sequenced in 2011 (Gui et al. 2011). This, together with a series of WES and whole genome 
sequencing (WGS) studies published within the last year, have helped us identify new pathways 
involved in UBC (Guo et al. 2013; Cazier et al. 2014; CGARN 2014a; Nordentoft et al. 2014). I have 
focused my work on two genes involved in the chromatin remodeling pathway (ARID1A) and the 
chromosome segregation pathway (STAG2).  The findings extracted from the NGS studies, 
together with our work and other targeted sequencing studies will be explored in the discussion 
(Solomon et al. 2013; Kim et al. 2014; Ross et al. 2014; Taylor et al. 2014). 
9. ARID1A 
9.1. The BAF SWI/SNF chromatin remodeling complex 
SWI/SNF complexes remodel chromatin in an ATP-dependent way. They are thought to 
mobilize nucleosomes in a multi step process that starts with their binding to DNA at the 
nucleosomes, which hinders the contact between histones and DNA (Wilson and Roberts 2011). 
This is followed by ATP-dependent translocation of DNA through the formation of DNA loops. The 
sliding is propagated along the nucleosome to increase the accessibility of chromatin-repressed 
DNA binding sites. In mammals, there are two multiprotein complexes, BAF and PBAF, which 
differ in their subunit composition. BAF complexes contain three highly conserved catalytic 
subunits: BAF155, BAF170, and SNF5. BAF complexes include an ATPase subunit that can be either 
BRG1 or BRM (Wilson and Roberts 2011). There are six additional variant subunits, most of which 
have one or more paralogs that are thought to contribute to target specificity. 
9.2. The ARID1A subunit of BAF 
One of the non-catalytic variant subunits of BAF is either the AT-rich interactive domain-
containing protein 1A (ARID1A) or its mutually exclusive paralog ARID1B. The ARID proteins have a 
DNA-binding domain (ARID domain) that, in the case of ARID1A, binds DNA non-specifically 
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(Wilsker et al. 2004). The C terminus of ARID1A is believed to engage in protein-protein 
interactions. The specific role of ARID1A within the BAF complex has not been elucidated, but it is 
thought to contribute to specification of target recruiting (Wu and Roberts 2013).  
  
Figure 5. The BAF SWI/SNF Complex 
and ARID1A. (a) Diagram portraying 
core subunits in dark blue, ARID1 in 
green, and other members of the 
complex in light blue. (b) ARID1A 
protein scheme, showing its known 
functional domains. Adapted from Le 
Gallo et al. 2012.  
 
 
10. STAG2 
10.1. The cohesin complex 
Cohesin is a ring-shaped multiprotein complex comprised of four subunits. In somatic cells, 
these subunits are SMC1A, SMC3, RAD21, and either STAG1 or STAG2 (Remeseiro and Losada 
2013). SMC1A and SMC3 are ATPases that modulate chromosomal structure. RAD21 can be 
cleaved, causing cohesin disassembly, whereas STAG1 or STAG2 are thought to confer functional 
specificity. When the ring needs to dissociate from chromatin, PDS5A or B and WAPL associate to 
the complex, allowing its unloading from DNA.  
Cohesin binding to DNA is cell-cycle regulated (Losada 2014). The ring is loaded onto DNA by 
the NIBPL-MAU2 heterodimer at G1. Initially, it only encircles one chromatid but, upon DNA 
duplication during the S phase, the complex surrounds both sister chromatids and becomes 
cohesive through acetylation of SMC3 by ESCO1/2 and remains bound to DNA during G2. During 
prophase, STAG2 is phosphorylated by PLK1, leading to disassembly of the complex. This does not 
happen at the centromeres, where the SGO1-PP2A dimer protects STAG2 from phosphorylation, 
allowing chromosome alignment at the metaphase plate.  Centromeric cohesin remains 
assembled until anaphase, when RAD21 is cleaved by ESPL1 (separase), unloading all remaining 
cohesin and allowing for chromosome segregation. A failure in any of these steps would lead to 
incorrect chromosome segregation and hence to aneuploidy in the daughter cells. 
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10.2. Functions of the cohesin complex 
The canonical function of the cohesin complex is to regulate sister chromatid cohesion. This is 
essential not only to guarantee proper chromosome segregation but also to ensure appropriate 
DNA repair mediated by homologous recombination in response to DNA damage (Remeseiro and 
Losada 2013). Recent studies have unraveled additional roles of cohesin through DNA-looping, in 
collaboration with additional factors such as the insulator CTCF (Losada 2014). This affects the 
three-dimensional structure of DNA, playing a role in transcriptional regulation of gene 
expression, facilitation of genetic recombination in the immune system, and organization of DNA 
replication factories widening the functions of cohesin. 
 
Figure 6. Binding of mitotic cohesin to DNA is cell cycle regulated. (a) Composition of the 
multiprotein mitotic cohesin complex. Modified from Kitagawa 2009. (b) Cell cycle regulation of 
cohesin binding to chromatin. Adapted from Rhodes et al. 2011.  
10.3. STAG2 function within mitotic cohesin 
The distinct function of STAG2 within the cohesin complex is not well understood.  Studies in 
mouse models and human cell lines have shown that STAG1-containing rings are responsible for 
cohesion at telomeres, whereas STAG2-containing complexes specifically promote cohesion at 
telomeres (Canudas and Smith 2009; Remeseiro 2012a). Regarding transcriptional regulation, 
STAG1 has been shown to influence gene transcription in mouse embryonic fibroblasts (MEFs) 
and mouse brain, a role that STAG2 cannot fulfill (Remeseiro 2012b). Additional studies are 
required in order to determine the specific functions of each of the cohesin components within 
the complex, as well as to elucidate how such specificity is attained. 
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Bladder cancer encompasses a heterogeneous group of tumors with diverse clinical, 
histopathological, biological, and molecular features. Clinical and genetic evidences support the 
notion that there are at least two genetic pathways leading to urothelial bladder cancer but our 
knowledge of the genes involved in those pathways remains incomplete.  Improving our 
understanding of the molecular players involved in this disease would contribute to a better 
classification, assessment of prognosis, and selection of treatment of bladder cancer patients. 
Therefore, the main goal of this thesis was to identify novel genes involved in bladder cancer 
development and progression, place them in the context of the current knowledge, and 
investigate their role in urothelial biology, and studying their potential clinical relevance. 
The specific objectives of this PhD thesis were: 
1. To identify novel genes mutated in bladder cancer, with a focus on NMIUBC. 
2. To describe the frequency and type of mutations found in recurrently altered genes (ARID1A 
and STAG2) and assess their relationship with tumor stage and grade, the known pathways of 
bladder tumor development, and patient outcome. 
3. To determine the mechanisms of STAG2 inactivation in bladder cancer and the contribution of 
said inactivation to tumor development and progression. 
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El cáncer de vejiga abarca un grupo heterogéneo de tumores, con características clínicas, 
histopatológicas, biológicas y moleculares variadas. Las evidencias clínicas y genéticas apoyan la 
noción de que existen al menos dos vías genéticas que conducen al cáncer urotelial, pero nuestro 
conocimiento sobre los genes involucrados en dichas vías sigue siendo incompleto. La mejora de 
nuestra comprensión de los actores moleculares involucrados en esta enfermedad contribuiría a 
mejorar la clasificación, valoración del pronóstico y selección del tratamiento de los pacientes con 
cáncer de vejiga. Por tanto, el principal objetivo de esta tesis fue identificar nuevos genes 
involucrados en el desarrollo y la progresión del cáncer de vejiga, situarlos en el contexto de lo 
que ya se conoce, y describir su función en la biología del urotelio. 
 
Los objetivos específicos de esta tesis doctoral fueron: 
 
1. Identificar nuevos genes mutados en cáncer de vejiga, centrándonos en los tumores no 
invasivos. 
2. Describir la frecuencia y tipo de mutaciones encontradas en genes alterados de forma 
recurrente (ARID1A y STAG2) y valorar su relación con estadio y grado del tumor, las vías 
conocidas de desarrollo de tumores de vejiga y los resultados de los pacientes. 
3. Determinar los mecanismos de inactivación de STAG2 en cáncer de vejiga y la 
contribución de dicha inactivación al desarrollo y progresión tumoral. 
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1. PATIENTS  
Cases from two different series were included for exome sequencing and prevalent mutation 
screenings. The first cohort belongs to the Integrated Study of Bladder Cancer (ISBLAC), a study 
conducted between 2008-2012 at Hospital del Mar, Barcelona. The second is part of the 
EPICURO/Spanish Bladder Cancer Study (SBCS) (Hernández et al. 2006). Cases from the latter 
were also used for protein expression analysis by immunohistochemistry (see below). The main 
characteristics of the patients from these cohorts included in this work are summarized in 
Supplementary Tables 1-3.  
Grading, staging, and follow-up of the patients were performed as previously described 
(Hernández et al. 2006). Diagnostic slides from all tumors used for STAG2 protein expression 
detection by immunohistochemistry were reviewed by expert pathologists. The NMIUBC group 
comprised TaG1 and TaG2 tumors (low risk) and TaG3, T1G2, and T1G3 tumors (high risk). The 
MIUBC group included all tumors ≥T2. A more detailed description of subject characteristics can 
be found in Supplementary Table 2. For certain analyses, tumors were classified as "non-
aggressive" (comprising the low risk NMIUBC) and "aggressive" (comprising the high risk NMIUBC 
and the MIUBC). Tumors were grouped in this manner because there is extensive evidence 
indicating that high risk NMIUBC share the molecular/genetic characteristics of MIUBC and likely 
represent MIUBC tumors that have not yet invaded muscle. 
Subjects with NMIUBC were assessed for recurrence and progression. Recurrence was defined 
as the reappearance of a NMI tumor after a negative monitoring medical evaluation. NMIUBC 
progression was defined as the development of a MI tumor from a NMI one. Subjects with MIUBC 
were assessed for progression and death. In this case, progression was defined as the 
development of new local or metastatic tumors after the patient had received primary treatment. 
For subjects with MI tumors, all deaths were registered but only those related to UBC were taken 
into account in survival analyses.  Survival periods comprise the time elapsed between diagnosis 
and the either the last follow-up or the time of death. Written informed consent was provided by 
all patients. All studies were approved by the ethics committees of all institutions involved. 
2. CELL LINES  
Cell lines used in this thesis had the following origins: JON, MGH-U4, RT4, SCaBER, SW-800, 
SW-1710, T24T, VM-CUB-2, VM-CUB-3, 253J, 639V, and CM5637 were purchased from the 
American Type Culture Collection (Rockville, MD, USA); UM-UC-2 was provided by D. Theodorescu 
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(University of Colorado, Aurora, CO, USA); UM-UC-3, UM-UC-4, UM-UC-5, UM-UC-6, UM-UC-7, 
UM-UC-9, UM-UC-10, UM-UC-11, UM-UC-12, UM-UC-13, and UM-UC-18 were provided by H. B. 
Grossman (MD Anderson Cancer Center, Houston, TX, USA) (Sabichi 2006); J82, MGH-U3, and 
RT112 cells were provided by F. Radvanyi (Institut Curie, Paris, France); 92-1, 96-1, 97-1, and 97-7 
were generated by C. Reznikoff  (Yeager et al. 1998) and provided by M. Knowles (University of 
Leeds, Leeds, UK); and LGWO1 G600 was provided by J. Reeder (U. Rochester, NY, USA). All cells 
were periodically tested to make sure they were not contaminated with Mycoplasma. 
Cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) supplemented with 
10% heat-inactivated fetal bovine serum (FBS, Sigma) and 1 mM sodium pyruvate (Invitrogen).  
3. GENOMIC DNA EXTRACTION 
Sections from formalin-fixed paraffin-embedded tumor blocks were microdissected and 
genomic DNA was extracted as described elsewhere (Hernández et al. 2005). 
4. RNA ISOLATION 
For reverse transcriptase and quantitative PCR (RT-qPCR), cells in log-growth phase were 
washed with Phosphate Buffer Saline (PBS) (Sigma) and total RNA was isolated with the GenElute 
Mammalian Total RNA kit (Sigma). For RNA-sequencing, RNA from control and STAG2 knock-down 
UBC cells was extracted and purified using the phenol-chloroform method. RNA integrity was 
assayed on an Agilent 2100 Bioanalyzer (range 6.8-9.1).  
5. EXOME SEQUENCING 
The Agilent SureSelect Human All Exon plus capture kit was used for the preparation and 
enrichment of libraries. V3 50 Mb was used for samples 114, 116, 193, 251, 310, 331, 413, 418 
and Esp66, whereas the libraries for samples 062, 064, 179, 188, 274, 313, 343 and 451 were 
prepared using v4 51Mb. The libraries were hybridized to an Illumina flow cell and samples were 
sequenced on a HiSeq 2000 instrument, obtaining 75-bp paired-end reads.  
The Illumina Real-Time Analysis pipeline was used for base calling and quality control. The 
Genome Multitool Mapper was initially used to trim sequence reads. The limit was set at the first 
base with >10 mapping to the human genome build hg19 (GRCh37). The 27 (~4%) reads excluded 
from this process were subjected to a second round of mapping using BFAST. Non-duplicated, 
uniquely mapping, read pairs were selected and results from both mapping rounds were merged. 
Single nucleotide variants (SNVs) and short indels were called using the default settings of the 
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SAMtools suite version 0.1.18. SNVs falling within regions exhibiting read depth <10, having low 
mappability, strand bias P < 0.001, or tail distance bias P < 0.05 were excluded. The results from 
blood and tumor exome sequencing were compared to call for somatic mutations.  Variant-
supporting read counts were used to perform Fisher’s exact tests. Only those somatic SNVs with 
Fisher’s exact test P value <0.0001 were considered.  
5. 1. SNV damage prediction  
SNVs leading to non-synonymous changes or mapping to exon junctions were classified as 
‘relevant’. Variants causing amino acid substitutions were assessed for damaging potential using 
the scores of the SIFT (Kumar et al. 2009) and MutationAssessor (Reva et al. 2011) publicly 
available tools, which were normalized to fall within a 0-1 range. MutationAssessor ‘low risk of 
damage’ predictions were assigned a value of 0.5, ‘medium risk of damage’ was given 0.7, and 
‘high risk of damage’ was assigned a value of 1. Whenever both predictions could be obtained, an 
average score was calculated; if one of the tools did not yield a prediction, the score from the 
other one was used. SNVs were considered damaging when the final score was >0.8. Relevant 
exon junction SNVs were classified as damaging if they fell within the first 2 bases of the exon or 8 
bases of the intron, counting from donor junctions, or if they fell within 3 bases into the exon or 8 
into the intron, counting from acceptor junctions. Frameshifts and stop gains ablating >30% of a 
protein sequence or whole protein domains (as annotated in InterPro) were labeled as damaging. 
P values for the genes associated to the SNVs were calculated combining scores from both 
methods, combining recurrence and functional impact data as proposed in the Oncodrive-fm 
approach (González-Pérez and López-Bigas 2012). 
Mann-Whitney U test was used for statistical analyses comparing the ratio of non-
synonymous vs. synonymous mutations across different age groups, tumor stages, and smoking 
status. The frequency of mutations of recurrently altered genes in non-aggressive vs. aggressive 
tumors was compared using Fisher’s exact tests. 
5.2. Pathway analysis 
Pathway analysis was performed as outlined elsewhere (Vázquez et al. 2012). Three different 
gene lists were compiled: 1) Relevant genes (those with relevant mutations, see above); 2) 
Damaged genes (those with damaging mutations, see above); 3) Recurrently altered genes (those 
presenting relevant mutations in at least 2 samples). These lists were analyzed for enrichment 
based on a hypergeometric test, taking into account KEGG pathways and GO (Gene Ontology 
Materials and methods 
62 
 
biological process) components, correcting for genes present in different clusters. Benjamini-
Hochberg’s False Discovery Rate (FDR) scores were used to adjust P values and only FDR < 0.1 
were taken into account.  
6. PREVALENCE SCREENING OF RECURRENTLY MUTATED GENES 
6.1. HaloPlex targeted resequencing 
Targeted resequencing was performed for five of the cases included in the exome sequencing 
discovery screen, to validate and compare both experimental strategies, and for 60 additional 
cases. The HaloPlex Target Enrichment System (Agilent) was used to capture the exonic regions of 
the 110 genes of interest (see Supp. Table 4), following manufacturer’s instructions. Briefly, 
restriction digestion was performed to create a library of DNA fragments. This library was then 
hybridized with probes targeting regions of interest that incorporated Illumina paired-end motifs 
and index sequences.  This was followed by DNA capture and PCR amplification using Herculase II 
Fusion Enzyme or KAPA HiFi HotStart polymerase. AMPure XP beads were used to amplify PCR 
products. Illumina multiplex sequencing was performed on the purified amplicons. The Flexible 
Adapter Remover program was used to eliminate adaptor and primer sequences from the 
sequencing reads.  
Reads were mapped after eliminating adaptor and primer sequences. Indels and SNVs were 
called as described above; duplicates were included, but variants with strand bias P < 0.001 or tail 
distance bias P < 0.05 were excluded. SNVs falling outside the selected sequences, displaying low 
mappability or read depth <10, annotated as SNPs in the 1000 Genomes Project (21 May 2011 
version), or those occurring in >1% of the reads in paired normal blood samples were filtered out. 
Variants present in tumors were compared with their corresponding blood samples to select 
somatic mutations; those with Fisher’s exact test P value <0.0001 were included. The predicted 
effect of the mutations was annotated as detailed above. 
Frequency of mutations of recurrently altered genes in non-aggressive vs. aggressive tumors 
was compared using Fisher’s exact tests. All analyses were performed using the R 2.15.1 statistical 
software. P values <0.05 were required for observations to be considered statistically significant.  
6.2. ARID1A mutational analysis 
Concurrently, ARID1A mutational analyses were performed using tumor-blood DNA pairs from 
52 additional cases from the ISBLAC series and 5 UBC cell lines (MGH-U3, RT112, UM-UC-3, UM-
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UC-17, and VMCUB-3), following a protocol described elsewhere (Wiegand et al. 2010). In short, 
exons 2-20 were amplified using AccuPrime Taq DNA polymerase HiFi (Invitrogen). PCR products 
from all samples were pooled at equimolar concentrations and the Covaris S2 shearing instrument 
was used to fragment the amplimers to 100-300 bp. DNA (40-80 ng) from each sample was 
subject to end-repair and dA-tailing. Subsequently, fragments were ligated to indexed adapters 
according to the recommendations for DNA sample preparation from the TruSeq kit (Illumina). 
PCR (n=10 cycles) was used to amplify adapter-ligated libraries. Amplified libraries were 
multiplexed and subjected to single read sequencing for 38 cycles (Genome Analyzer IIx with SBS 
TruSeq v5 reagents, Illumina). 
Novoalign V2.07.04 (Novocraft, Selangor, Malaysia) was used to independently align sequence 
tags against the genomic ARID1A sequence in the Human February 2009 (GRCh37/hg19) 
assembly. Those positions that aligned were subjected to a quality filter and mapped combining 
custom Perl scripts and SAMtools. The SIFT tool (Kumar et al. 2009) was used to predict the 
functional consequence of all identified variants. 
6.3. FGFR3 mutational analysis 
Information on the FGFR3 mutational status of tumors from the EPICURO study was available 
from previous published studies of our laboratory, as described in detail elsewhere (Hernández et 
al. 2005; Hernández et al. 2006). Tumors from cases included in the ISBLAC study were analyzed 
using the SnapSHOT multiplex assay (Hafner et al. 2006), followed by capillary electrophoresis of 
the fragments. 
 6.4. Sanger sequencing 
Sanger sequencing was used to verify somatic SNVs called by bioinformatic analysis of the 
exome sequencing (see above). Additionally, Sanger sequencing was employed to assess STAG2 
mutational status in UBC cell lines. Genomic DNA was used to sequence exons 8-10. Overlapping 
cDNA amplicons comprising STAG2 exons 3-7, 11-31, and 33-36 were generated and sequenced.  
7. GENE COPY NUMBER ANALYSIS 
To assess copy number changes, two different platforms were used:  
- A subset of tumors from the EPICURO study, including 12 non-aggressive samples for which 
matching fixed tissue was available, was analyzed using Human 2.0 BAC arrays (UCSF Cancer 
Center) (Snijders et al. 2004). In short, each array contains triplicate spots of 2,464 BAC clones 
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uniformly distributed across the genome, giving a final resolution of 1.4 Mb. Genomic DNA (100 
ng for tumor and 50 ng for reference DNA) was amplified and fluorescently labeled by random 
priming. DNA was mixed with 100 mg Cot-1 DNA (Life technologies, Gaithersburg, MD) and 
precipitated. DNA was resuspended in 60 ml of hybridization solution (50% formamide, 10% 
dextran sulphate, 4% SDS, 100 mg yeast tRNA, and 2xSSC), denatured at 72 ºC for 10 min, and 
repetitive sequences were blocked by incubation at 37 ºC for 1 h. Samples were hybridized to the 
array for 48 h, washed, and mounted. Fluorescence intensities were measured for tumor and 
normal samples using a charged coupled device camera (Sensys, Photometric) coupled to a 1x 
optical system. SPOT and SPROC software (Jain et al. 2002) was used to calculate a test 
intensity/reference intensity single centered log2 ratio for each BAC clone. Only clones with 
detectable signal in > 2 of the triplicate spots, clones with detectable signal in > 20% of samples, 
and those where the triplicate standard deviation was < 0.33% were included in the analysis. 
Frequency of alterations > 40% were considered in the assessment of chromosomal-scale 
genomic changes.  
- An independent set of 11 non-aggressive tumors for which we also had available material for 
immunohistochemistry was analyzed using Illumina HumanHap 1M BeadChip high resolution SNP 
arrays, which contain >1 million SNP markers. This array includes 17,202 monomorphic probes 
located in regions of known or suspected copy number variations (CNVs). Manufacturer 
recommendations were followed for sample preparation and array hybridization. Briefly, DNA 
was denatured and amplified for 20 h at 37 ºC. Amplified genomic DNA was enzymatically 
fragmented, precipitated, and resuspended in Illumina’s hybridization buffer. Fragments were 
applied to BeadChips (1-2 samples per bead) and incubated for 16-24 h at 48 ºC. BeadChips were 
washed and oligonucleotides on the BeadChips were extended in a one-nucleotide elongation 
reaction with fluorescently labeled oligonucleotides, using captured DNA as template. 
Fluorescence intensities were measured using the Illumina iScan System, which records high-
resolution images of the light emitted from the fluorophore-labeled single-base extension 
products. Single nucleotide polymorphism (SNP) calling was performed as published (Rothman et 
al. 2010; Jacobs et al. 2012). Briefly, bead fluorescence intensities were normalized, and 
genotypes and R values were extracted using the Illumina Beadstudio software (v.3.1.3.0). After 
normalization of R values, log R ratios were calculated taking the average R values of blood 
leukocyte samples from EPICURO control individuals as a reference (Rodríguez-Santiago et al. 
2010). Log R ratios provide with a quantitative measure of copy number. Log R ratios = 0 
correspond to a sample carrying two copies of the DNA region, log R ratio < 0 indicate deletions, 
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and ratios > 0 correspond to amplification. The waviCGH software was used to obtain copy 
number calls (Carro et al. 2010).  
8. RNA SEQUENCING 
Total RNA was denatured to expose poly(A) tails, bound to oligo(dT) cellulose, and poly(A)+ 
RNA was eluted, purified, randomly fragmented, converted to double stranded cDNA, and 
processed through subsequent enzymatic treatments of end-repair, dA-tailing, and ligation to 
adapters as outlined in Illumina's "TruSeq Stranded mRNA Sample Preparation Part # 15031047 
Rev. D", to ensure that only the cDNA strand generated during the first strand synthesis is 
sequenced. The adapter-ligated library was completed by subjecting samples to 10 cycles of PCR 
with Illumina PE primers. The resulting purified cDNA library of template molecules was applied to 
an Illumina flow cell for cluster generation (TruSeq cluster generation kit v5) and sequenced on 
the Genome Analyzer IIx (GAIIx) with SBS TruSeq v5 reagents following manufacturer's 
instructions (SingleRead 1x40 bases).  
Illumina Real Time Analysis software (RTA1.13) was used for image analysis and per-cycle base 
calling. Conversion to FASTQ format and sequencing alignment with the ELAND algorithm (v2e) 
was performed using CASAVA-1.8 (Illumina).  Quality check was done using fastqc (v0.9.4, 
Babraham Bioinformatics). Raw reads were aligned to the reference genome hg19/GRCh37 with 
tophat (version 2.0.4). Gene expression levels (Fragments Per Kilobase of exon per Million 
fragments, FPKMs) were quantified with cufflinks (version 2.0.2), as annotated in the Ensembl 
version GRCh37.65. 
FPKM correlations and Principal Component Analysis (PCA) clustering of samples were carried 
out with the R statistical software’s (version 2.14.1) functions cor() and prcomp. Differential gene 
expression analysis was performed with the cuffdiff function included in cufflinks (version 2.0.2). 
Venn diagrams were created with the freely available software VENNY (accessible at 
www.bioinfogp.cnb.csic.es/tools/venny) (Oliveros 2007). 
9. GENE EXPRESSION ANALYSIS 
For gene expression analyses, RNA from 43 UBC tumors and 60 cell lines had been previously 
assessed using the Human Genome ST1.0 DNA and the U133A array, respectively (both from 
Affymetrix), as reported elsewhere (Fu et al. 2012). RNA (500 ng) was amplified, labeled, and 
hybridized to the arrays. Raw expression data from the Human Genome ST1.0 DNA and the 
U133A arrays was processed as previously described (Fu et al. 2012; Zieger et al. 2005). Briefly, 
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the ST1.0 DNA expression values were normalized using the Frozen Robust Multiarray Analysis 
method (McCall et al. 2010) before conducting further analyses. The U133A expression values 
were normalized using the GC-RMA procedure implemented in the ArrayAssist software 
(Stratagene, La Jolla, CA) and they were log2 transformed before analysis. Affymetrix control 
probes were removed from further assessment.  
9.1. Analysis of publicly available gene expression datasets 
Normalized data for studies GSE89 (Dyrskjøt et al. 2003) and GSE32894 (Sjödahl et al. 2012) 
was downloaded from the Gene Expression Omnibus (GEO) database. The data was pre-
processed with GEPAS 4.0 (http://www.gepas.org/), to obtain average values for all probes that 
mapped within a given locus. The average expression of ARID1A, FGFR3, and TP53 was calculated 
for each group and normalized with respect to the first group. Differentially expressed genes were 
identified as follows: pre-processed data were subjected to an Anova limma analysis with the 
POMELO online software (http://pomelo2.bioinfo.cnio.es), and differentially expressed genes 
were identified using an FDR adjusted P-value <0.5 as significance threshold and performing a t-
test on all qualifying samples.  
10. HISTOLOGICAL ANALYSIS   
10.1. Immunohistochemistry (IHC)   
Protein expression in tumors was analyzed using tissue microarrays (TMAs) containing 2 cores 
representative of the corresponding tumor. The cores were extracted from formalin-fixed 
paraffin-embedded tissue blocks from patients included in the EPICURO/SBCS. Slides were 
deparaffinized and rehydrated. Antigen retrieval was performed by boiling for 10 min in 10mM 
sodium citrate buffer (pH6.0). Samples were then incubated in 3% H2O2 in methanol for 30 min. 
Blocking was performed for 1 h with 2% Bovine Serum Albumin (BSA) (Sigma) in PBS. Sections 
were incubated with the corresponding primary antibodies, diluted in 1% BSA in PBS, overnight at 
4 ºC.  
The primary antibodies used and the experimental conditions are indicated in Table 3. It is 
important to note that two different antibodies, yielding 92% concordant results, were used for 
STAG2 detection. Sections were washed x3 in PBS for 10 min and they were incubated for 1 h with 
EnVision+HRP labeled secondary anti-rabbit or anti-mouse antibodies (Dako). Signal detection 
was performed using the DAB+Chromogen system (Dako) at room temperature for 2 min. Nuclear 
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counterstaining was performed for 2 min using Carazzi’s Hematoxylin solution DC (Panreac); slides 
were dehydrated and mounted. 
Table 3. Primary antibodies used in this dissertation. NA: Not applicable. 
Target 
protein 
Species Information Immunization peptide 
WB 
dilution 
IHC/IF 
dilution 
ARID1A 
Mouse 3H2, Abnova NA NA 2 μg/mL 
Mouse 
M02, clone 3H14, 
Abnova 
NA 1:1000 NA 
β -CAT  Mouse β -catenin-1, Dako NA NA ready-to-
use 
E-CAD Mouse NCH-38, Dako NA NA 1:50 
FGFR3 Mouse 
B-9/sc-13121, Santa 
Cruz 
NA NA 8 μg/mL 
Ki67 Mouse MIB-1, Dako NA NA 
ready-to-
use 
KRT5/6 Mouse D5/16B4, Dako NA NA 
ready-to-
use 
KRT14 Mouse 
LL002, Novocastra 
Laboratories 
NA NA 1:25 
KRT20 Mouse Ks20.8, Dako NA NA 
ready-to-
use 
Myosin IIa Rabbit Cell Signaling NA 1:1000 NA 
P-CAD Mouse 
Clone 56, B.D. 
Transduction 
Laboratories 
NA NA 1:75 
p53 Mouse DO-7, Novocastra NA NA 1:200 
PDS5A Rabbit 
Ana Losada, CNIO, 
Madrid (Spain) 
CKKAVPAERQIDLQ 
0.58 
mg/mL 
NA 
PDS5B  Rabbit VSTVNVRRRSAKRERR 
0.65 
mg/mL 
1 μg/mL 
RAD21  Rabbit GDQDQEERRWNKRTQQML 0.5 mg/mL 0.2 μg/mL 
SMC1 Rabbit CEMAKDFVEDDTTHG 1.3 mg/mL 1 μg/mL 
SMC3 Rabbit CDLTKYPDANPNPNEQ 
0.18 
mg/mL 
0.2 μg/mL 
STAG1  Rabbit CEDDSGFGMPMF 1 mg/mL 2 μg/mL 
STAG2 
Rabbit CDPASIMDESVLGVSMF 0.8 mg/mL 0.5 μg/mL 
Mouse 
Clone  J-12, Santa Cruz 
Biotechnology, sc-81852 
NA NA 1:200 
REC8 N’ 
K675 
Rabbit 
José Luis Barbero, CIB, 
Madrid (Spain) 
Last 143 amino acids 
(human) 
1:2000 NA 
SMC1β K976 Rabbit Amino acids 1047-1233 
(human) 
1:1000 NA 
STAG3 K403 Rabbit 
Amino acids 626–757 
(human) 
1:2000 NA 
STAG3 Rabbit 
HPA049106, Sigma 
Prestige 
NA 1:1000 1:200 
UPK3B  Rabbit 
HPA010506 Sigma 
Prestige 
NA NA 1:750 
Vinculin  Mouse Sigma NA 1:10000 NA 
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ARID1A and STAG2 expression was scored according to staining intensity (0-3) and percentage 
of positive cells (0-100%). Histoscores were obtained as the product of both variables. Histoscores 
were used as the input for unsupervised clustering analysis using the heatmap.2 function of the 
gplots package within the R 2.15.1 statistical environment. 
Categorical data reporting was done using number and percentages. Associations between 
STAG2 or ARID1A loss of expression/mutation and the main characteristics of patients were 
determined using the χ2 test, ANOVA, t- test, Mann-Whitney (MW) or Kruskal-Wallis (KW) 
analyses as appropriate. Associations between STAG2/ARID1A expression and other markers were 
examined using the χ2 test. Odds ratio (OR) and 95% confidence interval (95% CI) were used to 
assess the association between STAG2 expression and other categorical variables. Survival data 
was analyzed using Kaplan-Meier plots. The log-rank test was used to assess differences between 
curves. Multivariable analysis was performed using Cox proportional hazard models. Adjusting 
factors included are region, gender, age, T stage, grade, tumor size, number of recurrences, 
number of affected nodes, metastasis, and treatment, depending on the outcome measured. 
10.2. Immunofluorescence  
Normal human bladder tissue sections were processed as for IHC, with the addition of 0.5% 
Triton-X 100 to the 2%BSA blocking solution to improve cell permeabilization. Primary antibodies 
and concentrations used are indicated in Table 3. Sections were washed and incubated in the dark 
for 1 h with fluorescently labeled secondary antibodies: Cy3 anti-rabbit (1:200) (Jackson 
ImmunoResearch Laboratories, Inc.) and Alexa 488 anti-mouse (1:200) (Invitrogen).  Then, 
sections were incubated with DAPI (0.5μg/ml in PBS) for 5 min and mounted with ProLong® Gold 
Antifade Reagent (Life Technologies). 
11. PROTEIN ANALYSIS  
11.1. Protein lysate preparation  
Cells in log-growth phase were lysed in RIPA buffer (10 mM Tris–HCl, pH7.5, 1 mM EDTA, 1% 
Triton X 100, 0.1% SDS, 0.1% Na-deoxycholate, 100 mM NaCl) supplemented with Phosphatase 
Inhibitor Cocktail 3 (Sigma), 0.2 mM orthovanadate, and the cOmplete, Mini, EDTA-free Protease 
Inhibitor cocktail (Roche). Extracts were sonicated in an ultrasonic water bath (30 pulses), and 
centrifuged for 20 min at 15 000 g. Protein concentration was quantified by spectrophotometry 
using the BioRad Protein Assay Solution (BioRad). 
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11.2. SDS-PAGE western blotting 
Protein extracts were denatured and subjected to sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE). A discontinuous 4%-7.5% (for immunodetection of cohesion 
components) or 6% (for ARID1A immunodetection) resolving gel was used to separate 50 μg of 
total protein. Samples were blotted onto nitrocellulose membranes. Membranes were blocked for 
1 h with 5% skim milk (SM) in Tris-buffered saline with Tween (TBS-T) and subsequently washed 
in TBS-T. 
Membranes were incubated for 16 h at 4 ºC with primary antibodies as indicated in Table 3, 
washed, and incubated for an additional 1 h at 25 ºC with HRP-labeled anti-mouse or anti-rabbit 
secondary antibodies (Amersham Biosciences). Reactions were developed with the Amersham™ 
ECL™ western blotting detection reagents (GE Healthcare) and protein bands were visualized on 
Amersham™ Hyperfilm ECL™ (GE Healthcare). Bands of interest were identified by size 
comparison against the Dual Color Precision Plus Protein™ Standard molecular weight marker 
(BioRad). 
12. RT-qPCR 
DNase treatment (DNAfree, Ambion) was performed for 30 min at 37 ºC, and mRNA was 
reverse-transcribed (Taqman Reverse Transcription Reagents kit, Applied Biosystems). SYBR 
GreenER (Invitrogen) was used to perform quantitative PCRs in the 7900H Fast Real Time PCR 
System (Applied Biosystems), using 20ng of cDNA as template. The following primers were used: 
ARID1A CCCCTCAATGACCTCCAGTA (F, forward) and ATCCCTGATGTGCTCACTCC (R, reverse), 
STAG2 AGATACCGTGATGCGATAGC (F) and GGCATCACTATACATCTTCATCC (R), FYN 
AAGGACTCACCGTCTTTGG (F) and GTGTCACTCCTGTTCCTCC (R), TFEB ACCCTGAGAGGGAGTTGGAT 
(F) and CAGGGAGGCTGTGACCTG (R), and CDK6 ACCTACTTCTGAAGTGTTTGAC (F) and 
TCCTGGAAGTATGGGTGAG (R). Product quality and specificity was controlled by performing 
melting curve analyses for each reaction. All reactions were performed in triplicate. Reported 
expression levels are normalized to individual HPRT expression values, detected with the 
following primers: GGCCAGACTTTGTTGGATTTG (F) and TGCGCTCATCTTAGGCTTTGT (R). 
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13. IN VITRO FUNCTIONAL ASSAYS 
13.1. Gene silencing 
HEK293 cells were transfected using the calcium phosphate/HEPES technique (Kingston et al. 
2003). HEK293 cells were co-transfected with 15μg pSPAX, 5μg VSVG, and 15 μg of either 
lentiviral GFP or Sigma Mission expressing either lentiviral shNT (non-targeting control) or the 
corresponding shRNAs targeting STAG2 or ARID1A. Infection was allowed to proceed for 16 h and 
the medium was replaced with fresh complete DMEM. The virus-containing media was collected 
24 h later, filtered (Sartorius stedim 0.45 μm minisart), and used to infect the corresponding UBC 
cells in the presence of 5μg/ml hexadimethrine bromide polybrene (Sigma). Three rounds of 
infection of 24 h, 72 h, and 24 h, respectively, were performed. Infected cells were selected by 
trypsinization followed by exposure to 2μg/ml puromycin (Sigma). Cells were collected or seeded 
for further experiments after 48 h of puromycin selection. 
13.2. Gene overexpression 
The human STAG2 cDNA (b isoform; 1,231 residues) was PCR-amplified from Addgene pEGFP-
STAG2 plasmid (ref. 31972) and subcloned into the pLVX-puro lentiviral vector. HEK293 
transfection, viral supernant production, and subsequent UBC cell infection and selection were 
performed as described above. 
13.3. Colony formation assays 
Puromycin-selected cells (4x103 for ARID1A assays; 8x103 for STAG2 assays) were plated in 
triplicate in 6-well (ARID1A) or 12-well (STAG2) plates. Cells were allowed to grow under standard 
conditions for 4 or 7 days, respectively. After washing with PBS, cells were fixed with methanol at 
-20 ºC for 30 min and incubated with 0.5% crystal violet in 25% methanol for 10 min at room 
temperature. Cells were washed with distilled H2O; growth was measured by eluting crystal violet 
in 10% acetic acid and recording absorbance at 590 nm using a biophotometer (Eppendorf). 
13.4. Metaphase analysis 
Puromycin-selected cells were incubated with colcemid (0.1 µg/ml) for 6 h to arrest them at 
metaphase. After hypotonic treatment with 75 mM KCl at 37 ºC for 15, 25, or 30 min (RT112, 
639V, and UM-UC-11 respectively), cells were fixed in methanol:acetic acid 3:1, dropped from a 
height of >45 cm onto cleaned glass coverslips to obtain chromosome spreads that were stained 
by G-banding using standard methods. At least 50 metaphases per condition were examined; 
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chromosome number and centromeric cohesion defects were counted using an Axioplan II 
Imaging MetaSystem Microsoft and the Ikaros software (Metasystems, GmbH, Altlussheim, 
Germany). The Wilcoxon rank-sum test was used to compare chromosome number between 
control and interfered cells.  
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1. DISCOVERY AND PREVALENCE SCREENS  
1.1. Exome sequencing 
In order to unveil novel genes mutated in UBC, we performed exome sequencing on 17 
tumors and their paired normal leukocyte DNA. At least 70% of the cells in the samples included 
in the screen were tumoral. The study included tumors of different grades and stages but we 
focused on NMIUBC cases because other sequencing initiatives, such as The Cancer Genome Atlas 
Research Network (CGARN) project, are centered on MIUBC tumors (see Supp. Table 1 for patient 
characteristics). Sequencing coverage metrics are shown in Supplementary Table 5. The average 
coverage was 79±16X for tumors and 82±18X for leukocytes, and the fraction of exons covered by 
more than 15 reads was 83.7%. 
1.2. Mutation number or type is not significantly associated with tumor aggressiveness, patient 
smoking status, or age. 
 
 Bioinformatics analysis 
identified 2,927 somatic mutations. 
Individual tumors exhibited a wide 
range of somatic mutations (4-360). 
The average of 169±114 SNVs per 
tumor (Fig. 7a) falls within the range 
found for other adult solid tumors 
(Table 4). Among the identified 
somatic mutations, 1,263 were 
predicted to be relevant (leading to 
non-synonymous changes or 
mapping to intron-exon junctions) 
and 798 were predicted to be 
damaging (combined score >0.8 in a 
0-1 scale). The most frequent 
nucleotide changes were C>T 
transitions and C>G transversions 
(Fig. 7b).  
 
Figure 7. Distribution of the SNVs identified in the 
exome sequencing study. (a) Total number of SNVs per 
tumor. (b) SNVs classified according to type of nucleotide 
substitution for each case. (c) Predicted effect of all SNVs 
identified per tumor. 
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Table 4. Mean somatic mutations identified in other exome sequencing studies. 
Publication 
Patient 
number 
Tissue 
Mean somatic 
mutations per 
patient 
Mean Non-
synonymous 
Calling method 
Hypermutated 
patients 
removed 
Lee et al. 
2012 
32 
Rhabdoid 
cancers 
5 4 
Firehose (MuTect  
+ Genepattern) 
Pugh et al. 
2013 
221 Neuroblastoma 23 18 MuTect  
Biankin et al. 
2012 
99 
Pancreatic 
ductal 
adenocarcinoma 
26 20 SAMtools  
Barbieri et 
al. 2012 
111 Prostate cancer 43 32 
Firehose (MuTect  
+ Genepattern) 
Le Gallo et 
al. 2012 
12 
Endometrial 
tumors 
44 32 MPG algorithm 1 
Quesada et 
al. 2011 
105 
Chronic 
lymphocytic 
leukemia 
45 12 SIDRON  
Banerji et al. 
2012 
103 Breast cancer 48 37 Firehose (Mutect) 
Guichard et 
al. 2012 
24 
Hepatocellular 
carcinoma 
NA 41 NA  
Zang et al. 
2012 
15 
Gastric 
adenocarcinoma 
NA 50 GATK  
Brennan et 
al. 2013 
291 Glioblastoma 74 56 Firehose  
Guo et al. 
2013 
99 
Bladder 
carcinoma 
114 93 VarScan+SAMtools 
This study 17 
Bladder 
carcinoma 
169 74 SAMtools 
Nordentoft 
et al. 2014 
30 
Bladder 
carcinoma 
195 79 GATK (MuTect)  
Imielinski et 
al. 2012 
159 
Lung 
adenocarcinoma 
216 (median) 167 (median) 
Firehose (MuTect  
+ Genepattern) 
CGARN 
2014a 
130 
Bladder 
carcinoma 
302 NA Firehose (MuTect) 
CGARN 
2014b 
230 
Lung 
adenocarcinoma 
306 237 Firehose (MuTect) 
Kumar et al. 
2011 
20 Prostate cancer 362 215 SAMtools 3 
Thompson 
et al. 2012 
33 Breast cancer NA 284 GATK  
CGARN et al. 
2012 
224 
Colorectal 
carcinoma 
402 310 MuTect  
Seshagiri et 
al. 2012 
70 
Colorectal 
carcinoma 
921 350 GATK 2 
 
We used Sanger sequencing to verify a fraction of the mutations called as somatic. We 
sequenced a total of 226 amplicons from 13 samples (selected according to availability of 
material) and we verified 219 of them. Of those, 214 (94.7%) were confirmed to be somatic, 
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supporting the validity of the bioinformatic pipeline used. Supplementary Table 6 shows details of 
the mutations verified by DNA sequencing. 
The non-synonymous:synonymous (NS:S) ratio was <1 in 15/17 (88%) of the samples (Fig.7c, 
8a). The NS:S ratio was not significantly different between non-aggressive vs. aggressive tumors 
(P=0.87) or non-smokers vs. smokers (P=1). We observed a tendency for patients diagnosed at a 
later age to exhibit more synonymous mutations but the differences were not statistically 
significant (P=0.11) (Fig. 8b). This could be due to the relatively low number of tumors sequenced.  
 
 
The number of SNVs, indels, transitions, transversions, and mutation subtypes (synonymous; 
non-synonymous, non-damaging, and damaging) was not significantly different in non-aggressive 
vs. aggressive tumors (Fig. 9a). The same was true when comparing those variables between non-
smoking and smoking patients, although smokers exhibited more damaging mutations than non-
Figure 8. Comparison of non-synonymous (NS) and synonymous (S) variants in the exome 
sequencing analysis. (a) Log2 values for each tumor NS:S ratios. (b) NS:S comparison 
according to tumor aggressiveness (P=0.87), smoking habits (P=1), and patient age (P=0.11). 
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smokers (Fig. 9b). Similarly, patients diagnosed at >60 years old exhibited more alterations, 
regardless of mutation type, but this difference was not statistically significant (Fig. 9c).   
 
 
1.3. HaloPlex targeted resequencing 
To extend the analysis and identify genes that are frequently mutated in bladder cancer, we 
selected 110 genes either found to be recurrently mutated in the exome sequencing study or 
belonging to the same pathways as a recurrently mutated gene (Supp. Table 4). We used the 
HaloPlex Target Enrichment System followed by multiplex sequencing on 60 additional tumors, 51 
of which were NMI (see Supp. Table 1 for patient characteristics, and Supp. Table 7 for depth of 
Figure 9. Number of mutations identified classified by variant type. (a) According to tumor 
aggressiveness. (b) According to smoking status. (c) According to patient age. None of the 
comparisons was statistically significant. *P=0.09. 
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coverage information). Bioinformatics analysis identified 260 somatic variants. Of them, 200 were 
predicted to be relevant and 143 predicted to be damaging (see Materials and methods). Sanger 
sequencing verified 73/95 SNVs analyzed (76.13%); 72 (98.6%) of the verified alterations were 
found to be somatic. 
1.4. The mutational landscape of UBC in this study 
Using the variants called by the discovery and prevalence screens, we compiled a list of genes 
found to harbor relevant mutations in ≥3 tumors. We used microarray expression data from 43 
tumors covering the UBC spectrum to select only genes found to be expressed in >30% of UBC. 
The results are shown in Figure 10 and summarized in Table 5. As expected, well-established 
players in bladder tumor development, such as FGFR3, PIK3CA, RB1, and TP53, were among the 
recurrently mutated genes. 
 
 
 
 
 
1.5. The chromatin remodeling, apoptosis, DNA repair and DNA damage response, and cell cycle 
pathways are frequently altered in UBC 
To gain an understanding of the biological processes altered in UBC, we classified all relevant 
SNVs identified in the exome sequencing study according to their damaging potential and 
recurrence (see Materials and methods) and performed pathway analysis according to KEGG 
pathways and GO (Gene Ontology biological process) components. We found the chromatin 
modification, DNA repair and DNA damage response, apoptosis, and cell cycle pathways to be 
recurrently altered in UBC (false discovery rate (FDR) < 0.1). As shown in Supplementary Table 8, 
all pathways were significantly altered when analyzing only SNVs predicted to be damaging, and 
the chromatin modification, apoptosis, and DNA repair and DNA damage response pathways, but 
Figure 10. Cases harboring mutations in recurrently altered genes expressed in >30% of UBC in 
both the exome sequencing and the HaloPlex targeted resequencing. Each dark blue square 
represents one mutation. 22/77 (28.6%) of cases did not exhibit any mutations in these loci. For 
tumor aggressiveness, non-aggressive cases are depicted in blue, and aggressive tumors in red.
For smoking status, non-smokers are depicted in blue and smokers in red. Cases where 
information was not available are depicted in white. 
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not the cell cycle pathway, were still significantly altered when taking into account only recurrent 
SNVs, as well as recurrent mutations predicted to be damaging. 
Table 5. Expressed genes frequently mutated in UBC. *P-values calculated based on mutations 
identified in the exome sequencing screen. **P-values calculated comparing non-aggressive and 
aggressive tumors. NA: Not available. 
GENE 
Number of 
mutations in 
exome 
screen 
(n=17) 
P- 
value* 
Number of 
mutations 
in 
prevalence 
screen 
(n=60) 
Number of 
mutations 
in all 
tumors 
(n=77) 
Number of 
non-
aggressive 
mutant 
cases 
(n=29) 
Number of 
aggresssive 
mutant 
cases (n=47) 
P-value** 
ARID1A 7 0.0001 3 10 3 7 0.732 
STAG2 3 0.019 9 12 6 5 0.315 
KDM6A 4 0.019 6 10 3 7 0.732 
PDZD2 3 0.019 0 3 0 2 0.521 
MYCBP2 3 0.061 2 5 2 2 0.999 
LPHN3 3 0.096 0 3 0 2 0.521 
CREBBP 2 0.098 9 11 4 7 1 
EP300 2 0.098 5 7 3 4 1 
ATM 3 0.138 6 9 4 4 0.702 
TP53 3 0.2117 8 11 2 9 0.188 
RREB1 3 0.237 0 3 1 1 1 
PIK3CA 6 0.239 4 10 5 4 0.289 
WHSC1L1 2 0.241 1 3 1 2 1 
MYO5B 3 0.430 0 3 0 2 0.521 
MLL2 2 0.636 13 15 6 5 0.315 
FGFR3 2 0.659 12 14 10 4 0.011 
TEX15 3 0.778 0 3 0 2 0.521 
BRAF 1 NA 6 7 2 5 0.701 
ERCC2 0 NA 8 8 5 1 0.040 
MAPK8IP3 1 NA 4 5 3 2 0.363 
MLL 1 NA 5 6 3 2 0.363 
NUP93 1 NA 4 5 1 3 1 
STAG1 0 NA 5 5 0 3 0.282 
RB1 1 NA 3 4 1 3 1 
FANCA 0 NA 4 4 0 3 0.282 
MLL3 1 NA 4 5 2 3 1 
NOTCH1 0 NA 4 4 0 3 0.282 
ASXL2 3 NA 1 4 1 1 1 
 
Within the chromatin remodeling pathway, we found mutations in genes not previously 
identified as being mutated in bladder cancer (ASXL2, BPTF, and MLL2), as well as in genes 
recently reported to be altered in UBC (ARID1A, CREBBP, EP300, KDM6, MLL, and MLL3)  (Gui et 
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al. 2011). Interestingly, we also found mutations in several genes involved in DNA repair, including 
ATM, ERCC2, and FANCA; this group of genes had not been previously reported as being 
somatically mutated in bladder cancer. As of the cell cycle pathway, we identified mutations in 
several components of the cohesin complex, including STAG1, SMC1A, SMC1β, and STAG2, 
although only the latter was mutated in more than 3 cases.  
2. ARID1A  
2.1. ARID1A truncating mutations are frequent in aggressive UBC 
The exome discovery and HaloPlex prevalence screens detected 10 mutations in ARID1A 
(Table 6). To expand these findings, we performed targeted exon resequencing of exons 2-20 of 
ARID1A in 48 additional primary tumors and in 5 UBC cell lines. We also included 1 tumor that had 
been analyzed by exome sequencing and 3 cases that were part of the HaloPlex prevalence screen 
(total n=52). Details on the average depth of reads per exon for the ARID1A sequencing study are 
shown in Table 7. Figure 11 shows sequencing breadth and depth for individual tumor and cell 
line samples.  
Table 6. Relevant mutations in ARID1A identified in the discovery and prevalence screens. 
1Identified in the exome sequencing study. 2Identified in the HaloPlex prevalence screen. 
3Identified in the ARID1A mutational analysis. 
 
Sample  Stage/Grade Amino acid substitution Affected exon 
064 T1G2 1,2P459A 3 
116 T1G2 1L1014 frameshift 11 
188 T1G3 1,2S614* 4 
310 T1G3 1K1745 frameshift 20 
313 T1G3 1G1317 frameshift 16 
343 T1G3 1Q393* 2 
Esp66 T1G3 1,3Q403* 2 
416 TaG1 2G660V 5 
147 TaG1 2L1076I 12 
Esp21 TaG1 2,3N2066D 20 
Esp69 T3G3 3S769* 7 
800 T1G3 3C2052* 20 
803 T1G3 
3S571L 3 
3S614* 4 
559 T1G3 3Q393* 2 
VMCUB-3 Cell line 
3E1733* 
20 
3D1738N 
3Q2210H 
3L1922L 
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Considering the alterations present in at least 10% of the reads for the mutated nucleotide 
position, we found 6 tumors and one cell line harboring a total of 11 different SNVs (Table 6). We 
did not find any correlation between sequencing depth and the frequency at which variant alleles 
were detected (Figure 12a). All of the mutations identified in the ARID1A mutational study were 
independently confirmed with Sanger sequencing (Figure 13). Additionally, we found 6 mutations 
predicted to be damaging at a frequency <10% that were not validated by Sanger sequencing, 
possibly due to the lower sensitivity of this technique (Figure 12b). 
Table 7. Summary of reads per exon in the ARID1A resequencing study. Exon starting and ending 
positions are shown, along with the exon length (base pairs) and the average sequencing depth.  
ARID1A exon Start End Length Average depth 
E1 1001 2510 1509 0 
E2 34621 34833 212 9587 
E3 36122 36574 452 18256 
E4 37646 37762 116 6887 
E5 65826 66066 240 8571 
E6 66354 66443 89 8256 
E7 67122 67289 167 6007 
E8 67943 68255 312 10586 
E9 71191 71336 145 10867 
E10 71427 71536 109 9603 
E11 72760 72969 209 11690 
E12 76089 76296 207 9029 
E13 77470 77602 132 5867 
E14 77782 77957 175 8826 
E15 78316 78466 150 4283 
E16 78550 78687 137 3683 
E17 78772 78868 96 11134 
E18 79950 80190 240 16486 
E19 80547 80677 130 17715 
E20 83993 87080 3087 96890 
 
Integrating the results from the targeted exon resequencing screen and those from the exome 
discovery and HaloPlex prevalence screens, we identified a total of 15 damaging mutations in 
14/125 tumors (11.2%) (Table 6). There were 7 nonsense, 5 missense, and 3 frameshift mutations. 
One tumor presented 2 mutations, 1 truncating and 1 missense. All 10 tumors harboring 
nonsense (n=7) or frameshift (n=3) mutations belonged to the aggressive category. Three non-
aggressive tumors presented 1 missense mutation each, and 2 aggressive tumors also harbored 
missense SNVs, although 1 of them also exhibited a mutation leading to a premature stop codon  
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(Table 6). Overall, we found truncating mutations in 0/43 non-aggressive and 7/82 aggressive 
tumors (P = 0.048).  
 
       
An analysis of the ARID1A mutations reported by 7 independent studies in the course of this 
work in UBC revealed 119 relevant mutations in 556 tumors published (21.4% overall mutation 
rate) (Gui et al. 2011; Guo et al. 2013; Cazier et al. 2014; CGARN 2014a; Kim et al. 2014; 
Nordentoft et al. 2014; Ross et al. 2014). Considering together the information from this study 
and all published work, UBC harbors ARID1A relevant alterations in 14.4% of NMI and 23.6% of MI 
cases (P=0.02) (Table 8).  
Figure 11. Data metrics for ARID1A resequencing. (a) Average sequencing breadth (reads per 
exon) per case. (b) Average sequencing depth (reads per exon) per case. 
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Figure 13. ARID1A mutations in UBC. All mutations identified at a frequency > 10% were 
verified by Sanger sequencing of independent PCR products. Both the nucleotide change and 
the predicted effect on the amino acid sequence are shown. * denotes a truncating 
mutation. (a) Mutations found in three different tumors and their corresponding normal 
leukocyte DNA counterparts. (b) Mutations found in four additional tumors. (c) Three 
different mutations were identified in the VMCUB-3 UBC cell line. 
Figure 12. SNV frequency and type found in the ARID1A targeted exon resequencing study. 
(a) SNV frequency vs. sequencing depth. (b) Variant location and SIFT-predicted effect for 
alterations detected at high (top) and low (bottom) frequencies. 
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Table 8.  ARID1A mutations in all UBC studies. 
Study Study type 
Total cases 
(mutated) 
 NMI-LR cases 
(mutated) 
 NMI-HR cases 
(mutated)  
 MI cases 
(mutated) 
This study 
WES + 
targeted 
125 (14) 58 (5) 50 (8) 15 (1) 
Gui et al. 2011 + 
Guo et al. 2013  
WES + 
targeted 
105 (16) 36 (4) 3 (1) 66 (11) 
CGARN 2014a WES 130 (39) 0 (0) 0 (0) 130 (39) 
Nordentoft et al. 
2014 
WES 38 (10) 22 (8) 9 (0) 7 (2) 
Cazier et al. 2014 WGS  14 (2) 4 (0) 5 (1) 5 (1) 
Ross et al. 2014 targeted 35 (7) 0 (0) 0 (0) 35 (7) 
Kim et al. 2014 targeted 109 (31) NA NA NA 
 
Total 
556 (119) = 
21.4% 
120 (17) = 
14.2% 
67 (10) = 
14.9% 
258 (61) = 
23.6% 
Regarding cell lines, RT112, MGH-U3, UM-UC-3, and UM-UC-17 were found to be wild type for 
ARID1A. However, VM-CUB3 cells harbored three ARID1A mutations: 1 truncating, 2 missense, 
and 1 silent mutation (Fig. 13, Table 6). RT112 cells are TP53 wild type (Rieger et al. 1995), and 
express high levels of wild type FGFR3, all features reminiscent of low grade NMIUBC. On the 
other hand, VMCUB-3 cells harbor mutant TP53 (Rieger et al. 1995).  
2.2. Loss of ARID1A protein expression is associated with an aggressive phenotype 
Truncating mutations in ARID1A have been shown to associate with loss of protein expression 
in gynecological malignancies (Wiegan et al. 2010; Guan et al. 2011a). We assessed ARID1A 
protein and mRNA levels in a panel of UBC cell lines (Fig 14a). We found several cell lines, 
including VM-CUB3, that did not express the protein, but there was not a consistent correlation 
between mRNA and protein levels.  
We also found loss of ARID1A expression by IHC in a tumor from the exome screen harboring 
a truncating mutation (Figure 13a, 14b). Taking this into account, we performed an IHC analysis in 
a panel of 84 tumors, using ARID1A loss of expression as a surrogate for pathogenic mutations. 
ARID1A expression was lost significantly more often in MI tumors (>T2) (average histoscore 83.1 + 
91.1) than in high risk NMI (TaG3, T1G2, T1G3) (155.8 + 110.1) and low risk NMI (TaG1, TaG2) 
(206.4 + 80.2) tumors (ANOVA P= 9.9x10-6; KW P=3x10-5) (Supp. Table 9, Fig. 15a, top panel). 
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To place these findings in the context of the known pathways of UBC tumor progression, we 
compared ARID1A and FGFR3 mutational status in 50 tumors for which both data were available.  
 
 
 
The 5 tumors with truncating ARID1A mutations were all wild type for FGFR3 (p = 0.056, 
Fisher’s exact test). This suggests that the two genes might be involved in different genetic 
pathways. However, the low number of tumors included in the analysis did not allow us to draw 
definite conclusions. Therefore, we assessed FGFR3 IHC expression, finding that histoscores were 
higher in low risk NMI (73.5 + 67.2) than in MI tumors (47.8 + 75.5) (ANOVA P= 0.038, KW P= 
0.026) and significantly correlated with ARID1A expression (Spearman correlation P= 0.03) (Supp. 
Table 9, Fig. 15a middle panel). This indicates that alterations in ARID1A and FGFR3 occur 
independently and tend to be mutually exclusive in MIUBC. To further explore the relationship 
between ARID1A and other UBC markers, we used IHC as a surrogate for the mutational status of 
TP53, another well-established molecular player in the development of UBC. The majority of TP53 
mutations result in its nuclear accumulation. Accordingly, IHC scores for nuclear p53 were higher 
as tumor stage and grade increased (16.2+17.5 vs. 82.5+126.1 and 133.8+128.2)   (ANOVA P= 
0.05, KW P= 0.32) but no significant correlation was found when comparing p53 scores with 
ARID1A expression (1 vs. -0.1, P =0.30) (Supp. Table 9, Fig. 15a bottom panel).  
 
Figure 14. ARID1A expression in UBC. (a) ARID1A protein (top) and mRNA (bottom) 
expression in a panel of UBC cell lines. (b) An aggressive tumor with a truncating mutation in 
ARID1A losses protein expression (top), as opposed to a non-aggressive case with a wild type 
ARID1A sequence (bottom). The red arrowheads indicate tumor cells with loss of ARID1A; the 
black arrowheads point to stromal cells with positive ARID1A staining. 
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We next set out to determine whether ARID1A, FGFR3, and TP53 are differentially expressed 
at the RNA level in the low risk NMI, high risk NMI, and MI UBC tumor subgroups. We analyzed 2 
public expression datasets (Dyrskjot et al. 2003, Sjodahl et al. 2012). In both series, ARID1A, TP53, 
and FGFR3 mRNA levels were significantly lower in MI tumors (Fig 15 b). This further supports our 
finding that FGFR3 mutations are less frequent in aggressive tumors and associate with FGFR3 
overexpression at the mRNA level, whereas TP53 mutations, more common in aggressive cases, 
associate with decreased mRNA expression. 
2.3. ARID1A loss is associated with worse patient outcome 
To explore whether ARID1A expression is associated with patient outcome, we performed 
Kaplan-Meier analysis on recurrence, progression, and mortality data (Fig. 16, Supp. Table 10). 
Patients whose tumors had a IHC score <180 presented a significantly lower rate of tumor  
Figure 15. Loss of ARID1A protein expression associates with aggressive UBC. Tumors were 
classified into low grade NMI (TaG1, TaG2), high grade NMI (TaG3, T1G3), and MI (>T2). (a) 
ARID1A staining is significantly lower in more aggressive tumors. The same pattern is 
observed for FGFR3, whereas p53 immunohistochemical score is higher in more advanced, 
aggressive tumors. (b) Differential expression of ARID1A, FGFR3 and TP53 mRNA in two 
independent UBC microarray studies. Levels of the three genes are significantly lower in 
more aggressive tumors. *indicates a False Discovery Rate-adjusted P-value <0.05. 
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Figure 16. Low ARID1A protein levels associate with a poor outcome. ARID1A IHC score was 
calculated for 84 patients. The significantly lower risk of recurrence (left) and the increased 
risk of progression (right) are indicative of a more aggressive clinical course. 
Figure 17. Unsupervised clustering of ARID1A, FGFR3, KRT5/6, KRT14, and KRT20 levels. IHC 
scores are showed in a green (lowest)-red (highest) color code. Bars below the dendogram 
include information about tumor stage and grade (tones of blue) and FGFR3 mutational 
status (grey/black). White squares indicate information is not available. 
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recurrence (P=0.011) but exhibited a tendency to show an increased rate of tumor progression 
(P=0.112). This suggests that loss of ARID1A is associated with poor prognosis but further studies 
including a larger number of samples that allows for multivariable or stratified analyses will be 
required to adequately assess this relationship.  
2.4. Association between ARID1A loss and differentiation markers 
In UBC, altered differentiation has been shown to identify aggressive tumors (Volkmer 2012). 
To assess the relationship between ARID1A protein levels and urothelial differentiation, we 
performed unsupervised analysis of IHC scores for ARID1A, FGFR3 and KRT5/6, KRT14, and KRT20 
(Fig. 17). This analysis confirmed that the most aggressive tumors (>T2) expressing low levels of 
ARID1A tend to present low levels of wild type FGFR3, as well as low KRT20. A subset of those 
tumors also expresses high levels of KRT5/6, and KRT14, characteristic of basal urothelial cells. 
 
 
 
 
Figure 18. Effects of knocking down ARID1A in the RT112, VMCUB-3, and 253J UBC cell lines. 
(a) ARID1A knockdown with three different shRNAs was efficient at the protein (upper row) 
and mRNA (bottom row) levels. (b) ARID1A knockdown consistently and significantly 
associates with reduced colony formation in wild type RT112 and 253J but not in mutant 
VMCUB-3. Growth was quantified in triplicate experiments and is expressed in percentage +
Standard Error of the Mean. The bottom row shows representative morphological changes 
in cell lines interfered with control or ARID1A-targeting shRNAs. 
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2.5. ARID1A knockdown reduces cell viability in vitro 
To address whether ARID1A plays a role in the control of cell proliferation, we knocked it 
down in wild type ARID1A-expressing UBC cells. Out of the 12 UBC lines assessed, 6 lacked 
detectable levels of protein by western blotting (Fig. 14a). In both RT112 and 253J lines, knocking 
down ARID1A with 3 different lentiviral shRNA constructs led to a significant reduction in colony 
formation ability, as well as to a flatter morphology, in 3 independent experiments (Fig. 18b). 
However, mutant VMCUB-3 cells did not exhibit consistent changes in colony formation ability 
upon ARID1A knockdown. The dramatic reduction in cell viability upon ARID1A knockdown did not 
permit performance of additional functional studies to assess cell differentiation, invasion or 
migration. 
3. STAG2 
3.1. Expression of several components of the cohesin complex is frequently lost in UBC 
Given the fact that we found mutations in genes coding for several cohesin components, we 
analyzed IHC expression of STAG1, STAG2, SMC1, SMC3, PDS5B, and RAD21 in normal urothelium, 
finding all cell layers express these proteins (Fig. 19b). PDS5A was not analyzed due to the 
inadequate quality of the available antibodies. To get an overview of the expression of cohesin 
components in UBC, we used IHC to analyze 91 samples representative of the disease spectrum. 
We defined loss of expression as a histoscore <50 and we only considered cases where stromal 
cells exhibited clear positive staining. We observed a small fraction of tumors exhibiting loss of 
expression of all cohesin components assayed (4.3% for STAG1, 4.4% for SMC1, 5.2% for PDS5B, 
5.4% for RAD21, and 5.7% for SMC3) (Fig. 19c). Interestingly, STAG2 expression was lost in 33.7% 
of cases. Unsupervised analysis of IHC scores revealed that most tumors harboring loss of 
expression of other cohesin subunits also exhibited decreased STAG2 expression (Fig. 20).  
3.2. Meiotic cohesins are expressed in UBC 
The exome screen described earlier also identified two mutations in SMC1β, a component 
that replaces SMC1A in meiotic cohesin. We found that SMC1β is expressed at the RNA level in 
54% of UBCs. In addition, the transcripts coding for the meiotic cohesin components STAG3 
(which replaces STAG1/2) and REC8 (taking the place of RAD21) were also expressed in 84% and 
100% of UBCs respectively, as determined by Affymetrix microarray expression analyses (Fig. 21a, 
left panel). To explore the potential interest of these findings, we searched for antibodies of 
adequate specificity to assess expression in a panel of UBC cell lines. However, all the available 
antibodies tested failed a rigorous specificity test (Fig. 21a, right panel). A commercial antibody 
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detecting STAG3 has been reported to be specific using immunoblotting assays and a band with 
the mobility expected for STAG3 was found in lysates of 8 UBC cell lines (Fig. 21b). To further 
confirm the specificity of the antibodies for IHC assays, we used testis from STAG3 wild-type and 
KO mice (kindly provided by Dr. Alberto Pendás) and found non-specific, non-nuclear staining in 
both (Fig. 21c). This prevented us from further pursuing his line of inquiry.    
 
 
Figure 19. Expression of mitotic cohesin components in UBC cell lines, normal urothelium and 
UBC tumors. (a) Immunoblotting of different cohesin components in 33 different UBC cell lines. 
(b) Immunohistochemical expression of cohesins is detected in all layers of normal urothelium. 
(c) Immunohistochemical expression of cohesins in 91 UBC cases. Tumors were classified into 
low grade NMI (TaG1, TaG2), high grade NMI (TaG3, T1G3), and MI (>T2). The percentage of 
tumors expressing high levels of STAG2 is represented in dark grey, those with reduced levels in 
light grey, and tumors with complete loss of expression are portrayed in white. 
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3.3. STAG2 mutations and loss of expression are frequent events in UBC 
Given the high frequency of loss of STAG2 expression and the fact that we found frequent 
mutations in our discovery and prevalence screens, we focused on STAG2. Overall, we identified 3 
mutations predicted to be damaging in our exome sequencing study as well as 9 additional 
mutations predicted to be damaging in the HaloPlex resequencing analysis for a total of 12 
damaging mutations in 77 tumors analyzed (15.6%) (Table 9). Of those, 5 were nonsense, 4 fell 
within intron-exon junctions, 2 were missense, and 1 was an indel. Mutations were distributed 
along the whole STAG2 gene (Table 9, Fig. 22). We verified 9/11 mutations by DNA sequencing 
(Fig. 23). Damaging mutations were found both in non-aggressive (6/29, 20.7%) and in aggressive 
(5/47, 10.6%) tumors. A review of the reports concurrent and from other UBC sequencing studies 
Figure 20. Non-hierarchical clustering of levels of six cohesion components. IHC scores are 
showed in a green (lowest)-red (highest) color code. Bars below the dendogram include 
information about prognosis (pistachio/bourbon), tumor stage and grade (tones of blue), and 
FGFR3 mutational status (grey/black). White squares indicate information is not available. 
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 (Gui et al. 2011; Guo et al. 2013; Solomon et al. 2013; Cazier et al. 2014; CGARN 2014a; Kim et al. 
2014; Nordentoft 2014; Taylor et al. 2014)  (Table 10, Fig. 22). In total, 17.3% of analyzed cases 
harbor a relevant STAG2 mutation. Considering those cases for which adequate clinical and 
pathological information is available, STAG2 relevant mutations are found in 29.3% of non-
aggressive and 15.7% of aggressive cases (P< 0.0001) (Table 10).  
 
 
Figure 21. Meiotic cohesins are expressed in UBC. (a) The three meiotic-specific members of 
the cohesin complex are expressed in >50% of UBC. Homemade antibodies against SMC1β, 
STAG3, and REC8 (kindly provided by Dr. José Luis Barbero) showed multiple banding 
suggesting unspecific staining. (b) A commercial antibody targeting STAG3 shows mild to strong 
STAG3 expression in several UBC cell lines. (c) Immunohistochemical staining of testis from 
STAG3 wild type and KO mice. 
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Table 9. Relevant mutations in STAG2 identified in this study. * indicates a mutation introducing 
a premature stop codon. 
Sample  Stage/Grade 
Amino acid 
substitution 
Affected 
exon 
Study 
88 TaG1 Exon Junction  7/8 Haloplex  
193 T2G3 Exon Junction  24/25 Exome  
274 T1G2 R216*  8 Exome/Haloplex  
281 TaG2 R614*  20 Haloplex  
311 TaG3 W485*  16 Haloplex  
331 TaG1 Exon Junction  21/22 Exome  
414 T1G3 D1253H 34 Haloplex 
418 TaG1 Q573*  18 Exome  
427 TaG1 Exon Junction  14/15 Haloplex  
451 TaG2 R216*  8 Exome/Haloplex  
Esp27  T2G3 D898N  27 Haloplex  
 
 
 
 
 
 
Solomon et al. have reported, in non-epithelial tumors, that truncating mutations and 
deletions in STAG2 lead to loss of protein expression (2011). We assessed STAG2 expression by 
IHC on 41 tumors for which mutational status had been analyzed and tissue sections were 
available. Out of 7 tumors with damaging mutations, 6 had lost expression, and 3/34 cases 
harboring wild-type STAG2 did not express the protein either (P=0.0001) (Fig. 23, Table 10). 
 
 
Figure 22. Summary of type and distribution of STAG2 nonsynonymous somatic mutations 
found in our discovery and prevalence screens. 
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Table 10.  STAG2 mutations in all UBC studies. 
Study Study type 
Total cases 
(mutated) 
 NMI-LR cases 
(mutated) 
 NMI-HR cases 
(mutated)  
 MI cases 
(mutated) 
This study WES + targeted 77 (11) 34(7) 33 (2) 9 (2) 
Gui et al. 2011 + 
Guo et al. 2013  
WES + targeted 155 (16) 36(8) 3 (0) 66 (4) 
CGARN 2014a WES 130 (14) 0 (0) 0 (0) 130 (14) 
Solomon et al. 
2013 
targeted 111 (23) 24 (8) 29 (7) 58 (8) 
Taylor et al. 2014 targeted 306 (78) 127 (43) 99 (26) 80 (9) 
Nordentoft et al. 
2014 
WES 38 (7) NA NA NA 
Cazier et al. 2014 WGS + targeted 49 (4) 7(2) 2 (1) 5 (1) 
Kim et al. 2014 targeted 109 (16) NA NA NA 
 
Total 
975 (169) = 
17.3% 
228 (68) = 
29.8% 
166 (36) = 
21.7% 
348 (38) = 
10.9% 
 
 
 
 
 
Figure 23. STAG2 mutations and expression. (a) Sanger sequencing verification of a truncating 
(top) and exon-junction (bottom) mutation. T= tumor DNA, B= normal blood DNA. (b) 
Immunohistochemical analysis of STAG2 expression in UBCs of different stage and grade. Left 
column: low risk NMI tumors with and without loss of expression. T= tumor, S= stroma, NU= 
normal urothelium; the normal urothelium expresses STAG2. Middle column: high risk NMI tumors 
with and without loss of expression. Right column: MI tumors with and without loss of expression. 
STAG2 expression was found in the stroma of all tumor samples.  
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To determine whether other genetic mechanisms can lead to STAG2 inactivation in bladder 
cancer, we used data from SNP arrays corresponding to tumors included in our screens. STAG2 is 
the most frequently lost cohesin gene at the genetic level (Fig. 24a). We further analyzed genomic 
information from 18 males with UBC from whom we had available tumor tissue samples, finding 1 
case (5%) in which a focal chromosome X genomic loss was responsible for loss of STAG2 
expression (Fig. 24b). 
 
 
 
 
To confirm and extend these observations, we used IHC to analyze STAG2 expression in a 
panel of 671 incident UBC covering the full disease spectrum (Supp. Table 3). We observed loss of 
STAG2 expression in 197/671 tumors (29.3%) (Fig. 23). In a small fraction of cases (3%) STAG2 
expression was focally lost, indicating that inactivation of STAG2 in these cases might be an early, 
but not initiating, event in carcinogenesis. Additionally, 11% of tumors exhibited STAG2 
Figure 24. Genomic STAG2 losses in males contribute to loss of protein expression in UBC. (a) 
Frequency of copy number alterations (CAN) in cohesin components in UBC. The bars represent 
percentage of tumors exhibiting losses (red), gains (green) or no alterations (grey) at the given 
chromosomal locations. (b) A male patient without genomic changes in the X chromosome 
expresses STAG2 (upper panel) but another one with a focal loss at the STAG2 locus losses 
expression at the protein level (lower panel).  
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cytoplasmic localization (Fig. 25), suggesting that some alterations might hinder nuclear import of 
the protein or make it more prone to nuclear export. 
 
3.4. Loss of STAG2 expression associates preferentially with non-aggressive characteristics 
We analyzed the association between STAG2 expression and patient/tumor characteristics. 
STAG2 loss significantly associates with low stage (P=5.7x10-15), low grade (P=1.96x10-15), 
multicentricity (P=0.011), smaller tumor size (P=0.002), and lack of muscle invasion (P=2.71x10-8) 
(Supp. Table 11, Fig. 26). We did not find any significant association between STAG2 loss and 
patient gender, age, geographical origin, or number of tumors (Supp. Table 11). 
We then explored the relationship between STAG2 loss and other alterations characteristic of 
the NMI pathway of UBC development. In NMI tumors, loss of STAG2 was significantly associated 
with mutant FGFR3 status (42.7% mutant vs. 27.2% wild type, P=0.001), lack of p53 
overexpression (P=0.003), and a low Ki67 proliferative index (P=0.002) (Table 11).  
 
 
 
Figure 26. Loss of STAG2 expression significantly associates with features of low aggressivity.
STAG2 expression is lost more frequently in tumors presenting single rather than multicentric 
locations (left panel), in smaller tumors (middle panel) and in those of non-aggressive stages 
and grades (right panel).  
 
Figure 25. Abnormal 
STAG2 expression in 
UBC. (a) A non-
aggressive tumor 
exhibits heterogeneous 
STAG2 expression. (b) A 
non-aggressive tumor 
shows cytoplasmic but 
not nuclear STAG2 
expression. Scale bar: 
200 µm. 
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Table 11. Association between STAG2 expression and other markers in NMIUBC. 
  
N 
STAG2 <50 STAG2 > 50 
P-value * OR (95% CI) 
  N(%) N(%) 
FGFR3 WT 169 46 (35.94) 123 (54.19) 0.001 
0.47 
(0.3-0.74) 
FGFR3 Mut 186 82 (64.06) 104 (45.81) 
  
FGFR3 <30 ** 224 71 (43.29) 153 (58.17) 0.004 
0.55 
(0.37-0.81) 
FGFR3 >30 203 93 (56.71) 110 (41.83) 
  
Ki67 <15 $ 361 150 (93.75) 211 (82.75) 0.002 
3.13 
(1.53-6.41) 
Ki67 >15 54 10 (6.25) 44 (17.25) 
  
p53 <100 ** 354 145 (89.51) 209 (77.12) 0.002 
2.53 
(1.42-4.51) 
p53 >100 79 17 (10.49) 62 (22.88)     
* P-value of the chi-square test  
   ** Histoscore; range 0-300 
   $ Percentage positive cells 
    
Table 12. Association between STAG2 expression and other markers in low risk NMIUBC. 
  
N 
STAG2 <50 STAG2 > 50 
P-value * OR (95% CI) 
  N(%) N(%) 
FGFR3 WT 86 27 (27.55) 59 (40.14) 0.059 
0.57  
(0.33-0.99) 
FGFR3 Mut 159 71 (72.45) 88 (59.86) 
  
FGFR3 <30 ** 138 50 (37.88) 88 (47.06) 0.13 
0.69  
(0.44-1.08) 
FGFR3 >30 181 82 (62.12) 99 (52.94) 
  
Ki67 <15 $ 286 125 (94.7) 161 (88.95) 0.11 
2.22  
(0.91-5.41) 
Ki67 >15 27 7 (5.3) 20 (11.05) 
  
p53 <100 ** 292 126 (96.92) 166 (88.3) 0.011 
4.17  
(1.4-12.42) 
p53 >100 26 4 (3.08) 22 (11.7)     
* P-value of the chi-square test  
   
** Histoscore; range 0-300 
    
$ Percentage positive cells 
    
 
Assessing exclusively the low-risk NMIUBC (non-aggressive) subgroup, STAG2 loss showed a 
borderline association with mutant FGFR3 (P=0.059) and low p53 expression (P=0.011) (Table 12), 
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whereas in high risk NMIUBC, STAG2 loss of expression was significantly associated with increased 
FGFR3 expression (P=0.037), and a low Ki67 proliferative index (P=0.049) (Table 13). However, 
neither NMI nor MI tumors showed associations between STAG2 loss and p53 expression (Tables 
13, 14). 
Table 13. Association between STAG2 expression and other markers in high risk NMIUBC. 
  
N 
STAG2 <50 STAG2 > 50 
P-value * OR (95% CI) 
  N(%) N(%) 
FGFR3 WT 83 19 (63.33) 64 (80) 0.12 
0.43 
(0.17-1.09) 
FGFR3 Mut 27 11 (36.67) 16 (20) 
  
FGFR3 <30 ** 86 21 (65.62) 65 (85.53) 0.037 
0.32 
(0.12-0.85) 
FGFR3 >30 22 11 (34.38) 11 (14.47) 
  
Ki67 <15 $ 75 25 (89.29) 50 (67.57) 0.049 
4 
(1.1-14.57) 
Ki67 >15 27 3 (10.71) 24 (32.43) 
  
p53 <100 ** 62 19 (59.38) 43 (51.81) 0.6 
1.36 
(0.59-3.11) 
p53 >100 53 13 (40.62) 40 (48.19)     
* P-value of the chi-square test  
   ** Histoscore; range 0-300 
   $ Percentage positive cells 
    
Table 14. Association between STAG2 and p53 expression in MIUBC. 
  
N 
STAG2 <50 STAG2 > 50 
P-value * OR (95% CI) 
  N(%) N(%) 
p53 <100 ** 85 9 (37.5) 76 (48.1) 0.45 
0.65 
(0.27-1.57) 
p53 >100 97 15 (62.5) 82 (51.9)     
* P-value of the chi-square test  
   ** Histoscore; range 0-300 
     
STAG2 loss was more frequent in non-aggressive tumors, which are more differentiated, 
raising the possibility that loss might reflect urothelial cell differentiation. We confirmed STAG2 is 
expressed in all cell layers of normal urothelium (Fig. 27a), including the umbrella cells identified 
using antibodies detecting UPK3B and KRT20 (Fig.27b). This indicates that STAG2 expression is 
independent of urothelial cell maturation.  
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The cohesin complex can contain either STAG2 or STAG1; therefore, we investigated the 
relationship between the expression of both proteins in a TMA containing 94 UBCs of all stages 
and grades. Unsupervised clustering of STAG1 and STAG2 histoscores revealed that most tumors 
lacking STAG2 expression express STAG1, supporting the existence of a functional cohesin 
complex in STAG2-negative tumors (Fig. 28). Interestingly, 6 tumors lost both STAG1 and STAG2 
expression, all of which were FGFR3 wild type and of high grade (Fig. 28). 
3.5. STAG2 loss of expression is associated with good prognosis 
Next, we analyzed the association of lost STAG2 expression with patient outcome using 
Kaplan-Meier plots, univariable, and multivariable analysis. In addition, we performed the same 
analyses after stratification. In NMIUBC, patients whose tumors showed loss of STAG2 expression 
exhibited a significantly lower risk of tumor progression (hazard ratio (HR) 0.27, P=0.007) but not 
of recurrence (Fig. 29a, b, Tables 15, 16). In the multivariable analysis, adjusting for region, age, 
stage, grade, multiplicity, number of recurrences and treatment, STAG2 loss was not an 
independent predictor of outcome in NMIUBC:  the HR for progression- free survival was 0.56, 
P=0.163 (Fig 29b, Table 16). In the case of MIUBC, Kaplan-Meier analyses did not yield a 
significant association between loss of STAG2 and patient outcome (Fig. 29 c, d, Tables 17, 18). 
However, multivariable analysis adjusting for region, tumor stage, number of affected nodes, 
metastasis and treatment showed that loss of STAG2 expression was an independent predictor of 
cancer-specific survival (HR=0.44, P=0.018) (Fig. 29d, Table 18). 
Figure 27. STAG2 is expressed in all 
layers of normal urothelium. (a) 
STAG2 protein is detected 
throughout normal human 
urothelium, including umbrella 
cells, which also express KRT20, as 
well as basal and intermediate cells, 
positive for KRT5. The arrowheads 
point to umbrella cells positive for 
STAG2. The dotted red line marks 
the location of the basement 
membrane. (b) STAG2 (green) 
colocalizes with KRT20 (upper 
panel, red) and UPK3b (lower panel, 
red), both markers of umbrella 
cells. 
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Figure 29. Kaplan-Meier plots showing association between STAG2 expression and outcome. 
Expression was defined by histoschore (see Materials and methods). (a) Recurrence in NMIBC 
patients expressing high (n=309) and low (n=171) levels of STAG2. (b) Progression in NMIBC 
subjects displaying high (n=309) and low (n=171) levels of STAG2. (c) Progression in MIBC 
individuals presenting high (n=158) and low (n=24) levels of STAG2. (d) UBC-specific survival in 
MIBC patients expressing high (n=158) and low (n=24) levels of STAG2. P values correspond to the 
results of multivariable analyses, details on which are given in Tables 22-25.  
Figure 28. Expression of STAG1 and STAG2 in UBC. (a) Non-hierarchical clustering of STAG1 and 
STAG2 levels. IHC scores are showed in a green (lowest)-red (highest) color code. Bars below 
the dendogram include information about prognosis (pistachio/bourbon), tumor stage and 
grade (tones of blue), and FGFR3 mutational status (grey/black). White squares indicate 
information is not available. (b) Examples of one of the few tumors losing expression of both 
STAG1 and STAG2 (left), and another case displaying loss of STAG2 but positive staining of 
STAG1 (right). 
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Table 15. Association between STAG2 expression and risk of recurrence in NMIUBC. Kaplan-
Meier and Cox regression multivariable analyses. 
   
Unadjusted model Adjusted model 
STAG2 
histoscore 
Events 
N(%) 
Censored 
N(%) 
HR 95% CI 
P-value 
Cox PH 
P-value 
Log-
Rank 
HR 95% CI 
P-
value 
Cox PH 
50-300 101(32.7) 208(67.3) 1 (Ref) 
0.83 
0.6 - 1.16 0.283 0.282 0.81 0.57 - 1.17 0.269 
0-50 52(30.4) 119(69.6) 
Models adjusted for region, gender, TG, multiplicity, tumor size and treatment.  
  
Table 16. Association between STAG2 expression and risk of progression in NMIUBC. Kaplan-
Meier and Cox regression multivariable analyses. 
   
Unadjusted model Adjusted model 
STAG2 
histoscore 
Events 
N(%) 
Censored 
N(%) 
HR 95% CI 
P-value 
Cox PH 
P-value 
Log-
Rank 
HR 95% CI 
P-value 
Cox PH 
50-300 48(15.5) 261(84.5) 1 (Ref) 
0.13 - 0.56 0.001 0.0002 0.56 0.24 - 1.27 0.163 
0-50 8(4.7) 163(95.3) 0.27 
Models adjusted for region, age, TG, multiplicity, number of recurrences and treatment. 
 
Table 17. Association between STAG2 expression and risk of progression in MIUBC. Kaplan-
Meier and Cox regression multivariable analyses. 
   
Unadjusted model Adjusted model 
STAG2 
histoscore 
Events 
N(%) 
Censored 
N(%) 
HR 95% CI 
P-value 
Cox PH 
P-value 
Log-
Rank 
HR 95% CI 
P-value 
Cox PH 
50-300 96(60.8) 62(39.2) 1 (Ref) 
0.51 - 1.55 0.671 0.671 0.68 0.36 - 1.3 0.244 
0-50 14(58.3) 10(41.7) 0.89 
Models adjusted for region, tumor stage, number of affected nodes and treatment.  
 
Table 18. Association between STAG2 expression and risk of UBC-related death in MIUBC. 
Kaplan-Meier and Cox regression multivariable analyses. 
   
Unadjusted model Adjusted model 
STAG2 
histoscore 
Events 
N(%) 
Censore
d N(%) 
HR 95% CI 
P-value 
Cox PH 
P-value 
Log-
Rank 
HR 95% CI 
P-value 
Cox PH 
50-300 82(51.9) 76(48.1) 1 (Ref) 
0.42 - 1.48 0.463 0.462 0.44 0.22 - 0.87 0.018 
0-50 11(45.8) 13(54.2) 0.79 
Models adjusted for region, tumor stage, number of affected nodes, metastasis and treatment. 
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3.6. STAG2 loss of expression is not associated with aneuploidy neither in tumors nor in cell lines 
The known role of STAG2 in cohesin, together with some preliminary experimental analyses, 
has prompted the proposal that STAG2 loss promotes aneuploidy and that this mechanism would 
contribute to tumor development/progression in glioblastoma, melanoma and Ewing sarcoma 
(Solomon et al. 2011). To determine whether the same holds for UBC, we used BAC arrays or 
high-resolution SNP arrays to analyze gene/chromosome copy number changes in 23 non-
aggressive UBCs. Out of the 11 tumors lacking STAG2 expression, 9 (81.8%) exhibited normal 
chromosomal content; the remaining 2 tumors had lost one copy of chromosome 9 (Fig. 30, table  
Table 19. STAG2 expression histoscore and aneuploidy in non-aggressive UBC. 
ID* TG STAG2  histoscore$ Aneuploidy 
30104813* Ta, PUNLMP**  30 0 
10091210* TaG1 1 0 
10093410* TaG1 0 0 
10093510* TaG1 160 0 
30107610* TaG1 60 - chr. 9 
30106815* TaG2 180 - chr. 9 
30108611* TaG2 60 0 
30110214* TaG2 15 0 
30106712* TaG2 0 - chr. 9 
10090110* TaG1 0 0 
10092810* TaG2 0 - chr. 9 
51109411 TaG1 240 0 
41101319 TaG1 40 0 
41101917 TaG1 125 0 
23107618 TaG1 270 0 
11106713 TaG1 0 0 
20110017 TaG1 160 0 
23110614 TaG1 180 0 
40101419 TaG1 0 0 
20100519 TaG1 0 0 
50107313 TaG1 135 - chr. 9 
51100917 TaG1 270 0 
11111319 TaG1 270 0 
* Asterisk refers to samples analyzed for genomic changes using the Illumina HumanHap 1M 
BeadChip SNP arrays; the remaining samples were analyzed using BAC arrays 
** PUNLMP, Papillary urothelial neoplasm of low malignant potential 
$ Histoscore range: 0-300 
   
19). Similarly, 9 of 12 (75%) cases expressing STAG2 were diploid; the remaining 3 cases had also 
lost chromosome 9. These results indicate that, in UBC, loss of STAG2 does not result in 
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aneuploidy, in agreement with our finding that loss of STAG2 expression is more frequent in 
tumors of low grade and stage that are known to be genomically stable (Blaveri et al. 2005; 
Knowles 2008; Lindgren et al. 2010). 
 
      To determine whether STAG2 loss in cultured bladder cancer cells increases aneuploidy, we 
used lentiviral shRNA constructs to silence STAG2 expression. Twenty-seven out of 33 (81.8%) 
UBC cell lines express STAG2 at the protein level (Fig. 19a, Fig. 31a). We knocked down STAG2 in 3 
Figure 30. Loss of STAG2 expression is not associated with aneuploidy in primary UBC. Genomic 
profiles (Illumina HumanHap 1M BeadChip arrays) of low-risk, non-aggressive NMIUBC lacking 
STAG2 expression. The top 3 tumors (1034, Esp15, and 1001) do not exhibit gene copy number 
changes; tumor 104N shows interstitial losses at chromosomes 9, 11, and 14; case Esp49 exhibits 
loss of chromosome 9 and interstitial gains and losses of chromosome 13; and tumor 1028 
displays loss of chromosome 9 and interstitial losses at chromosome 11. Corresponding STAG2-
negative IHC stainings are shown on the right. 
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cell lines displaying a broad range of phenotypes: UM-UC-11 grow slowly and are wild type for all 
of the genes involved in UBC tested, RT112 cells harbor an FGFR3 amplification, and 639V cells 
grow rapidly, exhibit genomic instability, and also harbor mutations in PIK3CA, PTEN, and TP53 
(Julie Earl, unpublished). Despite the fact that the knockdown efficiency was good, we did not find 
consistent effects on chromosome numbers of metaphase-arrested cells (Fig. 31b-d, Table 20). 
We performed 3 independent experiments and counted chromosome number in >50 metaphase- 
arrested nuclei for each shRNA condition. Changes in mean and median chromosome numbers 
upon STAG2 silencing were very small (<1/metaphase) and inconsistent both when considering 
the 2 independent shRNAs that reduced STAG2 expression to similar levels and among different  
 
 
Figure 31. Loss of STAG2 is not associated with aneuploidy in vitro. (a) Immunoblotting analysis 
of STAG2 in UBC cell lines shows undetectable expression in 4 of the cell lines used for functional 
studies. (b-d) Efficient STAG2 knockdown was achieved in three UBC cell lines, as demonstrated by 
immunobloting. This did not lead to consistent changes in chromosome number (quantification 
shown in Table 27). (e) Depletion of STAG2 in RT112 cells did not cause consistent changes in the 
occurrence of aberrant centromeric cohesion. The grey color code refers to the number of 
chromosomes with defective centromeric cohesion in a given metaphase. shNT: non-targeting 
short hairpin RNA. 
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cell lines. The experimental differences observed were not statistically significant with the 
exception of sh1 in 639V (which exhibited an average of 60.61 chromosomes per metaphase in 
the control-shRNA treated cells, vs. 59.39 in cells infected with sh1, P= 0.022) (Table 20).  
Since STAG2-cohesin has been shown to be responsible for centromeric cohesion (Canudas 
and Smith 2009; Remeseiro et al. 2012a), we also measured centromeric cohesion defects upon 
STAG2 knockdown in RT112 cells, but found no significant changes in cohesion (Fig. 31e). 
3.7. STAG2 overexpression and silencing in vitro impairs cellular growth 
To explore additional mechanisms through which STAG2 could contribute to tumorigenesis, 
we assessed proliferation and colony formation upon STAG2 knockdown in vitro. Surprisingly, a 
consistent and significant decrease in colony formation was observed in 5 different UBC cell lines 
(Fig. 32a-e). The strongest effect was observed in RT112 cells, where knockdown resulted in a 81 
and 82% reduction in colony number with two different shRNAs (P=0.006 and 0.005), respectively 
(Fig. 32a). The mildest effect was detected in UM-UC-11 cells, where the reduction was of 28% 
with both shRNAs, although the difference was statistically significant only for one of them 
(P=0.02 and 0.06) (Fig. 32e). This is at odds with the extensive evidence implicating STAG2 
function as a tumor suppressor in UBC. Therefore, we introduced wild type STAG2 cDNA in 3 cell 
lines lacking STAG2: UM-UC-6 harbor R305* (exon 11) and F1228L (exon 33) alterations, VM-CUB-
3 harbor a 10-bp deletion in exon 6, and LGW0 1 G600 cells are wild-type in exons 3–35. In all 
three cases, STAG2 rescue also resulted in decreased colony formation (Fig. 32 f-h).  
 
Table 20. Relationship between STAG2 knock-down and chromosome number in metaphase-
arrested bladder cancer cell lines. 
Cell line n   shNT sh1 sh3 
639v 59 
Mean chromosome number 60.61 59.39 60.05 
Median 61 60 60 
P (Wilcoxon) - 0.022 0.24 
RT112 50 
Mean chromosome number 51.64 51.74 47.4 
Median 42 42 42.5 
P (Wilcoxon) - 0.86 0.25 
UM-UC-11 50 
Mean chromosome number 54.24 53.24 54.34 
Median 55 54 55 
P (Wilcoxon) - 0.2 0.81 
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3.8. Knocking down STAG2 in UBC cell lines does not significantly affect transcriptional profiles 
The lack of significant effects on chromosome cohesion and ploidy prompted the possibility 
that STAG2 might contribute to UBC development through its role as a regulator of chromatin and 
gene expression. Therefore, we effectively knocked down STAG2 in 2 cell lines (RT112 and 639V) 
using lentivirus coding for control shRNA or 2 different shRNA constructs targeting STAG2 (Fig. 
33a), and analyzed the transcriptome using RNA-Seq (Table 21). Principal component analysis 
disclosed a clear separation between the two cell lines but, within each line, samples infected 
with control and the two STAG2-targeting shRNAs were very close to each other (Fig. 33b). In 
agreement with this observation, only 0.2% - 0.8% genes were significantly regulated (Table 21). 
We considered a gene to be differentially expressed when Q<0.05 (where Q-values correspond to 
the false discovery rate-adjusted P values). 
Figure 32. In vitro knockdown and re-expression of STAG2 leads to impaired colony formation 
ability. (a-e) Efficient STAG2 knockdown, as demonstrated by immunoblotting, consistently and 
significantly associates with reduced colony formation in RT112, UM-UC-5, 639V, SW1710, and 
UM-UC-11 cell lines. (f-h) Efficient STAG2 re-expression, as demonstrated by immunoblotting, 
consistently and significantly associates with reduced colony formation in UM-UC-6, LGWO 1 
G600, and VM-CUB-3 cell lines. Growth was quantified in triplicate experiments and is expressed 
in percentage + Standard Error of the Mean. shNT: non-targeting short hairpin RNA; Empty: empty 
overexpression vector; STAG2: STAG2-expressing vector. 
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There were no genes regulated that were common between the 2 shRNAs and the 2 cell 
lines. A less stringent analysis, focused on genes that showed an expression fold-change equal or 
greater to that of STAG2 in the different conditions compared to the control shRNA (Table 22), 
yielded 126 genes altered in both cell lines with both shRNAs (Fig. 33c). We selected 25 genes for 
RT-qPCR validation, including STAG2: 6 genes that were regulated in both cell lines, 8 changing 
 
 
Figure 33. RNA-sequencing upon STAG2 silencing in UBC cell lines. (a) Efficient STAG2 silencing 
leading to decreased colony formation capabilities was achieved in 639V and RT112. (b) 3D 
Principal Component Analysis shows distinct separation between both cell lines; within each cell 
line, there is a slight separation between control shRNA (shNT) and the shRNas targeting STAG2 
(sh1 and sh3). PC: principal component. (c) Venn diagram showing the number of common genes 
between the RT112 and 639V cell lines upon STAG2 silencing; each data sets includes the genes 
up or downregulated at fold-changes >STAG2 comparing a given silencing construct (sh1 or sh3) 
with the control (shNT) for each cell line. 126 genes were found to be altered in both cell lines 
using both shRNA constructs. (d) A subset of genes was chosen for RT-qPCR validation; some were 
common for both cell lines and some were found only in one. Genes up and downregulated to 
different extents were chosen to ensure the validation subset was as representative as possible. 
Shown are RT-qPCR results for four genes validated in independent biological triplicates for 639V. 
The fold-change value obtained in the RNA-sequencing study is shown in red. 
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only in 639V, and 10 that exhibited different expression solely in  RT1121. We also made sure that 
the genes belonged to different pathways and ensured the inclusion of genes that were both up 
and down-regulated, to get a representative overview of the sequencing quality. The regulation of 
22/25 of the genes assayed was confirmed using RNA from the same experiment used for RNA-
Seq. However, when mRNA from independent experiments was used, only 8 genes were 
consistently regulated. STAG2 was the only one downregulated in both cell lines. In 639V, FYN and 
TFEB were downregulated and CDK6, TSC22D2, and CD83 were upregulated; in RT112, WNT7A 
was downregulated and KRT14 was upregulated (Fig. 33d).  
Table 21. Summary of the RNA sequencing study. RIN: RNA Integrity Number. % Align (PF): The 
percentage of filtered [Passing Filter] reads that were uniquely aligned to the reference. % >=Q30 
bases (PF): Yield of bases with Q30 or higher from clusters passing filter divided by total yield of 
clusters passing filter. Illumina Q30 quality score is associated with an error rate of 0.001 and 
therefore a 99.9% inferred accuracy for base calling. 
Run 
type 
Read 
length 
Sample RIN 
Number of 
high quality 
reads  
(Clusters PF) 
Yield 
(Mbases) 
% of reads 
mapped 
confidently 
(% Align PF) 
% 
>=Q30 
bases 
(PF) 
Single 
Read 
40 
639v-p27-shNT 6.8 17,885,709 715 72.6 91.4 
639v-p27-STAG2-sh1 8.5 18,104,376 724 70.6 91.3 
639v-p27-STAG2-sh3 7.8 17,691,116 708 74.1 91.3 
RT112-p33-shNT 9.1 17,749,443 710 75.8 93.4 
RT112-p33-STAG2-sh1 6.8 18,372,849 735 71.6 93.4 
RT112-p33-STAG2-sh3 7.7 16,390,860 656 73.2 93.4 
 
Table 22. Results of the RNA sequencing analysis. 
  
shNT vs sh1 shNT vs sh3 
639v 
# significant differentially expressed genes 75/17069 109/17069 
% 0.4 0.6 
fold-change range of DEGs (abs) 1.3 - 7.7  1.4 - 7.1  
STAG2 log2 fold-change  -1.9 -1.5 
RT112 
# significant differentially expressed genes 148/17678 27/17787 
% 0.8 0.2 
fold-change range of DEGs (abs)  1.5 - 7.9  1.7 - 11.2  
STAG2 log2 fold-change  -0.6 -0.8 
 
                                                      
1 We tested FYN, TSC22D3, NPR2, TFEB, CDK6, MFGE8, CD83, and MAPK15, which were regulated only in 
639V, PIM1, MET, KRT14, IGF1R, WNT6, WNT7A, WNT9A, and GLI2 in RT112, and STAG2, TSC22D2, 
RHOBTB3, MTMR3, IFI6, CCDC88B, and COL1A1 in both. 
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Despite its high incidence and cost, the molecular landscape of UBC remains relatively 
understudied. We used WES to identify novel genes involved in UBC. We were aware of a major 
sequencing initiative of MIUBC by the CGARN, so we focused our analyses on NMIUBC.  
1. THE MUTATIONAL LANDSCAPE OF UBC 
Five other UBC sequencing initiatives have been published besides our study (Gui et al. 2011; 
Guo et al. 2013; CGARN 2014a; Cazier et al. 2014; Nordentoft et al. 2014) (Table 23), the first 3 of 
them focusing on MIUBC. As expected, the WGS study identified more SNVs, even when taking 
into account only exonic regions (Cazier et al. 2014). Gui et al. reported a much lower mutation 
number than the rest of studies, but this is accounted for by the fact that they reported somatic 
mutations after filtering SNPs out (2011). However, the CGARN study identified 1.8x more 
mutations per patient as we did (2014a). The differences in mutation number in our study could 
be accounted by the fact that we included NMI tumors, as well as by the relatively low number of 
cases of NMIUBC studied. However, other reasons likely contribute to discrepancies between the 
studies by Nordentoft et al., Guo et al. and the CGARN. All studies used Illumina HiSeq for 
sequencing, but data were processed differently. The CGARN SNV calling strategy did not include 
filtering out known germline variants, possibly accounting for the observed differences, especially 
when we take into account that the CGARN used MutSig (Lawrence et al. 2013) to call for 
mutations, taking into account background mutation rate, a process that should yield a lower 
number of false-positive SNVs called than traditional strategies. 
Table 23. Summary of NGS studies of UBC. WES: Whole Exome Sequencing. WGS: Whole 
Genome Sequencing. *Known SNPs were filtered out. 
Study 
Study 
type 
Total cases 
(NMI-LR, NMI-
HR, MI) 
NMI 
LR 
cases 
NMI 
HR 
cases 
MI 
cases 
Average somatic 
mutations per 
patient (exonic) 
This study WES 17 5 10 2 169 
Gui et al. 2011  WES 9 0 0 9 52* 
Guo et al. 2013  WES 99 5 33 61 114 
CGARN 2014q WES 130 0 0 130 302 
Cazier et al. 2014 WGS 14 4 5 5 417 
Nordentoft et al. 
2014 
WES 38 20 18 195 
 
A recent meta-analysis of 27 tumor types sequenced mainly at the Broad Institute revealed a 
>1,000 fold variation in the number of non-synonymous variants per tumor depending on the 
tumor type (or site) (Lawrence et al. 2013). Pediatric tumors exhibited the lowest number of 
mutations whereas cancers known to be associated with environmental carcinogens, such as 
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those from the lung or melanoma, presented the highest number. The frequencies identified by 
Guo, Nordentoft, and our group fell in the mid-high range among solid tumors of the adult; the 
CGARN frequencies approached the rates found in lung and melanoma tumors.  
Consistently, the 6 bladder cancer studies identified C>T/G>A transitions as the most common 
nucleotide change in exons. C mutations in a TpC dinucleotide context have been recently shown 
to occur frequently in several cancer types (Lawrence et al. 2013) and have been proposed to be 
caused by APOBEC, enzymes that deaminate cytosine nucleotides in single stranded DNA, giving 
rise to uracil that is excised by uracil DNA glycosylases. This process yields an apurinic site, 
opposite to which an A can be inserted, resulting in C>T transitions (Loeb and Preston 1986). The 
comprehensive study of 38 UBCs by Nordentoft and colleagues showed that around 1/3 of UBCs 
exhibit an APOBEC mutational pattern (2014). Moreover, APOBEC3B levels have been shown to 
be upregulated in bladder tumors exhibiting the APOBEC mutational signature (Burns et al. 2013; 
Roberts et al. 2013).  
All the studies included a small number of tumors with very few mutations, mainly in genes 
different from those reported to be frequently altered in UBC or newly identified in these studies. 
Technical limitations may contribute to this observation, including those derived from sequencing 
only the coding part of the genome. Other kinds of driver mutations, such as those mapping to 
non-coding regions, or alterations involving larger chromosomal stretches (chromosomal 
rearrangements or copy number changes), might play a driver role in those cases. Alternatively, it 
is possible that a subgroup of UBC develops mainly through epigenetic alterations that have not 
been analyzed so far, such as is the case of medulloblastoma (Hovestadt et al. 2014).  
2. ARID1A MUTATIONS AND EXPRESSION IN UBC  
NGS studies have uncovered a previously unsuspected role of genes coding for histone 
modifiers and chromatin remodelers acting as tumor suppressors in many human cancers 
(reviewed in Wilson and Roberts 2011). A recent meta-analysis showed that the SWI/SNF is the 
most commonly altered chromatin-regulatory complex in human tumors (Kadoch et al. 2013). 
ARID1A was identified as the most frequently mutated SWI/SNF subunit. ARID1A somatic 
mutations were first identified in ovarian carcinomas (Jones et al. 2010; Wiegand et al. 2010). 
Shortly after, mutations were reported in uterine endometrioid tumors, esophageal and gastric 
carcinomas, hepatocellular tumors, and other less common malignancies, at frequencies of 10-
40% (reviewed in Wu 2014). In 2011, mutations in ARID1A and other chromatin remodelers were 
reported in the first UBC WES study of mostly aggressive tumors (Gui et al. 2011). Besides being 
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inactivated by mutations, ARID1A was also shown to be inactivated by epigenetic silencing in 
invasive ductal breast tumors (Zhang et al. 2013). 
In this study, we found that 11.2% of UBC harbor ARID1A pathogenic mutations. This mutation 
rate is lower than the overall 21.4% rate identified in 7 independent studies of this tumor (Gui et 
al. 2011; Guo et al. 2013; Cazier et al. 2014; CGARN 2014a; Nordentoft et al. 2014; Ross et al. 
2014; Kim et al. 2014). However, our analysis included 36% of non-aggressive tumors, as opposed 
to only 6.7% of the cases analyzed by the other groups (Table 8). In our study, all of the truncating 
mutations identified were found in aggressive tumors. Joint analysis of the eight studies shows 
that ARID1A relevant mutations occur in 14.4% of NMI and 23.6% of MI cases (P=0.02) (Supp. 
Table 12). Overall, 54/66 (81.8%) mutations found in aggressive tumors were truncating, 
compared to 5/9 (55.6%) in non-aggressive tumors (P=0.09). In agreement with this observation, 
we found ARID1A protein expression to be lost significantly more frequently in aggressive tumors. 
Interestingly, we identified 1 patient and 1 cell line harboring multiple relevant mutations; Guo et 
al. also identified 2 patients with multiple mutations (2013). This could be indicative of biallelic 
inactivation of the gene, as well as of intratumoral heterogeneity, both common events in other 
tumor types (Jones et al. 2010; Guan et al. 2011a).  
 
 
 
      Taking into account all studies for which information was available, we did not identify 
significant differences in the frequency of ARID1A mutations according to sex, age, or smoking 
status, although there was a tendency for ARID1A mutations to be more common in females than 
males in the five studies for which this information was available (23.8% vs. 16.9%) (P=0.2) (Supp. 
Table 12). Interestingly, there is evidence that women present with more aggressive tumors and 
that they have a worse outcome than men when adjusting for stage and grade (Cook et al. 2011). 
A summary of all reported identified mutations can be found in Figure 34. Although mutations 
were distributed all along the protein, there was a cluster of truncating mutations in exons 3-4, 
although no known functional domain maps to that location. 
Figure 34. Summary of type and distribution of ARID1A nonsynonymous somatic mutations 
found in all published studies. The amino acid changes in mutations occurring more than once are 
specified above their location. 
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3. ARID1A ALTERATIONS IN THE CONTEXT OF UBC’S GENETIC LANDSCAPE 
We also explored the relationship between mutations in ARID1A and in other genes involved 
in UBC. Mutual exclusivity analyses of all studies published to date suggested that alterations in 
ARID1A were exclusive with alterations in FGFR3 (OR=0.4, P=0.007), and STAG2 (OR=0.4, P=0.03) 
(Supp. Table 13). In agreement with this, we found that ARID1A mutations usually occurred in 
poor-prognosis FGFR3 wild type tumors. Consistently, we have shown that ARID1A and FGFR3 
immunoscores exhibited a significant direct correlation.  
We did not find any relationship between ARID1A expression and nuclear p53 staining 
(associated with TP53 alterations). Similarly, in a joint analysis of all available studies we found no 
association between TP53 and ARID1A alterations (OR=1.3) (Supp. Table 13), suggesting that 
ARID1A inactivation is an alternative pathway of UBC progression. Similarly, no association 
between ARID1A and TP53 alterations has been detected in other tumor types (Wang et al. 2011; 
Bosse et al. 2013; Kadoch et al. 2013; Allo et al. 2014), suggesting a broader functional 
significance of this observations. In vitro studies in ovarian cancer cells have shown that ARID1A 
and p53 co-immunoprecipitate and are both required for p21-mediated cell cycle arrest (Guan et 
al. 2011b), suggesting that the tumor suppressor functions of ARID1A and p53 converge in 
multiple human tumors. Accordingly, we found ARID1A expression to be associated with worse 
patient outcome. Further studies are required to ascertain the functional relationship of these 
two tumor suppressors.  
Regarding the sequence of mutational events, Nordentoft et al. have proposed - on the basis 
of sequencing studies of 4 pairs of primary NMIUBC-progressor tumors - that mutations in 
chromatin modifiers (KDM6A, MLL2, ARID1A) occur early in tumor development and associate 
with worse prognosis (2014). Moreover, several pretumoral lesions have been reported to exhibit 
ARID1A mutations in endometriotic cysts, endometriosis, endometrial hyperplasia, and normal 
squamous esophageal epithelium (Ayhan et al. 2012; Yamamoto et al. 2012; Werner et al. 2013; 
Streppel et al. 2014). Although most of the precursor lesions analyzed are related to gynecologic 
cancers, this suggests that ARID1A alterations causing SWI/SNF inactivation might be an early 
event in carcinogenesis, at least in some instances.  
Co-occurrence analyses of all published reports suggested that alterations in ARID1A 
associated with alterations in KRAS, which was mutated in a subset of non-aggressive UBC 
(OR=5.2, P=0.02) (Supp. Table 13). Moreover, us an others have identified a small subset of non-
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aggressive UBCs with mutations in ARID1A. Altogether, we propose that ARID1A alterations that 
occur early during UBC evolution are important in a subset of poor-prognosis TP53 wild type 
tumors belonging to the aggressive pathway of UBC development. Additionally, KRAS-mutant, 
non-aggressive tumors might progress to MI status via the acquisition of further alterations in 
ARID1A. 
4. ARID1A: A ROLE IN THE CONTROL OF DIFFERENTIATION AND PROLIFERATION?  
Despite the wealth of data on mutations in SWI/SNF chromatin remodelers, the mechanisms 
through which these act as tumor suppressors in human cancer remain unclear (Wilson and 
Roberts 2011). This is especially true for ARID1A, whose function within the BAF SWI/SNF complex 
is not well characterized. 
The SWI/SNF complex participates in the control of tissue-specific gene expression programs 
by regulating promoter accessibility to transcription factors and epigenetic modifiers. ARID1A 
mutations might contribute to global epigenetic changes upon BAF inactivation. The region of 
ARID1A that interacts with DNA has been shown to be required for BAF complexes to bind to 
nucleosomes in MEFs (Chandler et al. 2013). Therefore, BAF-mediated nucleosomal remodeling 
could be globally altered upon ARID1A mutation, rendering CpG islands and gene promoters 
accessible to the action of epigenetic modifiers. Supporting this, ARID1A mutations have been 
found in colorectal tumors with abnormal CpG island hypermethylation (Tahara et al. 2014). 
Moreover, Duymich and colleagues have reported preliminary results suggesting that UBC cells 
harboring ARID1A mutations exhibited differentially methylated CpG sites (2013). Given the 
mutual exclusivity between ARID1A and FGFR3 mutations we have identified, it is tempting to 
hypothesize that alterations in ARID1A might be involved in the multiple regional epigenetic 
silencing phenotype described in FGFR3-wild type, aggressive UBC (Vallot et al. 2011).  
This effect could be particularly important in the context of cell differentiation and 
proliferation. The BAF subtype of SWI/SNF complexes can contain either BRG1 or BRM, and either 
ARID1A or ARID1B. SWI/SNF subunits have been shown to facilitate MEF reprogramming: cell 
fractionation identified several BAF components significantly enriched in reprogramming-
competent extracts, including Brg1, Baf155, Arid1a, and Arid1b (Singhal et al. 2010). Specifically, 
Brg1 and Baf155 were shown to mediate faster demethylation of Oct4 and Nanog promoters, 
thus enhancing reprogramming (Singhal et al. 2010).  
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BRG1 is the best studied BAF component with regards to differentiation. The group of 
Sánchez-Céspedes has focused on studying BRG1 alterations in the context of lung cancer. They 
first identified common BRG1 homozygous mutations in lung cancer cell lines (Medina et al. 2008) 
and proceeded to confirm those findings in lung tumors (Rodríguez-Nieto et al. 2011). They then 
demonstrated that re-introducing wild type, but not mutant BRG1, in lung cancer cells lacking the 
protein switched gene expression to a signature typical of normal lung (Romero et al. 2012). 
Interestingly, among the differentially expressed genes they found MYC targets. They proceeded 
to demonstrate that BRG1 binding to regions near the promoter of MYC targets repressed their 
expression.  
This repression could be accounted for by global epigenetic changes upon BRG1 inactivation: 
the CpG islands of MYC targets could become methylated in the absence of functional BRG1-BAF. 
Myc is unable to bind its targets when its DNA binding sequences (CACGTG, called E boxes) are 
methylated (Prendergast et al. et al. 1991; Perini et al. 2005). Therefore, inactivating mutations in 
BRG1 causing E box methylation could result in repression of the MYC transcriptional programme. 
It is tempting to speculate that alterations in other BAF components, such as ARID1A, also 
result in the maintenance of undifferentiated gene expression, possibly also via the control of 
MYC activity. In fact, Arid1a has been shown to directly repress c-Myc expression, contributing to 
cell cycle arrest-dependent differentiation in an osteoblastic mouse cells (Nagl et al. 2006). In 
humans, loss of ARID1A expression is more common in poorly differentiated gastric tumors than 
in well-differentiated ones (Wang et al. 2012). Interestingly, mutations in ARID1A and BRG1 are 
mutually exclusive in high grade UBCs (Kim et al. 2014), suggesting that disruption of either of 
them affects the function of the SWI/SNF complex. In our IHC analyses, the cluster of ARID1A-
negative aggressive tumors also exhibited low levels of KRT20, and a subset of these tumors 
expressed mid to high levels of KRT5/6 and KRT14, suggesting a blockade in urothelial 
differentiation.  
With all this in mind, it seems plausible for ARID1A inactivation in UBC to have a tumor 
suppressive effect that affects global epigenetic status, as well as cell proliferation and 
differentiation via the control of MYC activity, as shown for BRG1. However, BRG1 is the catalytic 
subunit of the BAF complex, unlike ARID1A, which does not have catalytic activity but is required 
for ARID1A-BAF binding to DNA and is believed to influence selectivity of target recruiting. It has 
been shown that ARID1A and ARID1B have differential activities. In the study mentioned above, 
knocking down ARID1B did not hinder osteoblast arrest (Nagl et al. 2006). This could imply that, in 
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the absence of ARID1A, ARID1B-BAF complexes, unable to restrict proliferation and induce 
differentiation, might become prevalent. Moreover, chromatin immunoprecipitation (ChIP)-
sequencing experiments have shown that SWI/SNF is present at promoters of its own subunits 
and thus can control their relative abundances (Euskirchen et al. 2011). ARID1A inactivation could 
lead to feedback loops that alter the stoichiometry of BAF subunits, promoting the formation of 
ARID1B-BAF complexes in lieu of ARID1A-BAF.  
ARID1A has also been shown to restrict proliferation in several tumor cells in vitro (Wu et al. 
2014). Surprisingly, knocking down ARID1A in three different UBC cells resulted in reduced colony 
formation and very low cell viability. Modest knockdown in gastric (Zang et al. 2012), 
hepatocellular (Huang et al. 2012), breast (Mamo et al. 2012), bile duct (Chan-on et al. 2013) and 
ovarian (Guan et al. 2011b) cancer cell lines has been reported to lead to increased proliferation. 
However, more efficient depletion of ARID1A in immortalized pancreatic and keratinocytic 
epithelial cells also reduced proliferation (Shain et al. 2012). These differences could be explained 
by context-specific or dose-dependent effects of ARID1A.  In fact, inactivation of a single Arid1a 
allele is lethal for mouse pre-implantation embryos (Gao et al. 2008), indicating that changes in 
ARID1A protein dose can be deleterious. Experiments with inducible shRNAs targeting ARID1A, or 
inducible overexpression, would shed some light on the role of ARID1A in normal urothelial cells. 
The creation of a urothelial-specific inducible ARID1A KO mouse model would also contribute to 
test these hypotheses, using a combination of ChIP, bisulfite assays, and expression analyses, 
either at concrete loci or in a genome-wide manner. 
5. STAG2: A NEW, COMMON, TUMOR SUPPRESSOR GENE WITH A MAJOR ROLE IN UBC  
In 2011, inactivating STAG2 mutations were reported in glioblastoma, Ewing sarcoma, and 
melanoma, with up to 20% of these tumors exhibiting loss of protein expression using IHC 
(Solomon et al. 2011). In the last year, our group and others have shown that UBC is the tumor 
type most commonly harboring STAG2 alterations (Guo et al. 2013; Solomon et al. 2013; Cazier et 
al. 2014; CGARN 2014a; Kim et al. 2014; Nordentoft et al. 2014; Taylor et al. 2014).  
In this work, we found that 14.3% of all UBCs harbor pathogenic mutations in STAG2. This 
mutation rate fell within the 8.2-25.5% rates identified in 7 independent studies published with 
ours or subsequently (Table 10) (Guo et al. 2013; Solomon et al. 2013; Cazier et al. 2014; CGARN 
2014a; Kim et al. 2014; Nordentoft et al. 2014; Taylor et al. 2014). In our cohort, 22.2% of non-
aggressive vs. 10.2% of aggressive tumors were found to be mutated. Joint analysis with the six 
studies for which stage and grade information was available showed that STAG2 relevant 
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mutations were present in 29.6% of non-aggressive and 15.7% of aggressive cases (P<0.001), 
supporting our findings (Supp. Table 14). In agreement with this, we also found that the frequency 
of STAG2 protein losses directly associated with the benign nature of the various UBC subtypes.  
 
 
Joint analysis of all studies with available information unveiled a tendency for a higher 
frequency of mutations in tumors from patients <60, females, and in individuals with a history of 
smoking, although these differences were only significant for gender (P=0.01) (Supp. Table 14). 
This finding is of interest because STAG2 is on the X chromosome. Truncating STAG2 mutations 
were most common although missense mutations of undetermined biological significance have 
also been reported (Fig. 35). Overall, all (39/39) truncating mutations (nonsense, frameshifts, and 
splice-site) led to loss of protein expression, as opposed to none of the missense (0/9) mutations 
(Solomon et al. 2013; Taylor et al. 2014). Interestingly, missense mutations were more common in 
aggressive (15/66, 22.7%) than in non aggressive (5/69, 7.2%) tumors (P= 0.02). 
The exact timing at which STAG2 mutations occur is not well understood yet. Using IHC, the 
majority of the tumors analyzed showed homogeneous STAG2 expression. This, together with the 
high prevalence of mutations in non-aggressive tumors, suggests that STAG2 inactivation is an 
early ancestral genetic event. We, and others, have reported a small subset of tumors with 
heterogeneous STAG2 expression (Solomon et al. 2013; Taylor et al. 2014) supporting a role in 
clonal evolution in some tumors. Moreover, 1/4 matched cases studied by Nordentoft et al. 
exhibited an indel mutation in STAG2 in the tumor ancestral branch (2014). A small subset of 
cases harbored more than one STAG2 mutation, possibly suggesting convergent evolution as 
reported for other tumor suppressors in renal cancer (Gerlinger et al. 2012; Real et al. 2014). 
In addition to mutations, STAG2 inactivation can take place through other mechanisms 
including genomic deletions, identified by us and by Guo et al. (2013), and epigenetic silencing. 
Guo and colleagues have reported STAG2 promoter hypermethylation in 7/30 (23%) of tumors 
(2013). This could account for the 9% of tumors where STAG2 protein was not expressed but we 
did not find gene mutations. The participation of multiple mechanisms converging in frequent 
Figure 35. Summary of type and distribution of STAG2 nonsynonymous somatic mutations 
found in all UBC published studies. Recurrent mutations are indicated. The amino acid changes 
in mutations occurring more than once are specified above their location. 
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STAG2 inactivation, and their occurrence early in tumor development, support that STAG2 is a 
driver gene in UBC.  Studying these in a greater number of cases and relating their prevalence to 
tumor stage and grade would help to test this hypothesis. 
6. PLACING STAG2 ALTERATIONS IN THE GENETIC LANDSCAPE OF UBC 
We have found that STAG2 loss of expression is associated with non-aggressive tumors, which 
present the highest frequency of FGFR3 mutations. The analysis of all available data from UBC 
also showed that mutations in STAG2 and FGFR3 frequently co-occur (OR=4.6, P<0.0001) (Supp. 
Table 15). Mutations in TP53 and p53 overexpression are frequent in MIUBC. In our analysis, 
STAG2 loss was associated with normal p53 expression in LR-NMIUBC (OR=4.2, P=0.01) (Table 12). 
Similarly, mutations in STAG2 were found to be mutually exclusive with mutations in TP53 in our 
analysis of the data by Guo and colleagues, which included mainly aggressive cases (P=0.05, 
OR<0.0001), and truncating mutations in STAG2 were associated to wild type TP53 in another 
study including cases of all stages and grades (Taylor et al. 2014). However, Solomon and 
colleagues reported that UBCs frequently exhibit STAG2 mutations and p53 overexpression in 
tumors of all stages and grades (2013). A more thorough analysis of these data revealed that 5/10 
tumors with STAG2 mutations overexpressing p53 belonged to the aggressive category, which 
might have acquired TP53 alterations during tumor progression. More work is needed to place 
STAG2 mutations in the context of p53 alterations but we propose that STAG2 mutations occur 
mainly leading to non-aggressive tumors, some of which acquire additional alterations in 
important tumor suppressors - such as TP53 or PTEN - and progress to become muscle-invasive. 
At another level, it has been proposed that UBC harbor a mutational signature associated with 
APOBEC3B cytidine deaminase activity, enriched in C>T transitions (Burns et al. 2013). Nordentoft 
and colleagues have reported a negative correlation between STAG2 mRNA levels and the 
APOBEC mutational signature (2014). However, we did not find STAG2 and APOBEC3B mRNA 
levels to be significantly correlated in our cases (data not shown). Moreover, in our study all of 
the STAG2 mutant cases we found in our exome sequencing study presented a high frequency of 
C>T alterations, and we did not identify differences in the frequency of C>T mutations according 
to STAG2 mutational status. Additionally, the APOBEC signature is not associated to tumor grade 
or stage in UBC (Nordentoft et al. 2014), whereas the association of STAG2 with these parameters 
is very consistent across studies. Therefore, more work is needed to confirm the findings of 
Norderntoft and colleagues.  
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7. STAG2 MUTATIONS AND ANEUPLOIDY: UNRELATED IN UBC 
We were struck by the finding that STAG2 alterations and loss of expression were more 
frequent among non-aggressive UBCs, which are generally genomically stable. We then went on 
to confirm that STAG2 loss did not consistently lead to aneuploidy in UBC. Among 23 tumors of 
the non-aggressive category, there was no difference in the aneuploidy rate between STAG2 
negative or positive tumors and 82% of STAG2-negative tumors lacked aneuploidy.  Additionally, 
knocking down STAG2 in 3 different UBC cells failed to yield consistent, significant changes in 
chromosome number of metaphase-arrested cells. The two groups reporting an important role of 
STAG2 in UBC concurrently with us reached the opposite conclusion (Guo et al. 2013; Solomon et 
al. 2013). However, we believe that their conclusion is not supported by their data which - indeed 
- support our findings. Guo et al. reported that STAG2-mutant tumors exhibited a significantly 
higher genomic instability score than STAG2 wild type tumors (2013). However, genomic 
instability does not equal aneuploidy (Gordon et al. 2012) and - in fact - their study does not find 
significant differences when considering whole chromosome changes. Solomon et al. described 
that 9/12 (75%) STAG2 mutant and 10/12 (83%) STAG2 wild-type cases exhibited chromosomal 
aberrations (2013). Importantly, they inappropriately defined aneuploidy as clonal chromosomal 
aberrations rather than whole chromosome copy number changes. Their study, as ours, found 
STAG2 mutant cases lacking aneuploidy. Moreover, none of these studies performed a stratified 
analysis comparing tumors in the aggressive vs. non-aggressive categories. Their results possibly 
reflect the fact that about half of the STAG2 mutant and wild-type cases they analyzed are 
aggressive, and aggressive UBCs are frequently aneuploid. Moreover, they did not find changes in 
chromosome counts upon introduction of wild-type STAG2 in a non-expressing UBC cell line.  
Finally, a more recent study including a cohort of 220 cases reported an inverse correlation 
between mutations in STAG2 and both whole chromosome copy number changes and fraction of 
genome altered (Taylor et al. 2014). Therefore, we believe that our conclusion that STAG2 loss 
does not lead on increased aneuploidy is supported by the available data. The findings in UBC are 
consistent with observations in myeloid malignancies where STAG2 mutations have been 
reported to occur predominantly in the subgroup of diploid tumors (Welch et al. 2012; Kon et al. 
2013). Additionally, a large study of Ewing’s sarcoma cases confirmed frequent mutations of 
STGA2 in a cohort exhibiting a very low rate of aneuploidy (Brohl et al. 2014).  
We do not imply that STAG2 alterations are universally unrelated to aneuploidy. It is possible 
that the functions of STAG2/cohesin, and the effects of STAG2 inactivation, are tissue-specific. 
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Chromosomal instability is a frequent event in colorectal cancer (CRC) and STAG2 knockdown in 
CRC cells has been shown to increase chromosome numbers and to cause centromeric separation 
of sister chromatids (Barber et al. 2008). Similarly, Solomon and colleagues reported an increase 
in chromosome number upon STAG2 silencing in a near-diploid CRC cell line, as well as a decrease 
in the average number of chromosomes upon STAG2 reintroduction in a mutant glioblastoma line 
(2011).  
Given all the data available at the moment, we hypothesize that STAG2 acts through 
mechanisms different from its role in chromosome segregation in non-aggressive UBC 
development. A caveat to the functional studies reported to date is that they have been 
performed predominantly using established cancer cell lines. There is a need to more carefully 
determine the effect of STAG2 inactivation on chromosome segregation in normal cells in vitro 
and in vivo. 
8. STAG2 IN UBC: WHAT, IF NOT COHESION? 
The findings summarized above raise the question of the mechanism through which STAG2 
loss contributes to UBC. Besides its role in chromosome segregation, the cohesin complex has 
been shown to influence the three-dimensional structure of DNA, regulating gene transcription 
(reviewed in Losada 2014), and to participate in DNA repair. Genome-wide, the distribution of 
cohesin largely overlaps with that of CTCF in humans and mice (Parelho et al. 2008; Wendt et al. 
2008), regardless of whether the complex contains STAG1 (Rubio et al. 2008) or STAG2 (Xiao et al. 
2011). In MEFs, the transcriptional regulatory role of cohesin was strictly dependent on Stag1 and 
Stag2 could not replace it in this function (Remeseiro et al. 2012b). In agreement with this 
observation, depleting STAG2 or re-expressing it in wild-type or mutant human glioblastoma, CRC, 
and neuroglioma cell lines did not significantly alter their transcriptional profile assessed by 
microarrays (Solomon et al. 2011). To explore a role in gene regulation in the urothelium, we 
analyzed the transcriptome of control and STAG2-interfered UBC cells using RNA-sequencing 
which has the power of detecting low-abundance transcripts - unlike microarrays (Malone and 
Oliver 2011). However, we found less than 1% of genes being differentially expressed with no 
genes found to be commonly altered in two different cell lines. In this experiment, STAG2 
downregulation was efficient and we were able to validate changes in individual gene expression 
by RT-qPCR, proving that the sequencing results were reliable. These exploratory results do not 
provide support to the notion that STAG2 is a main regulator of gene expression in UBC.  
However, there are several caveats to this preliminary conclusion including that the experiment 
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was performed using established tumor cell lines which might not recapitulate the effects of 
STAG2 inactivation in normal tissue, that the effects might not be mediated through mRNA 
regulation, or that residual STAG2 levels might be sufficient for its function in UBC cells. Further 
work is required, and is ongoing in our laboratory, to conclusively establish whether STAG2 
participates in urothelial homeostasis through the regulation of transcription, including an 
analysis of the transcriptome of normal urothelial cells upon STAG2 knockdown in vitro or its in 
vivo inactivation using a Stag2 conditional mouse model. 
Interestingly, knocking down STAG2 on wild-type UBC cell lines led to reduced cell 
proliferation, unlike we would have expected for a tumor suppressor. These results were similar 
to our findings with ARID1A. It is conceivable that the effects of STAG2 inactivation are context-
specific. Alternatively, reduced cell proliferation upon STAG2 loss might impose the selection of 
genetic alterations leading to an escape phenotype associated with tumor development. These 
possibilities are also currently being explored in our laboratory.  
The strong association of STAG2 loss and low grade, low stage, papillary tumors raises the 
question of the cell type where these tumors are initiated. There is some debate as to urothelial 
p63- umbrella and p63+ basal/intermediate cells represent independent lineages (Signoretti et al. 
2005). An analysis of the transcriptome of microdissected basal and umbrella cells with 
transcriptional signatures of stage/grade-specific UBC has led to propose that NMIUBC and 
MIUBC originate from different progenitors (Dancik et al. 2014). While umbrella cells do not 
proliferate, a subgroup of basal cells are capable of dividing (Kurzrock et al. 2008). These findings 
lead us to speculate that alterations of STAG2 in umbrella cells might induce proliferation, 
contributing to the formation of NMIUBC, whereas MIUBC could arise from STAG2 mutations in 
basal cells or from the progression of STAG2-altered NMI tumors. To confirm this hypothesis, it 
will be important to delete STAG2 in different urothelial layers using cell-specific promoters.  
Cohesin has also been shown to participate in homologous recombination-mediated repair of 
double strand DNA breaks. Lack of chromosome arm cohesion would hamper the use of sister 
chromatids as repair templates, promoting the use of the homologous chromosomes instead and 
thus leading to loss of heterozygosity (Stark and Jasin 2003). Even the least aggressive bladder 
tumors exhibit frequent LOH at chromosome 9 (Spruck et al. 1994; Hartmann et al. 2002; 
Mhawech-Fauceglia et al. 2006). It is possible that structural characteristics of chromosome 9 
make it more prone to suffering double strand breaks than the rest of chromosomes, and that 
inactivation of STAG2 in the bladder promotes LOH at this particular chromosome due to faulty 
Discussion 
129 
 
repair. This is supported by the finding that, in Saccharomyces cerevisiae, a reduction of 70% in 
cohesin levels causes defects in homologous recombination repair, but reductions in cohesion 
levels greater than 85% are required for chromosome segregation defects (Heidinger-Pauli et al. 
2010). Upon STAG2 inactivating mutations, STAG1-cohesin can still be formed, so it is plausible 
that the same effect observed in yeast is taking place in the human urothelium, with the 
remaining STAG1-cohesin being sufficient for appropriate chromosome segregation but not for 
cohesin-dependent homologous recombination. 
9. CLINICAL IMPLICATIONS 
A recent study integrated expression information for 12 human tumor types, finding that 
bladder tumors primarily fall in as many as 3 out of the 11 integrated molecular subtypes 
identified (Hoadley et al. 2014). This highlights the heterogeneity of UBC compared to other 
human tumors. Interestingly, Hoadley et al. found that all UBCs with STAG2 mutations belong to 
the bladder-only subtype, enriched in FGFR3, MLL, MLL2, MLL3, EP300, and KDM6 mutations, 
among others. Additionally, UBCs with ARID1A mutations were also enriched in that same 
subtype. This highlights the importance of these genes in the urothelial context, the clinical 
implications of which we will explore here. 
In other tumor types (ovarian clear cell carcinoma, endometrium, breast, cervix), where more 
studies have been carried out, ARID1A expression has not been found to be consistently 
associated with prognosis (Maeda et al. 2010; Katagiri et al. 2012; Lowery et al. 2012; Mamo et al. 
2012; Cho et al. 2013; Fadare et al. 2013; Rahman et al. 2013; Zhang et al. 2013; Allo et al. 2014). 
On the other hand, multivariate analyses in clear cell renal tumors (Lichner et al. 2013) and a 
subset of gastric tumors (Abe et al. 2012) found significant, independent associations between 
loss of ARID1A and poor prognosis.  
In UBC, the studies of Gui, the CGARN, and Ross did not assess the relationship between 
ARID1A loss or alterations and patient prognosis (2011; 2014; 2014a). Nordentoft and colleagues 
observed a non-significant tendency for ARID1A-negative MIUBCs to exhibit increased progression 
free survival in a univariate analysis (2014). Finally, a recent study focused on high-grade UBCs did 
not identify a significant relationship between ARID1A mutations and patient outcome (Kim et al. 
2014). In our series, comprising a broader disease spectrum, we have shown that UBC patients 
exhibiting low levels of ARID1A are more likely to experience tumor progression and UBC-derived 
death. However, ARID1A expression was not an independent predictor of outcome and this 
association could merely reflect the fact that losses are more common among aggressive tumors. 
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To ascertain the prognostic significance of ARID1A loss of expression in MI tumors, larger studies 
allowing stratified analysis need to be performed. 
Independently of their prognosis, ARID1A negative tumors could be considered as therapeutic 
targets. Drugs targeting epigenetic modifications might have therapeutic potential in ARID1A 
negative tumors. There are two DNA demethylators approved by the American Food and Drug 
Administration to treat myeloid malignancies: 5-Azacytidine and 5-Aza-2-deoxycytidine (reviewed 
in Yang et al. 2010). They are analogues of cytosine that incorporate into replicating DNA, causing 
global demethylation (reviewed in Kelly et al. 2010). However, these drugs are not stable in 
plasma and cause neutropenia (low neutrophil blood counts) at high doses, so their efficacy 
treating solid tumors has been shown to be limited (Pohlmann et al. 2002; Samlowski et al. 2005). 
Nevertheless, a recent preclinical trial has shown that dogs with naturally occurring MIUBC 
respond favorably to 5-Azacytidine treatment (Hahn et al. 2012). It would be informative to 
compare the effect of 5-Azacytidine in subjects with and without alterations in members of the 
SWI/SNF complex, including ARID1A in both clinical and pre-clinical trials. 
As reviewed by Sajesh and colleagues, synthetic lethality therapies specifically targeting tumor 
cell features are starting to be considered to improve cancer drug selectivity (2013).  UBCs with 
alterations in ARID1A might respond to drugs targeting other pathways involved in the 
maintenance of genomic stability. Recently, ARID1B has been identified as a good candidate 
target gene for synthetic lethality with ARID1A. Depleting ARID1B in ARID1A mutated cells 
prevents SWI/SNF complex formation, which impairs proliferation in human tumor cells and MEFs 
(Helming et al. 2014). 
Regarding STAG2, we describe that loss of protein expression, determined using IHC, is 
associated with improved prognosis in UBC, although we only found it to be an independent 
predictor of increased survival in MI tumors. This finding is counterintuitive considering that 
cohesion defects and aneuploidy might be expected to associate with more aggressive tumors, 
but it is consistent with the strong association of STAG2 inactivation and tumors of lower 
stage/grade. Solomon et al showed that loss of STAG2 - assessed using IHC - was significantly 
correlated with increased survival in NMIUBC. However, they found that it was associated with 
increased recurrence and mortality in MIUBC (Solomon et al. 2013). Guo et al. described that 
patients with STAG2 mutations presented significantly lower survival in both NMI and MI UBC 
(2013). However, these authors did not test for IHC expression and included in the analysis 
missense mutations whose biological significance is not known.  
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Several factors could explain the observed discrepancies. Our larger tumor series allowed us 
to perform both stratified and multivariate analysis, which strengthens the statistical power of 
our findings. In contrast, both Solomon and colleagues and Guo and colleagues performed only 
Kaplan-Meier analyses, not considering the effect of other risk factors such as tumor stage and 
grade (2013; 2013). The strong association between STAG2 alterations and stage and grade makes 
the use of multivariable analysis a must to assess whether STAG2 expression studies might be of 
any clinical usefulness. Additionally, Solomon et al. did not specify how they defined loss of STAG2 
expression (2013); differences in the scoring systems could account for the observed disparities. 
Finally, the study of Guo et al. had a very small sample size (2013). Additional, carefully stratified, 
analyses accounting for these potential confounders are required to draw definite conclusions 
about the putative clinical usefulness of the study of STAG2 alterations in UBC. 
The study of STAG2 alterations might unveil novel therapeutic opportunities for UBC. A recent 
study in pancreatic cancer cell lines showed that loss of STAG2 increased sensitivity to platinum-
based treatments (specifically, to carboplatin, cisplatin, and oxaliplatin) (Evers et al. 2014). 
Cisplatin is the standard for MIUBC treatment (Stenzl et al. 2011); therefore it will be important to 
determine whether STAG2 status could predict the efficiency of chemotherapy treatment. If so, 
this might explain the improved outcome we observed in MIUBC patients whose tumors displayed 
loss of STAG2. One possible mechanism for this increase in sensitivity is that STAG2 negative 
tumors are especially sensitive to agents inducing DNA damage because of the role of cohesion in 
double-strand break repair mediated by homologous recombination.  
In agreement with this potential mechanism, studies performed in yeast and later confirmed 
in Caenorhabditis elegans have suggested the existence of a synthetic lethal relationship between 
mutations in cohesin complex members and in PARP1 (McLellan et al. 2012). In human CRC cells, 
this synthetic lethality was shown for PARP1 and either STAG1 or STAG3 (O’Neil et al. 2013). A 
recent study showed that loss of STAG2 causes hypersensitivity to PARP inhibitors in glioblastoma 
cell lines (Bailey et al. 2014). Moreover, the effect of agents inhibiting PARP was maximized upon 
treatment with drugs causing DNA damage. However, none of the 9 different PARP inhibitors 
currently undergoing clinical trials focuses on UBC. Preliminary experiments in UBC cell lines did 
not show increased mortality upon STAG2 silencing accompanied by PARPi treatment (data not 
shown). However, the development of the more physiological UBC STAG2 knockout models in our 
laboratory will be paramount to evaluate this therapeutic strategy in bladder tumors in vivo.
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In light of the results presented here, the conclusions drawn from the study are: 
1. Pathways frequently altered in UBC include chromatin remodeling, DNA repair, and 
chromosome segregation. We have identified recurrent mutations in genes for which a 
role in UBC had not been previously reported: MLL2, ASXL2, BPTF (chromatin 
remodeling); ATM, ERCC2, FANCA (DNA repair); and STAG1, STAG2, SMC1A, SMC1β 
(chromosome segregation). 
2. UBCs harbor an average of 169 somatic exomic mutations, with a predominance of 
synonymous mutations. The most common nucleotide changes are C>T/G>A transitions. 
We have not found significant associations between mutation number or type and age, 
tumor aggressiveness, or patient smoking status. 
3. ARID1A truncating mutations frequently lead to loss of protein expression. Loss of ARID1A 
is commonly accompanied by low levels of FGFR3, and KRT20. ARID1A mutations and loss 
of expression are more common in aggressive than in non-aggressive tumors and 
associate with an increased risk of tumor progression.  
4. STAG2 truncating mutations frequently lead to loss of protein expression and are more 
common in non-aggressive than in aggressive tumors. Loss of STAG2 expression 
significantly associates with unicentric, small, NMI tumors of low stage and grade. STAG2 
loss associates with low proliferative index, mutations in FGFR3, and normal p53 
expression. In MIUBC, loss of STAG2 expression is an independent predictor of survival. 
5. In addition to point mutations, genomic losses contribute to STAG2 inactivation. 
6. Loss of STAG2 expression does not associate with increased aneuploidy in UBC tumors or 
cell lines, nor with increased centromeric cohesion defects in vitro, supporting the notion 
that STAG2 inactivation contributes to UBC through mechanisms different from those 
involved in chromosome segregation. 
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A la luz de los resultados presentados, las conclusiones obtenidas en este estudio son: 
1. Las vías alteradas frecuentemente en el CV incluyen remodelación de la cromatina, 
reparación del ADN y segregación cromosómica. Hemos identificado mutaciones 
recurrentes en genes cuya función en el CV no había sido descrita con anterioridad: 
MML2, ASXL2 y BPTF (remodelación de la cromatina; ATM, ERCC2 y FANCA (reparación 
del ADN); y STAG1, STAG2, SMC1A y SMC1β (segregación cromosómica). 
2. Los CV presentan una media de 169 mutaciones somáticas en el exoma, con un 88% de las 
muestras que exhiben un ratio de mutaciones no sinónimas vs. sinónimas <1. Los cambios 
de nucleótidos más comunes son las transiciones C>T/G>A. No hay diferencias 
significativas en número o tipo de mutación dependiendo de la agresividad del tumor, la 
edad del paciente, ni de su exposición al tabaco. 
3. Las mutaciones truncantes en ARID1A son más comunes en los tumores agresivos que en 
los no agresivos y suelen conllevar la pérdida de expresión de la proteína. La pérdida de 
expresión de ARID1A suele ir acompañada de niveles bajos de FGFR3 y KRT20 y, en un 
subgrupo de casos, también de niveles altos de KRT5/6 y KRT14. La pérdida de ARID1A se 
correlaciona con tasas más bajas de recurrencia tumoral y con un incremento en el riesgo 
de progresión tumoral. 
4. Las mutaciones truncantes en STAG2 son más comunes en los tumores no agresivos que 
en los agresivos y suelen conllevar la pérdida de expresión de la proteína. La pérdida de 
expresión de STAG2 se asocia significativamente con tumores no invasivos de bajo estadio 
y grado que son monocéntricos y de menor tamaño. La pérdida de STAG2 se asocia con 
un bajo índice proliferativo, mutaciones en FGFR3 y expresión normal de p53. En los CV 
invasivos, la pérdida de expresión de STAG2 es un predictor independiente de la 
supervivencia. 
5. Además de las mutaciones puntuales, hay pérdidas genómicas que contribuyen a la 
inactivación de STAG2. 
6. La pérdida de expresión de STAG2 no se asocia con un incremento en la aneuploidía en los 
tumores o líneas celulares de CV ni con mayor número de defectos en la cohesión 
centromérica in vitro, apoyando la noción de que la inactivación de STAG2 contribuye al 
CV a través de mecanismos distintos a los involucrados en segregación cromosómica. 
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Supplementary Table 1. Characteristics of the patients included in the discovery and prevalence 
screens. E: Sample included in the exome sequencing screen. P: Sample included in HaloPlex 
prevalence screen. A: Sample included in the ARID1A mutational screen. NA: Information not 
available. S: Smoker. NS: Non-smoker. ES: Ex-smoker. 
Sample Age Gender 
Stage/ 
Grade 
Smoking 
status 
Study of 
inclusion 
62 60 Male T1G3 S E 
114 76 Female T2G3 NS E 
116 83 Male T1G2 S E 
179 56 Male TaG1 S E 
193 71 Male T2G3 S E 
251 84 Female TaG2 NS E 
310 46 Male T1G3 NS E 
331 47 Male TaG1 S E 
343 81 Female T1G3 NS E 
413 58 Male TaG3 S E 
1418 77 Female TaG1 NS E 
Esp66 68 Male T1G3 S EA 
64 95 Female T1G2 NS EP 
188 53 Male T1G3 S EP 
274 35 Male T1G2 NS EP 
313 73 Male T1G3 S EP 
451 78 Male TaG2 S EP 
11 66 Male T1G3 NA P 
47 78 Male T1G3 NA P 
76 64 Male T1G3 S P 
80 73 Male TaG2 NA P 
88 83 Male TaG1 ES P 
102 75 Male TaG1 ES P 
121 80 Male TaG3 ES P 
131 77 Male T1G3 NA P 
147 51 Male TaG1 S P 
181 59 Male TaG1 NA P 
207 59 Male T1G2 S P 
248 82 Male T1G3 NA P 
272 36 Male T1G3 ES P 
275 82 Male T2G3 NA P 
280 74 Male T2G3 S P 
281 86 Male TaG2 ES P 
304 76 Male TaG2 NS P 
308 85 Male TaG3 NA P 
311 57 Male TaG3 S P 
312 84 Male TaG3 ES P 
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325 73 Male TisG2 NA P 
339 53 Male TaG2 NA P 
344 60 Male TaG1 NA P 
358 75 Male T2G3 NA P 
375 79 Male T1G2 NS P 
395 82 Female TaG3 ES P 
402 73 Male T1G3 NA P 
411 82 Male TisG3 ES P 
414 71 Male T1G3 ES P 
416 74 Male TaG1 S P 
424 72 Male TaG3 ES P 
427 51 Male TaG1 ES P 
432 70 Male T1G3 S P 
433 66 Male T1G3 S P 
435 83 Male T1G3 ES P 
438 81 Male T1G3 ES P 
439 74 Male T1G3 ES P 
450 81 Male T1G3 ES P 
453 95 Male TaG2 NS P 
473 69 Female TaG1 NS P 
479 58 Male TaG1 NA P 
489 63 Female NA NS P 
497 77 Male T1G3 S P 
508 66 Male TaG2 NA P 
512 74 Female T1G3 NA P 
533 53 Male TaG2 S P 
562 83 Male T1G2 ES P 
597 83 Male TaG1 ES P 
630 89 Female T2G3 NS P 
639 48 Male T1G2 S P 
718 69 Male T1G3 ES P 
776 66 Male T1G3 NA P 
811 80 Male T2G3 ES P 
818 76 Female TaG2 NS P 
823 76 Male T1G3 ES P 
Esp104 45 Male TaG2 ES P 
Esp21 74 Male TaG1 S PA 
Esp27 77 Male T2G3 ES PA 
Esp44 69 Male TaG3 S P 
Esp86 56 Male T2G3 S PA 
Esp55 67 Male T3G3 NA A 
Esp64 64 Male TaG1 NA A 
Esp46 72 Male TaG3 NA A 
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Esp95 77 Male TaG1 NA A 
Esp49 68 Male TaG2 NA A 
Esp41 79 Male T3G3 NA A 
Esp69 75 Male T3G3 NA A 
Esp37 71 Male TaG3 NA A 
Esp52 73 Male TaG2 NA A 
Esp29 71 Male TaG3 NA A 
Esp61 58 Male T1G2 NA A 
5 54 Male TaG1 NA A 
19 72 Male TaG1 NA A 
28 74 Male TaG2 NA A 
31 54 Male TaG1 NA A 
34 50 Male TaG1 NA A 
35 56 Male TaG1 NA A 
43 NA Male T4G3 NA A 
12 71 Male T1G3 NA A 
789 51 Male TaG1 NA A 
791 82 Male T1G2 NA A 
793 80 Male TaG3 NA A 
796 76 Male T1G3 NA A 
798 60 Male T1G3 NA A 
800 64 Male T1G3 NA A 
803 53 Male T1G3 NA A 
811b 83 Male TaG1 NA A 
814 76 Female T2G3 NA A 
818b 59 Male T1G2 NA A 
826 95 Female T1G2 NA A 
828 86 Male TaG3 NA A 
830 73 Male TaG2 NA A 
833 51 Male T1G2 NA A 
835 84 Female TaG2 NA A 
842 81 Male T1G3 NA A 
851 81 Male T2G3 NA A 
856 56 Male TaG1 NA A 
870 46 Male T1G3 NA A 
871 57 Male TaG3 NA A 
874 84 Male TaG3 NA A 
875 73 Male T1G3 NA A 
877 76 Male TaG2 NA A 
557 47 Male TaG1 NA A 
559 82 Female T1G3 NA A 
563 72 Male TaG3 NA A 
742 53 Male TaG2 NA A 
816 NA NA NA NA A 
744 80 Male T1G2 NA A 
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Supplementary Table 2. Characteristics of the patients with UBC for which ARID1A expression 
was assessed. NA: Information not available. 
 
 
N (%) 
Total 84 
Age Mean (SD) 66.4 (9.7) 
Gender Male 74 (88.1) 
 
Female 10 (11.9) 
Stage/Grade TaG1 21 (25.0) 
 
TaG2 18 (21.4) 
 
TaG3 7 (8.3) 
 
T1G2 NA 
 
T1G3 12 (14.3) 
 
> T2 26 (31.0) 
Tumor size < 3 cm 27 (32.1) 
 
> 3 cm 17 (20.2) 
 
Unknown 40 (47.7) 
Multiplicity Single 47 (56.0) 
 
Multiple 29 (34.5) 
 
Unknown 8 (9.5) 
Treatment TUR alone 12 (14.4) 
 
TUR+endovesical chemo 15 (17.6) 
 
TUR+BCG 30 (35.8) 
 
Cystectomy 10 (11.9) 
 
TUR+BCG+endov chemo NA 
 
TUR+cystectomy NA 
 
Systemic Chemotherapy 8 (9.6) 
 
Radiotherapy 5 (5.9) 
 
Others 4 (4.8) 
 
Missing NA 
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Supplementary Table 3. Characteristics of the patients with UBC for which STAG2 protein 
expression was assessed. NA: Not applicable. 
 
 
NMIUBC MIUBC 
  N % N % 
Total 480 100 182 100 
Gender   
 
  
 
Male 427 89 160 87.9 
Female 53 11 22 12.1 
Age   
 
  
 
<60 118 24.6 39 21.4 
61-70 190 39.6 74 40.7 
>70 172 35.8 69 37.9 
Area   
 
  
 
Barcelona 84 17.5 33 18.1 
Valles-Bages 84 17.5 33 18.1 
Alicante 43 9 11 6 
Tenerife 101 21 31 17 
Asturias 168 35 74 40.7 
Tumor number   
 
  
 
Solitary 303 67.6 122 73.9 
Multiple 145 32.4 43 26.1 
Tumor site   
 
  
 
1 site 298 63.5 84 46.9 
>1 site 171 36.5 95 53.1 
Tumor size   
 
  
 
<3cm 254 52.9 40 22 
>3cm 96 20 57 31.3 
Unknown 130 27.1 85 46.7 
Histological grade   
 
  
 
Benign (PUNLMP) 1 0.2 NA NA 
G1 156 32.5 NA NA 
G2 173 36 14 7.7 
G3 150 31.2 168 92.3 
T stage   
 
  
 
Ta 359 74.8 NA NA 
T1 121 25.2 NA NA 
T2 NA NA 92 50.5 
T3 NA NA 48 26.4 
T4 NA NA 42 23.1 
TG category   
 
  
 
TaG1 157 32.7 NA NA 
TaG2 167 34.8 NA NA 
TaG3 35 7.3 NA NA 
T1G2 6 1.2 NA NA 
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T1G3 115 24 NA NA 
T2G2 NA NA 6 3.3 
T2G3 NA NA 86 47.3 
T3G2 NA NA 5 2.7 
T3G3 NA NA 43 23.6 
T4G2 NA NA 3 1.6 
T4G3 NA NA 39 21.4 
Risk groups   
 
  
 
Low-risk (TaG1, TaG2) 324 67.5 NA NA 
High-risk (T1G2,TaG3, T1G3) 156 32.5 NA NA 
Treatment   
 
  
 
Others 27 5.6 51 28.2 
RTU 188 39.2 NA NA 
RTU + BCG 149 31 NA NA 
RTU + BCG + Intravesical Chemoth. 16 3.3 NA NA 
RTU + Intrav. Chemotherapy 100 20.8 NA NA 
Cystectomy NA NA 58 32 
Cystectomy+chemotherapy NA NA 31 17.1 
Chemotherapy NA NA 20 11 
Radiotherapy + Chemotherapy NA NA 13 7.2 
Intravesical treatment NA NA 8 4.4 
Number of recurrences   
 
  
 
0 327 68.1 NA NA 
1 - 2 110 22.9 NA NA 
> 2 43 9 NA NA 
Nodal status    
 
  
 
0 NA NA 119 65.4 
1 NA NA 45 24.7 
2 NA NA 18 9.9 
Metastasis   
 
  
 
M0 NA NA 146 80.2 
M1 NA NA 24 13.2 
Mx NA NA 12 6.6 
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Supplementary Table 4. Genes included in the prevalence screen and reason for inclusion. 
Gene Name Pathway/Reason for Inclusion 
APEX1  Base Excision Repair 
APEX2 Base Excision Repair 
BPTF Chromatin remodelling 
BRCA2 Fanconi anemia 
BRIP1 Fanconi anemia 
BTBD12 Fanconi anemia 
ERCC2 DNA repair 
ESCO1 Cohesin/Chromosome segregation 
ESCO2 Cohesin/Chromosome segregation 
ESPL1 Cohesin/Chromosome segregation 
EXO1 DNA repair 
FANCA Fanconi anemia 
FANCB Fanconi anemia 
FANCC Fanconi anemia 
FANCE Fanconi anemia 
FANCF Fanconi anemia 
FANCG  Fanconi anemia 
FANCI Fanconi anemia 
FANCL Fanconi anemia 
HRAS Involved in UBC 
kiaa0892 Cohesin/Chromosome segregation 
KRAS Involved in UBC 
LIG3 Base Excision Repair 
MBD4 Base Excision Repair 
MLH1 DNA repair 
MPG Base Excision Repair 
MSH4 DNA repair 
MTMR15/FAN1 DNA repair 
MUTYH Base Excision Repair 
NEIL3 Base Excision Repair 
NOTCH1 DNA repair 
NOTCH2 DNA repair 
OGG1 Base Excision Repair 
PARP1 DNA repair 
PDS5A Cohesin/Chromosome segregation 
PDS5B Cohesin/Chromosome segregation 
PMS1 DNA repair 
PNKP Base Excision Repair 
POLD1 DNA repair 
POLE DNA repair 
POLN DNA repair 
PTEN Involved in UBC 
RAD18 DNA repair 
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RAD21 Cohesin/Chromosome segregation 
RAD50 DNA repair 
RAD51C  Fanconi anemia 
REC8 Cohesin/Chromosome segregation 
SMC1A Cohesin/Chromosome segregation 
SMC3 Cohesin/Chromosome segregation 
SMUG1 Base Excision Repair 
STAG1 Cohesin/Chromosome segregation 
STAG3 Cohesin/Chromosome segregation 
TOP2A Cohesin/Chromosome segregation 
TP53BP1 DNA repair 
UNG Base Excision Repair 
WAPAL Cohesin/Chromosome segregation 
XRCC1 Base Excision Repair 
ARHGAP5  Recurrent in Discovery screen 
ARID1A Recurrent in Discovery screen 
ASXL1 Recurrent in Discovery screen 
ASXL2 Recurrent in Discovery screen 
ATM DNA repair 
BCLAF1  Recurrent in Discovery screen 
BCOR Recurrent in Discovery screen 
BRAF Recurrent in Discovery screen 
CASP5 Recurrent in Discovery screen 
CHD6 Recurrent in Discovery screen 
CHEK2 DNA repair 
CREBBP  Recurrent in Discovery screen 
CSE1L Recurrent in Discovery screen 
DHX32  Recurrent in Discovery screen 
DISP1 Recurrent in Discovery screen 
EIF2C4 Recurrent in Discovery screen 
ELF3 Recurrent in Discovery screen 
EP300 Recurrent in Discovery screen 
ERBB3 Involved in UBC 
FANCD2 Fanconi anemia 
FANCM Fanconi anemia 
FBXW7 Cohesin/Chromosome segregation 
FGFR3 Involved in UBC 
ILK Recurrent in Discovery screen 
IREB2 Recurrent in Discovery screen 
KDM6A/UTX Recurrent in Discovery screen 
KHSRP Recurrent in Discovery screen 
KIF2B Cohesin/Chromosome segregation 
MAP3K7 Recurrent in Discovery screen 
MAP4K4 Recurrent in Discovery screen 
MAPK14 Recurrent in Discovery screen 
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MAPK8IP3 Recurrent in Discovery screen 
MLL Recurrent in Discovery screen 
MLL2 Recurrent in Discovery screen 
MLL3 Recurrent in Discovery screen 
MYCBP2 Recurrent in Discovery screen 
MYSM1 Recurrent in Discovery screen 
NBN DNA repair 
NCOR1 Recurrent in Discovery screen 
NIPBL Cohesin/Chromosome segregation 
NLRP5 Recurrent in Discovery screen 
NRAS Involved in UBC 
NUP93 Recurrent in Discovery screen 
PALB2 Fanconi anemia 
PIK3CA Involved in UBC 
RAD51 DNA repair 
RAD54B DNA repair 
RB1 Involved in UBC 
SMC1B Cohesin/Chromosome segregation 
SMCHD1 Recurrent in Discovery screen 
STAG2 Cohesin/Chromosome segregation 
TP53 Involved in UBC 
WHSC1L1  Recurrent in Discovery screen 
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Supplementary Table 5. Coverage metrics for samples included in the exome sequencing screen. 
N: Normal leukocyte DNA. T: Tumor DNA. tROI: Targeted Regions of Interest. C10: Percentage of 
bases covered by more than 10 reads. C15: Percentage of bases covered by more than 15 reads. 
Sample tROI Specificity Enrichment C10 C15 Mean_cov Median_cov 
418 N 46830265 73.27 148.10 84.30 79.68 83.79 58 
418 T 46830265 73.09 146.72 84.26 79.38 72.66 53 
331 N 46830265 72.10 139.65 82.09 76.36 62.02 44 
331 T 46830265 72.99 146.01 81.47 75.41 53.95 40 
179 N 50570842 71.19 123.42 93.14 88.48 73.30 55 
179 T 50570842 72.40 131.02 95.49 92.26 93.51 70 
251 N 46830265 73.03 146.31 84.16 79.46 78.64 56 
251 T 46830265 72.83 144.81 84.02 79.22 75.60 54 
451 N 50570842 71.05 122.63 96.43 94.05 115.31 88 
451 T 50570842 71.66 126.34 94.83 91.51 100.73 73 
413 N 46830265 72.33 141.19 81.78 75.89 58.39 42 
413 T 46830265 72.07 139.42 81.64 75.58 55.65 40 
064 N 50570842 71.72 126.68 94.98 91.63 93.70 71 
064 T 50570842 72.09 129.01 95.00 91.62 98.14 71 
274 N 50570842 70.16 117.44 95.53 92.38 92.04 71 
274 T 50570842 70.77 120.93 95.18 92.09 97.83 75 
116 N 46830265 71.92 138.34 83.22 78.21 75.83 52 
116 T 46830265 71.08 132.78 80.82 74.53 55.59 39 
313 N 50570842 70.49 119.35 95.55 92.52 101.34 75 
313 T 50570842 69.17 112.08 92.96 88.34 76.79 56 
188 N 50570842 70.20 117.66 95.05 91.60 91.58 68 
188 T 50570842 70.10 117.10 94.96 91.65 98.67 71 
062 N 50570842 69.43 113.46 96.61 94.13 112.33 84 
062 T 50570842 68.97 111.05 94.53 90.75 85.49 64 
Esp66 N 46830265 74.39 156.92 79.87 73.77 50.97 39 
Esp66 T 46830265 43.47 41.54 66.93 62.20 74.59 33 
310 N 46830265 69.19 121.34 83.69 78.80 75.83 53 
310 T 46830265 72.56 142.89 83.35 78.12 68.83 49 
343 N 50570842 70.85 121.41 94.13 90.19 83.90 62 
343 T 50570842 68.46 108.43 93.21 88.77 79.80 57 
114 N 46830265 73.09 146.76 83.69 79.02 83.91 57 
114 T 46830265 71.80 137.55 83.04 78.47 88.49 59 
193 N 46830265 71.20 133.56 86.09 81.24 66.85 50 
193 T 46830265 69.63 123.88 84.89 79.33 59.07 44 
Mean   70.55 127.82 88.14 83.72 80.44 58.03 
SD   5.00 19.88 7.10 8.00 16.87 13.77 
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Median   71.43 127.85 85.49 80.46 79.22 56.50 
Min   43.47 41.54 66.93 62.20 50.97 33.00 
Max   74.39 156.92 96.61 94.13 115.31 88.00 
Mean N 71.51 131.42 88.84 84.55 82.34 60.29 
SD N 1.43 13.28 6.33 7.40 17.77 14.10 
Median 
N 71.20 126.68 86.09 81.24 83.79 57.00 
Min N 69.19 113.46 79.87 73.77 50.97 39.00 
Max N 74.39 156.92 96.61 94.13 115.31 88.00 
Mean T 69.60 124.21 87.45 82.90 78.55 55.76 
SD T 6.89 24.72 7.93 8.71 16.24 13.47 
Median 
T 71.66 129.01 84.89 79.38 76.79 56.00 
Min T 43.47 41.54 66.93 62.20 53.95 33.00 
Max T 73.09 146.72 95.49 92.26 100.73 75.00 
P-value 0.48 0.45 0.43 0.41 0.61 0.47 
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Supplementary Table 6. Sanger sequencing validation of alterations identified by exome 
sequencing. 
Sample Gene Symbol Genomic Position 
Base 
change 
Exon junction 
mutation 
Sanger 
validation 
114 
BCLAF1 6:136599393 G>C   Yes/Germline 
BCOR X:39930312 C>A 
 
Yes 
CAP2 6:17514088 G>A 
 
Yes 
NBEAL1 2:203977847 C>A 
 
Yes 
NCOA6 20:33328965 G>C   Yes 
116 
ACOT12 5:80640707 G>A Yes Yes 
APAF1 12:99109247 C>A 
 
Yes 
APAF1 12:99119192 G>C Yes Yes 
ARHGEF38 4:106587443 T>A 
 
Yes 
ARSD X:2836238 G>A 
 
Yes 
ATP11B 3:182631645 G>A Yes Yes 
BCAS3 17:59067579 C>T 
 
Yes 
BCLAF1 6:136599393 G>C 
 
Yes/Germline 
C20orf43 20:55093380 C>T 
 
Yes 
CASP5 11:104877890 G>C 
 
Yes 
DCAF4L1 4:41984354 T>A 
 
Yes 
DGKG 3:186024771 A>G Yes Yes 
DHX32 10:127530345 C>T 
 
Yes 
DPYD 1:98164907 C>A Yes Yes 
ENOX1 13:43986126 G>T 
 
Yes 
ERBB3 12:56482552 G>C 
 
Yes 
ERBB3 12:56488226 G>A 
 
Yes 
FANCD2 3:10084271 C>T 
 
Yes 
FBXO15 18:71749182 T>G 
 
Yes 
GGTLC2 22:22989270 G>C 
 
Yes 
HECW1 7:43351361 G>A Yes Yes 
IREB2 15:78770698 C>T 
 
Yes 
MAP4K4 2:102476144 G>A 
 
Yes 
MAPK8IP3 16:1817211 C>G 
 
Yes 
NBN 8:90955475 A>G Yes Yes 
OBSCN 1:228487711 G>C 
 
Yes 
OR8D4 11:123777880 G>A 
 
Not validated 
RELL2 5:141017844 C>T 
 
Yes 
SLITRK2 X:144905201 A>G 
 
Yes 
TMEM126A 11:85366652 G>C 
 
Yes 
WDR67 8:124153010 G>C 
 
Yes 
WWC1 5:167850687 C>G 
 
Yes 
ZNF382 19:37118108 A>G 
 
Yes 
ZNF513 2:27600816 G>A 
 
Yes 
ZNF645 X:22291997 C>G   Yes 
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179 
EP300 22:41545917 T>+T   Yes 
NUP98 11:3735079 T>C 
 
Yes 
PIK3CA 3:178916944 A>G 
 
Yes 
TBC1D19 4:26640413 A>T 
 
Yes 
UBE3B 12:109935628 T>C   Yes 
188 RBM10 X:47034489 C>T Yes Yes 
193 
ADCYAP1R1 7:31146175 C>G   Yes 
AKNAD1 1:109391616 G>A 
 
Yes 
ANK2 4:114161701 C>T 
 
Yes 
ART4 12:14993738 G>A 
 
Yes 
ASXL1 20:31024236 G>A 
 
Yes 
ATP2A3 17:3853842 C>T 
 
Yes 
AUTS2 7:70246606 G>A 
 
Yes 
CEP70 3:138224288 G>A 
 
Yes 
COL27A1 9:116930982 A>C 
 
Yes 
CREBBP 16:3790439 G>C 
 
Yes 
CREM 10:35477169 G>A 
 
Yes 
CSE1L 20:47689123 C>T 
 
Yes 
DNAH2 17:7674239 G>A 
 
Yes 
DOCK3 3:51352413 G>A Yes Yes 
FAM83D 20:37580315 C>T 
 
Yes 
FBXO43 8:101153886 C>T 
 
Yes 
FBXW7 4:153247184 G>A 
 
Yes 
GABRA1 5:161277884 G>A 
 
Yes 
GABRP 5:170222429 G>A Yes Yes 
GHR 5:42689058 G>A 
 
Yes 
IMPA1 8:82593792 C>T 
 
Yes 
KCTD10 12:109893973 C>T 
 
Yes 
KDM6A X:44894233 A>----- Yes Yes 
NCOA4 10:51582942 C>T Yes Yes 
NSD1 5:176683980 G>C 
 
Yes 
NSD1 5:176684158 G>C Yes Yes 
NUP93 16:56782202 C>T 
 
Yes 
PDZD2 5:32010451 G>T 
 
Yes 
PHIP 6:79679800 T>C 
 
Yes 
PIK3CA 3:178921553 T>A 
 
Yes 
PRAMEF11 1:12884817 C>A 
 
Yes 
PTPRD 9:8389266 A>G 
 
Yes 
PUM1 1:31426622 A>T 
 
Yes 
RGMA 15:93588794 C>T 
 
Yes 
STAG2 X:123204998 G>A Yes Yes 
TIMM23B 10:51582942 C>T Yes Yes 
TMEM117 12:44782322 C>T 
 
Yes 
WHSC1L1 8:38186970 T>C   Not validated 
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251 
ARHGAP5 14:32562174 A>G   Yes 
CHD6 20:40161768 C>T 
 
Yes 
CREBBP 16:3808977 C>T Yes Not validated 
CTTN 11:70253616 C>G Yes Yes 
CUL3 2:225422486 G>C 
 
Yes 
EHBP1 2:63176088 G>A 
 
Yes 
ELF3 1:201984363 A>-------- 
 
Yes 
KCNK2 1:215256745 C>T 
 
Yes 
KIAA1370 15:52902548 T>A 
 
Yes 
LY75 2:160755489 C>T Yes Yes 
LY75-CD302 2:160755489 C>T Yes Yes 
MAP2 2:210560516 C>A 
 
Yes 
MTIF2 2:55481309 G>A 
 
Yes 
MYSM1 1:59127132 C>T 
 
Yes 
NUP133 1:229600575 C>G 
 
Yes 
PIK3CA 3:178916876 G>A 
 
Yes 
RHOA 3:49405915 G>T 
 
Yes 
SAMD9L 7:92762797 C>T 
 
Yes 
TMEM173 5:138858001 C>T 
 
Yes 
WHSC1L1 8:38162239 T>C   Yes 
274 GNAS 20:57480483 C>T   Yes 
310 
KDM5B 1:202715021 T>C   Yes 
RSC1A1 1:15986544 G>A 
 
Yes 
AC022098.3 19:14269152 C>G 
 
Yes 
ADD3 10:111876075 G>+CA 
 
Yes 
BRMS1L 14:36334139 A>G Yes Yes 
CACNA1D 3:53757641 C>T 
 
Yes 
DHX32 10:127555638 C>T 
 
Yes 
KDM6A X:44969442 T>- 
 
Yes 
LPHN1 19:14269152 C>G 
 
Yes 
MLL2 12:49418394 C>A 
 
Yes 
NLRP5 19:56539603 G>A 
 
Yes 
RAD54B 8:95448825 G>C 
 
Yes 
STAG2 X:123200023 A>T Yes Yes 
ZNF428 19:44111720 C>T   Yes 
413 
ABHD13 13:108881846 A>T   Yes 
ADAM32 8:39114795 G>T 
 
Yes 
ATM 11:108143533 G>A 
 
Yes 
BRAF 7:140481441 T>C 
 
Yes 
CHD9 16:53262979 G>C 
 
Yes 
DISP1 1:223168260 C>G 
 
Yes 
FGFR3 4:1806092 A>T 
 
Yes 
GOT1 10:101166543 G>A 
 
Yes 
HBP1 7:106820415 C>T 
 
Yes 
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ICAM5 19:10402180 T>C 
 
Yes 
IQGAP2 5:75969287 G>A 
 
Yes 
LIMK1 7:73535377 G>A Yes Yes 
MAPK14 6:36041477 T>- 
 
Yes 
MLL2 12:49420607 G>A 
 
Yes 
MLL3 7:151851423 A>T 
 
Yes 
MYH7 14:23894113 C>G 
 
Yes 
NIPBL 5:37008194 A>G Yes Yes 
NME7 1:169292395 C>A 
 
Yes 
NPR1 1:153653686 G>C 
 
Yes 
PRDX4 X:23704428 G>A 
 
Yes 
PRKCH 14:61952298 G>A 
 
Yes 
PROCR 20:33764632 C>G 
 
Yes/Germline 
RAD51 15:41001249 G>T 
 
Yes 
SMC1B 22:45795226 C>T 
 
Yes 
STXBP5 6:147588215 C>G Yes Yes 
TRPM2 21:45819236 G>A 
 
Yes 
UBR4 1:19474549 G>A 
 
Yes 
XKR4 8:56270260 G>T 
 
Yes 
ZNF462 9:109688261 G>C 
 
Yes 
ZNF716 7:57528942 C>T   Yes 
418 
ASXL2 2:25978922 G>T   Yes 
ASXL2 2:25982401 C>A 
 
Yes 
ASXL2 2:25982439 C>T 
 
Yes 
CHD4 12:6707456 C>G 
 
Yes 
CHEK2 22:29095903 C>G 
 
Yes 
CTNND1 11:57571085 T>C Yes Yes 
FGFR3 4:1806099 A>G 
 
Yes 
GAB2 11:77936174 C>T 
 
Yes 
GPR98 5:90079045 G>A 
 
Yes 
ILK 11:6631209 A>C 
 
Yes 
KHSRP 19:6418562 G>A 
 
Yes 
MTHFR 1:11863014 C>G 
 
Yes 
MYEF2 15:48450972 C>A 
 
Yes 
MYSM1 1:59125701 C>T 
 
Yes 
NBEA 13:36220438 C>T 
 
Yes 
PIK3CA 3:178936091 G>A 
 
Yes 
SMCHD1 18:2703807 C>----- 
 
Yes 
STAG2 X:123196830 C>T 
 
Yes 
ULK4 3:41757012 G>C   Yes 
451 
CR2 1:207647031 C>G   Yes 
DNAH3 16:21147804 G>A 
 
Yes 
FLT3 13:28626737 C>G 
 
Yes 
LIPG 18:47101866 G>T 
 
Yes 
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MADCAM1 19:504757 C>T 
 
Yes 
MAGI3 1:114193672 G>A 
 
Yes 
MDN1 6:90372684 C>G Yes Yes 
PABPC1L 20:43585027 G>A Yes Yes 
RAPGEF2 4:160279265 G>A Yes Yes 
SLFN13 17:33767862 C>T 
 
Yes 
SULT1E1 4:70710007 G>A 
 
Yes 
TAF5 10:105146985 C>G 
 
Not  validated 
TOMM34 20:43585027 G>A Yes Yes 
TP53 17:7578394 T>A   Yes 
064 
ADRA1A 8:26722392 A>G   Yes 
HCN3 1:155254496 C>G 
 
Yes 
HCN3 1:155254514 C>T 
 
Yes 
KDM4D 11:94731144 A>G 
 
Yes 
NF1 17:29701298 C>T 
 
Yes 
PHKA2 X:18938281 G>A 
 
Yes 
PPP4R4 14:94732129 A>C Yes Yes 
SLC38A9 5:54931377 C>G 
 
Yes 
TP53 17:7578211 C>A   Yes 
Esp66 
BCHE 3:165547615 C>A   Yes 
CDKAL1 6:20846406 C>T 
 
Yes 
DSP 6:7568676 C>T 
 
Yes 
EIF2C1 1:36367916 C>A 
 
Yes 
FANK1 10:127668859 C>T 
 
Yes/Germline 
KRT35 17:39633349 G>C 
 
Yes/Germline 
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Supplementary Table 7. Depth of coverage metrics for samples included in the HaloPlex 
targeted resequencing screen. B: Normal DNA from blood (note that some of the normal samples 
were analyzed in pools). Targeted Regions of Interest: 485,052 for all cases. C10: Percentage of 
bases covered by more than 10 reads. C15: Percentage of bases covered by more than 15 reads. 
C30: Percentage of bases covered by more than 30 reads. 
Sample ID C10 C15 C30 Mean_Cov Median_Cov 
011 96,3324 95,4584 93,6745 1243,0404 796 
047 78,8775 74,1898 63,7771 180,2932 62 
076 67,9502 62,3383 51,6780 128,5843 33 
080 97,1898 96,5674 94,7686 1003,3752 584 
088 95,8081 94,9366 92,6789 869,1008 576 
102 96,7278 96,0992 94,7134 2397,8991 1612 
121 74,4968 69,0241 57,4992 139,7130 45 
131 67,0973 61,5705 50,2105 90,3180 31 
147 59,3483 53,4959 42,6482 121,8625 19 
181 95,0601 94,0584 91,7625 1466,4578 748 
207 68,8048 63,1681 50,4797 99,1697 31 
248 91,4506 89,4271 84,3835 348,6409 205 
272 81,3408 79,1422 74,5403 1055,5705 409 
275 91,5250 89,6211 85,0459 420,4908 240 
280 94,6218 93,4240 90,2578 563,3873 384 
281 98,0085 97,6215 96,6791 1114,3599 871 
304 93,7998 92,6672 89,9083 714,7739 426 
308 98,4198 98,1895 97,5576 1655,5875 1340 
311 90,6233 88,5495 83,5791 367,8674 203 
312 89,4003 86,7150 80,1974 270,9763 141 
325 95,3553 94,1901 90,9488 1872,3075 407 
339 92,3464 90,5330 86,0780 404,6770 242 
344 95,3923 94,2909 91,6786 592,1638 419 
358 88,5757 86,8579 83,2255 1088,7451 624 
375 89,2195 87,5088 83,7972 818,3309 363 
395 68,6599 62,7133 50,6954 139,0895 32 
402 94,2790 92,8678 89,3725 519,6964 341 
411 75,6098 71,1460 61,9812 236,9898 63 
414 92,1145 90,5528 86,6157 428,4106 271 
416 93,2820 92,1153 89,3964 836,3758 569 
424 98,4558 98,1835 97,4966 1721,2199 1168 
427 90,5862 89,1739 85,8279 563,4743 319 
432 93,5714 92,4573 89,4450 904,5724 471 
433 95,7586 95,0055 92,6975 991,9533 626 
435 98,3018 98,0355 97,3285 1863,1357 1297 
438 92,4130 91,1350 88,4054 1163,1750 579 
439 86,4235 84,1081 78,7858 412,4881 169 
450 98,3449 98,0579 97,3073 1510,1652 1172 
453 87,7809 85,9040 82,2732 1152,5467 619 
473 97,5596 96,9624 95,4737 1278,7138 866 
479 97,8388 97,4003 96,1990 1364,3534 927 
489 85,9063 84,1211 79,9995 862,9771 511 
497 96,8403 96,1814 94,0182 861,7447 473 
508 76,5159 73,9426 68,8038 498,6970 175 
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512 98,4193 98,1647 97,3902 1447,0394 1104 
533 98,1171 97,8545 97,0343 1960,5307 1451 
562 85,3407 83,2694 79,0606 909,6617 464 
597 98,4781 98,2517 97,6135 1896,5084 1360 
630 96,3420 95,4727 92,8521 544,5656 334 
639 86,8787 85,0843 80,9697 1020,0184 564 
718 95,9755 95,0230 91,9501 540,5156 339 
776 84,3699 82,0792 77,6836 1108,3872 425 
811 81,8597 79,7403 76,1815 1128,2851 477 
818 80,7761 78,7495 75,0732 1195,5729 535 
823 84,1394 82,0275 78,0755 1068,0800 540 
Esp104 96,8694 96,2470 94,5410 808,2399 550 
Esp21 97,0915 96,4119 94,5414 689,7494 450 
Esp27 96,3373 95,5992 93,4296 793,9407 464 
Esp44 95,9969 95,0335 91,9681 391,3194 254 
Esp86 97,9153 97,5009 96,5457 1078,6478 756 
011B_088B_432B 98,6670 98,4480 97,8518 1709,0528 1187 
076B_181B_439B 98,6834 98,4833 97,9771 2643,8851 1896 
121B_047B_207B 96,2810 95,5685 94,1243 5299,8896 3401 
131B_Esp21B_188B_4
38B 
98,7220 98,5383 98,0582 7927,1577 4818 
133B_304B_402B 96,4136 95,5986 93,9875 2015,3740 1136 
248B_275B_311B_31
2B 
98,7449 98,5160 98,0788 3273,4870 2208 
280B_450B_424B_59
7B 
98,9393 98,8193 98,4756 5283,2169 3861 
281B_512B_433B 98,9028 98,7403 98,2757 3247,6938 2231 
313B_339B_375B_45
1B 
98,4593 98,1971 97,5205 2334,3425 1502 
344B_414B_080B 95,7403 95,0572 93,3211 2157,1065 1381 
395B_411B_147B 98,5288 98,2575 97,5580 2974,4779 2050 
435B_416B_427B 98,9535 98,7803 98,3674 3206,8752 2431 
473B_102B_497B 98,6789 98,4781 97,9800 2434,4296 1741 
479B_325B_308B 98,8333 98,6597 98,2416 3305,0814 2307 
630B_640B_644B_53
3B 
98,8562 98,7146 98,3517 3384,1756 2386 
718B_064B_274B 98,7337 98,4958 97,8714 3084,5725 2298 
Esp27B_Esp104B_Esp
44B_Esp86B 
98,9045 98,7496 98,3437 3028,3054 2129 
272-B 86,8670 85,0296 81,2766 1519,3046 820 
358-B 86,5769 84,7008 81,2907 1454,8019 816 
453-B 85,4754 83,1513 79,2080 977,7152 517 
489-B 84,4332 82,3246 77,6954 1122,0791 581 
508-B 79,1746 77,0606 72,7320 1016,9928 324 
562-B 86,0217 83,8419 79,8595 923,8382 503 
639-B 83,0971 80,7876 76,5724 1132,2674 461 
818-B 75,6667 73,4816 68,6609 1113,7520 236 
776-B 84,3233 82,2386 78,1648 1373,3648 620 
811-B 82,3314 80,2877 75,9494 1182,5767 449 
823-B 80,9810 78,8153 74,6514 1103,7262 409 
 
Annex I. Supplementary tables 
181 
 
Supplementary Table 8. Recurrently altered pathways in the discovery and prevalence screens. 
 
Summary. Y: yes; N: no. 
Pathway 
Non synonymous 
(NS) 
NS 
damaging 
NS 
recurrent 
NS 
recurrent 
damaging 
Chromatin modification Y Y Y Y 
Apoptosis Y Y Y Y 
DNA repair and DNA 
damage response 
Y Y Y Y 
Cell cycle Y Y N N 
Sister chromatid cohesion Y Y N N 
 
Gene Ontology Biological Processes enrichment (Including non-synonymous mutations and mutations in 
exon junctions, n=908) 
GO ID 
p-value 
(Adjusted by 
FDR) 
positive regulation of transcription, DNA-dependent 0.00153 
negative regulation of gene-specific transcription from RNA polymerase II promoter 0.00153 
blood coagulation 0.00153 
response to DNA damage stimulus 0.00153 
chromatin modification 0.00198 
negative regulation of smoothened signaling pathway 0.00200 
regulation of transcription, DNA-dependent 0.00200 
heart development 0.00271 
N-terminal peptidyl-lysine acetylation 0.00399 
androgen receptor signaling pathway 0.00480 
regulation of heart contraction 0.00509 
cellular response to ionizing radiation 0.00647 
positive regulation of protein import into nucleus, translocation 0.00647 
axon guidance 0.00647 
smooth muscle cell differentiation 0.00819 
base conversion or substitution editing 0.00819 
maintenance of organ identity 0.00819 
cell-cell adhesion 0.00833 
base-excision repair 0.00855 
Rho protein signal transduction 0.00855 
cell-matrix adhesion 0.00952 
neuron projection development 0.01061 
protein transport 0.01184 
ATP catabolic process 0.01282 
positive regulation of gene-specific transcription from RNA polymerase II promoter 0.01863 
skin development 0.01863 
activation of adenylate cyclase activity 0.01946 
lung morphogenesis 0.02004 
interspecies interaction between organisms 0.02150 
transcription, DNA-dependent 0.02150 
cell cycle 0.02230 
negative regulation of transcription from RNA polymerase II promoter 0.02248 
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cellular protein localization 0.02248 
ion transport 0.02248 
regulation of angiogenesis 0.02438 
gene silencing by RNA 0.02438 
positive regulation of canonical Wnt receptor signaling pathway 0.02438 
axonogenesis 0.02503 
cell morphogenesis 0.02641 
establishment or maintenance of cell polarity 0.02641 
mesenchymal to epithelial transition involved in metanephros morphogenesis 0.02641 
cell redox homeostasis 0.02641 
response to calcium ion 0.02689 
negative regulation of transcription, DNA-dependent 0.03008 
integrin-mediated signaling pathway 0.03008 
cell cycle arrest 0.03008 
histone H3-K4 methylation 0.03008 
estrogen receptor signaling pathway 0.03008 
negative regulation of translation 0.03072 
stress fiber assembly 0.03072 
replicative senescence 0.03072 
regulation of transcription factor activity 0.03072 
double-strand break repair via homologous recombination 0.03072 
cell morphogenesis involved in differentiation 0.03072 
positive regulation of osteoblast differentiation 0.03072 
regulation of epithelial cell differentiation 0.03072 
cellular response to UV 0.03172 
nerve growth factor receptor signaling pathway 0.03748 
leukocyte migration 0.03779 
platelet activation 0.03779 
negative regulation of gene expression 0.03993 
detection of calcium ion 0.04034 
positive regulation of transcription from RNA polymerase II promoter 0.04160 
branching involved in ureteric bud morphogenesis 0.04311 
negative regulation of DNA binding 0.04311 
positive regulation of axon extension 0.04311 
branched chain family amino acid catabolic process 0.04311 
MAPKKK cascade 0.04390 
in utero embryonic development 0.04390 
regulation of insulin secretion 0.04494 
response to hormone stimulus 0.04591 
small GTPase mediated signal transduction 0.04591 
regulation of vasoconstriction 0.04591 
vesicle-mediated transport 0.04591 
regulation of JNK cascade 0.04591 
2-oxoglutarate metabolic process 0.04591 
DNA damage response, signal transduction resulting in induction of apoptosis 0.05098 
digestive tract development 0.05098 
response to organic nitrogen 0.05098 
transcription from RNA polymerase I promoter 0.05098 
regulation of glucose transport 0.05098 
transcription initiation from RNA polymerase I promoter 0.05098 
positive regulation of reactive oxygen species metabolic process 0.05098 
sister chromatid cohesion 0.05189 
cytoskeletal anchoring at plasma membrane 0.05189 
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midgut development 0.05189 
regulation of mitotic metaphase/anaphase transition 0.05189 
positive regulation of protein tyrosine kinase activity 0.05189 
oocyte development 0.05189 
activation of phospholipase C activity 0.05436 
cell cycle checkpoint 0.05436 
determination of left/right symmetry 0.05599 
protein phosphorylation 0.05971 
Wnt receptor signaling pathway 0.05971 
positive regulation of dendrite morphogenesis 0.05971 
chromatin silencing 0.05971 
negative regulation of apoptosis 0.05971 
Ras protein signal transduction 0.05971 
sensory perception of light stimulus 0.05971 
photoreceptor cell maintenance 0.05971 
positive regulation of gene expression 0.06513 
mitosis 0.06782 
DNA damage checkpoint 0.06782 
protein localization 0.06782 
negative regulation of macrophage derived foam cell differentiation 0.06843 
cell division 0.06843 
adult heart development 0.06843 
mRNA stabilization 0.06843 
regulation of small GTPase mediated signal transduction 0.06843 
lens morphogenesis in camera-type eye 0.06843 
cellular response to insulin stimulus 0.06861 
response to wounding 0.06889 
mitotic cell cycle 0.07027 
neuron apoptosis 0.07065 
response to morphine 0.07065 
negative regulation of cell growth 0.07339 
cell migration 0.07491 
response to inorganic substance 0.07491 
skeletal muscle tissue development 0.07491 
insulin-like growth factor receptor signaling pathway 0.07491 
protein heterooligomerization 0.07491 
hair follicle morphogenesis 0.07491 
negative regulation of osteoclast differentiation 0.07491 
potassium ion transport 0.07491 
protein localization to nucleus 0.07491 
nervous system development 0.07594 
response to hydrogen peroxide 0.07897 
positive regulation of MAPKKK cascade 0.07897 
G2/M transition of mitotic cell cycle 0.08044 
3'-phosphoadenosine 5'-phosphosulfate metabolic process 0.08044 
protein ubiquitination 0.08044 
positive regulation of erythrocyte differentiation 0.08044 
negative regulation of angiogenesis 0.08044 
activation of JUN kinase activity 0.08044 
blood vessel development 0.08044 
face morphogenesis 0.08044 
cilium assembly 0.08044 
regulation of translational initiation 0.08044 
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phosphatidylinositol phosphorylation 0.08044 
spindle assembly 0.08044 
regulation of type I interferon-mediated signaling pathway 0.08455 
cellular process 0.08455 
histone acetylation 0.08455 
mRNA transport 0.08455 
positive regulation of peptidyl-serine phosphorylation 0.08845 
potassium ion transmembrane transport 0.08845 
induction of apoptosis by intracellular signals 0.08845 
cAMP-mediated signaling 0.08845 
synapse organization 0.08845 
phospholipid catabolic process 0.08845 
regulation of interferon-gamma-mediated signaling pathway 0.08845 
vasculogenesis 0.08845 
forebrain development 0.09038 
DNA repair 0.09058 
vitamin metabolic process 0.09065 
regulation of cell migration 0.09316 
hexose transport 0.09316 
cell differentiation 0.09488 
G1 phase of mitotic cell cycle 0.09539 
positive regulation of epithelial to mesenchymal transition 0.09539 
cellular response to organic cyclic compound 0.09539 
response to salt stress 0.09539 
positive regulation of cell-substrate adhesion 0.09539 
positive regulation of Wnt receptor signaling pathway 0.09539 
positive regulation of branching involved in ureteric bud morphogenesis 0.09539 
protein secretion 0.09539 
 
 
Gene Ontology Biological Processes enrichment (Including non-synonymous mutations and mutations in 
exon junctions that were recurrent, n=68) 
GO ID 
p-value 
(Adjusted by 
FDR) 
positive regulation of apoptosis 0.00417 
positive regulation of neuron apoptosis 0.00417 
cell adhesion 0.00444 
chromatin modification 0.00707 
liver development 0.00865 
Ras protein signal transduction 0.00865 
heart development 0.00898 
negative regulation of gene-specific transcription from RNA polymerase II promoter 0.00898 
response to hypoxia 0.01054 
positive regulation of gene-specific transcription from RNA polymerase II promoter 0.01054 
regulation of transcription, DNA-dependent 0.01054 
cell migration 0.01054 
interspecies interaction between organisms 0.01108 
positive regulation of transcription, DNA-dependent 0.01201 
negative regulation of apoptosis 0.01719 
homophilic cell adhesion 0.01719 
response to DNA damage stimulus 0.01719 
positive regulation of transcription from RNA polymerase II promoter 0.02126 
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negative regulation of transcription, DNA-dependent 0.02302 
blood coagulation 0.02569 
negative regulation of cell proliferation 0.04140 
transcription, DNA-dependent 0.04865 
Gene Ontology Biological Processes enrichment (Including non-synonymous mutations and mutations in 
exon junctions that were predicted to be damaging, n=565) 
GO ID 
p-value 
(Adjusted by 
FDR) 
chromatin modification 0.00009 
androgen receptor signaling pathway 0.00159 
response to DNA damage stimulus 0.00159 
regulation of transcription, DNA-dependent 0.00159 
N-terminal peptidyl-lysine acetylation 0.00159 
cellular response to ionizing radiation 0.00159 
maintenance of organ identity 0.00325 
cell-cell adhesion 0.00411 
cell cycle arrest 0.00435 
transcription, DNA-dependent 0.00435 
negative regulation of gene-specific transcription from RNA polymerase II promoter 0.00508 
base-excision repair 0.00508 
heart development 0.00508 
blood coagulation 0.00630 
cell redox homeostasis 0.00876 
positive regulation of transcription, DNA-dependent 0.00944 
histone H3-K4 methylation 0.00949 
cell morphogenesis 0.01062 
cellular response to UV 0.01109 
negative regulation of transcription, DNA-dependent 0.01164 
Rho protein signal transduction 0.01178 
regulation of epithelial cell differentiation 0.01178 
stress fiber assembly 0.01178 
replicative senescence 0.01178 
cell morphogenesis involved in differentiation 0.01178 
cell-matrix adhesion 0.01214 
positive regulation of gene-specific transcription from RNA polymerase II promoter 0.01214 
ion transport 0.01341 
double-strand break repair via homologous recombination 0.01364 
2-oxoglutarate metabolic process 0.01364 
protein phosphorylation 0.01364 
ATP catabolic process 0.01416 
leukocyte migration 0.01504 
skin development 0.01504 
DNA damage response, signal transduction resulting in induction of apoptosis 0.01504 
interspecies interaction between organisms 0.01504 
signal transduction 0.01504 
positive regulation of reactive oxygen species metabolic process 0.01504 
axon guidance 0.01504 
regulation of JNK cascade 0.01518 
negative regulation of gene expression 0.01587 
negative regulation of transcription from RNA polymerase II promoter 0.01592 
positive regulation of MAPKKK cascade 0.01629 
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regulation of angiogenesis 0.01629 
photoreceptor cell maintenance 0.01629 
regulation of small GTPase mediated signal transduction 0.01629 
MAPKKK cascade 0.01671 
regulation of mitotic metaphase/anaphase transition 0.01671 
regulation of heart contraction 0.01671 
sister chromatid cohesion 0.01671 
DNA damage checkpoint 0.01743 
protein transport 0.01793 
Ras protein signal transduction 0.01883 
neuron apoptosis 0.01913 
sensory perception of light stimulus 0.01913 
positive regulation of dendrite morphogenesis 0.01913 
negative regulation of translation 0.02140 
integrin-mediated signaling pathway 0.02224 
mRNA stabilization 0.02224 
lens morphogenesis in camera-type eye 0.02224 
induction of apoptosis by intracellular signals 0.02224 
in utero embryonic development 0.02224 
histone acetylation 0.02539 
cellular process 0.02539 
positive regulation of transcription from RNA polymerase II promoter 0.02656 
protein localization 0.02656 
cellular response to insulin stimulus 0.02830 
Wnt receptor signaling pathway 0.02890 
protein ubiquitination 0.02973 
estrogen receptor signaling pathway 0.02973 
G1 phase of mitotic cell cycle 0.02973 
smooth muscle cell differentiation 0.02973 
apoptosis 0.03047 
cell aging 0.03227 
negative regulation of smoothened signaling pathway 0.03367 
transcription initiation from RNA polymerase I promoter 0.03430 
cell cycle checkpoint 0.03430 
transcription from RNA polymerase I promoter 0.03430 
neuron projection development 0.03430 
response to hormone stimulus 0.03430 
positive regulation of gene expression 0.03823 
mitotic cell cycle 0.03978 
forebrain development 0.03978 
patterning of blood vessels 0.03978 
skeletal muscle tissue development 0.03978 
branched chain family amino acid catabolic process 0.03991 
positive regulation of axon extension 0.03991 
negative regulation of DNA binding 0.03991 
small GTPase mediated signal transduction 0.03991 
nerve growth factor receptor signaling pathway 0.04227 
metanephros development 0.04534 
protein autophosphorylation 0.04689 
digestive tract development 0.04862 
histone methylation 0.04862 
gastrulation with mouth forming second 0.04862 
positive regulation of osteoblast differentiation 0.04862 
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transcription initiation from RNA polymerase II promoter 0.04862 
retinoic acid receptor signaling pathway 0.04862 
cell differentiation 0.04929 
response to calcium ion 0.05282 
negative regulation of neuron apoptosis 0.05458 
negative regulation of apoptosis 0.05579 
positive regulation of neuron apoptosis 0.05807 
nervous system development 0.06068 
double-strand break repair 0.06146 
branching involved in ureteric bud morphogenesis 0.06146 
establishment or maintenance of cell polarity 0.06476 
regulation of mitotic cell cycle 0.06476 
positive regulation of peptidyl-serine phosphorylation 0.06492 
actin cytoskeleton organization 0.06515 
regulation of cell migration 0.06907 
response to morphine 0.06941 
regulation of long-term neuronal synaptic plasticity 0.06941 
endocytosis 0.07078 
response to organic nitrogen 0.07143 
positive regulation of canonical Wnt receptor signaling pathway 0.07143 
glucose metabolic process 0.07204 
ventricular cardiac muscle tissue morphogenesis 0.07289 
regulation of multicellular organism growth 0.07289 
hair follicle morphogenesis 0.07289 
protein heterooligomerization 0.07298 
regulation of protein localization 0.07701 
regulation of translational initiation 0.07701 
positive regulation of multicellular organism growth 0.07701 
transcription elongation from RNA polymerase I promoter 0.07701 
spindle assembly 0.07701 
extracellular matrix organization 0.08074 
G2/M transition of mitotic cell cycle 0.08119 
positive regulation of muscle cell differentiation 0.08305 
S phase of mitotic cell cycle 0.08322 
intracellular signal transduction 0.08405 
vesicle-mediated transport 0.08697 
termination of RNA polymerase I transcription 0.08698 
transcription from RNA polymerase II promoter 0.08698 
negative regulation of neuron differentiation 0.08698 
embryonic hindlimb morphogenesis 0.08698 
activation of adenylate cyclase activity 0.09208 
fertilization 0.09208 
cell migration 0.09208 
calcium ion transport 0.09208 
response to organic cyclic compound 0.09804 
response to glucocorticoid stimulus 0.09831 
neuroprotection 0.09831 
negative regulation of protein kinase activity 0.09942 
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Gene Ontology Biological Processes enrichment (Including n-synonymous mutations and mutations in 
exon junctions that were recurrent and predicted to be damaging, n=58) 
GO ID 
P-value 
(Adjusted by 
FDR) 
positive regulation of neuron apoptosis  0.00195 
positive regulation of apoptosis  0.00195 
heart development  0.00383 
Ras protein signal transduction  0.00383 
cell adhesion  0.00383 
regulation of transcription, DNA-dependent  0.00383 
negative regulation of gene-specific transcription from RNA polymerase II promoter  0.00383 
liver development  0.00383 
response to hypoxia  0.00497 
interspecies interaction between organisms  0.00497 
positive regulation of gene-specific transcription from RNA polymerase II promoter  0.00497 
chromatin modification  0.00767 
homophilic cell adhesion  0.00937 
positive regulation of transcription from RNA polymerase II promoter  0.00937 
response to DNA damage stimulus  0.00937 
negative regulation of apoptosis  0.00937 
blood coagulation  0.01133 
negative regulation of transcription, DNA-dependent  0.01133 
negative regulation of cell proliferation  0.01913 
positive regulation of transcription, DNA-dependent  0.01913 
transcription, DNA-dependent  0.01913 
cell differentiation  0.06563 
 
KEGG pathways enrichment (Including n-synonymous mutations and mutations in exon junctions, 
n=908) 
KEGG Pathway ID 
p-value 
(Adjusted by 
FDR) 
Regulation of actin cytoskeleton 0.02121 
Adherens junction 0.02998 
Cell cycle 0.09840 
 
KEGG pathways enrichment (Including n-synonymous mutations and mutations in exon junctions that 
were recurrent, n=68) 
KEGG Pathway ID 
p-value 
(Adjusted by 
FDR) 
Cell cycle 0.00005 
Adherens junction 0.00718 
Wnt signaling pathway 0.00718 
Apoptosis 0.00946 
Leukocyte transendothelial migration 0.01619 
Jak-STAT signaling pathway 0.02880 
Focal adhesion 0.04778 
Regulation of actin cytoskeleton 0.04957 
MAPK signaling pathway 0.07623 
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KEGG pathways enrichment (Including n-synonymous mutations and mutations in exon junctions that 
were predicted to be damaging, n=565) 
KEGG Pathway ID 
p-value 
(Adjusted by 
FDR) 
Regulation of actin cytoskeleton 0.01436 
Adherens junction 0.01436 
Bacterial invasion of epithelial cells 0.03650 
Tight junction 0.04867 
Leukocyte transendothelial migration 0.04867 
p53 signaling pathway 0.06443 
Cell cycle 0.06578 
Focal adhesion 0.06736 
Toxoplasmosis 0.06736 
MAPK signaling pathway 0.06736 
Homologous recombination 0.06736 
Pantothenate and CoA biosynthesis 0.07308 
 
 
 
KEGG pathways enrichment (Including n-synonymous mutations and mutations in exon junctions that 
were recurrent and predicted to be damaging, n=56) 
KEGG Pathway ID 
p-value 
(Adjusted by 
FDR) 
Cell cycle  0.00003 
Adherens junction  0.00541 
Wnt signaling pathway  0.00541 
Apoptosis  0.00715 
Leukocyte transendothelial migration  0.01234 
Jak-STAT signaling pathway  0.02215 
Focal adhesion  0.03717 
Regulation of actin cytoskeleton  0.03869 
MAPK signaling pathway  0.06028 
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Supplementary Table 9. Descriptive analysis of ARID1A mutations and expression in relationship 
with other UBC markers. 
  
N Mean(SD) Median(IQR) P-value P-value 
     
t-test/Anova MW/KW 
ARID1A_Score ALL 84 156.8 (104.5) 180 (135)     
ARID1A_Score by Sup_Inv 
  
9.7x10
-6
 3.5x10
-5
 
 
Sup 58 189.8 (93.2) 200 (132.5) 
  
 
Invas 26 83.1 (91.1) 50 (180) 
  
ARID1A_Score by Risk Groups 
  
9.9x10
-6
 3.7x10
-5
 
 
Low 39 206.4 (80.2) 200 (120) 
  
 
High 19 155.8 (110.1) 180 (160) 
  
 
Invas 26 83.1 (91.1) 50 (180) 
  
ARID1A_Score by FGFR3_mutation 
  
0.41 0.78 
 
WT 17 181.8 (109.2) 200 (200) 
  
  Muta 30 207 (81.3) 200 (120)     
FGFR3_Score ALL 77 57.3 (68.2) 30 (98) 
  
FGFR3_Score by Sup_Inv 
  
0.46 0.28 
 
Sup 54 61.3 (65.2) 47.5 (99.5) 
  
 
Invas 23 47.8 (75.5) 5 (73) 
  
FGFR3_Score by Risk Groups 
  
0.038 0.026 
 
Low 39 73.5 (67.2) 70 (117) 
  
 
High 15 29.7 (48.4) 0 (47.5) 
  
 
Invas 23 47.8 (75.5) 5 (73) 
  
FGFR3_Score by FGFR3_mutation 
  
3.1x10
-5
 0.00032 
 
WT 15 19.3 (32.9) 0 (30) 
  
  Muta 29 90 (67.4) 80 (110)     
p53_1801_Score ALL 34 65.5 (100.7) 14.5 (56.2) 
  
p53_1801_Score by Sup_Inv 
  
0.017 0.21 
 
Sup 22 28.3 (56.6) 12 (16.8) 
  
 
Invas 12 133.8 (128.2) 120 (258) 
  
p53_1801_Score by Risk Groups 
  
0.05 0.32 
 
Low 18 16.2 (17.5) 11 (15.8) 
  
 
High 4 82.5 (126.1) 30 (82.5) 
  
 
Invas 12 133.8 (128.2) 120 (258) 
  
p53_1801_Score by 
FGFR3_mutation   
0.11 0.17 
 
WT 3 5.3 (7.6) 2 (7) 
  
  Muta 15 35.9 (67.6) 12 (34.5)     
p53_DO7_Score ALL 83 81.7 (102.6) 30 (108) 
  
p53_DO7_Score by Sup_Inv 
  
0.0042 0.029 
 
Sup 57 56.6 (82) 20 (48) 
  
 
Invas 26 136.9 (121.7) 120 (274.5) 
  
p53_DO7_Score by Risk Groups 
  
6.3x10
-5
 0.0022 
 
Low 38 28.7 (45.6) 18 (20) 
  
 
High 19 112.3 (108.3) 60 (180) 
  
 
Invas 26 136.9 (121.7) 120 (274.5) 
  
p53_DO7_Score by FGFR3_mutation 
  
0.011 0.014 
 
WT 17 123.5 (115.7) 105 (216) 
  
  Muta 30 38.8 (65.6) 20 (26)     
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Pearson Correlations 
     
       
  
ARID1A FGFR3 p53_1801 p53_DO7 
 
ARID1A 1 0.208  -0.209  -0.189 
 
FGFR3 
 
0.208 1  -0.244  -0.249 
 
p53_1801  -0.209  -0.244 1 0.979 
 
p53_DO7  -0.189  -0.249 0.979 1 
 
       
Pearson Correlations P-Value 
    
       
  
ARID1A FGFR3 p53_1801 p53_DO7 
 
ARID1A   0.070 0.236 0.088 
 
FGFR3 
 
0.070 
 
0.186 0.030 
 
p53_1801 0.236 0.186 
 
0.000 
 
p53_DO7 0.088 0.030 0.000   
 
       
       
Spearman Correlations 
    
       
  
ARID1A FGFR3 p53_1801 p53_DO7 
 
ARID1A 1 0.247  -0.207  -0.115 
 
FGFR3 
 
0.247 1  -0.157  -0.146 
 
p53_1801  -0.207  -0.157 1 0.929 
 
p53_DO7  -0.115  -0.146 0.929 1 
 
       
Spearman Correlations P-Value 
    
       
  
ARID1A FGFR3 p53_1801 p53_DO7 
 
ARID1A   0.030 0.239 0.300 
 
FGFR3 
 
0.0300 
 
0.400 0.208 
 
p53_1801 0.239 0.400 
 
0.000 
 
p53_DO7 0.300 0.208 0.000   
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Supplementary Table 10. Survival analysis of UBC according to ARID1A expression. 
    Events Censored HR 95% CI P-Value P-Value 
    N(%) N(%)     Cox PH Log-Rank 
Recurrence - All             
  Low ARID1A 5(14.7) 29(85.3) 1 (Ref)       
  High ARID1A 22(44) 28(56) 3,28 1.24 - 8.67 0.017 0.011 
                
Recurrence - NMI             
  Low ARID1A 5(31.2) 11(68.8) 1 (Ref)       
  High ARID1A 22(52.4) 20(47.6) 1,93 0.73 - 5.11 0.184 0.177 
                
Recurrence - Low Risk (NMI)           
  Low ARID1A 2(25) 6(75) 1 (Ref)       
  High ARID1A 16(51.6) 15(48.4) 2,62 0.6 - 11.42 0.199 0.182 
                
Recurrence - High Risk (NMI)           
  Low ARID1A 3(37.5) 5(62.5) 1 (Ref)       
  High ARID1A 6(54.5) 5(45.5) 1,53 0.38 - 6.17 0.552 0.549 
Progression - All             
  Low ARID1A 10(29.4) 24(70.6) 1 (Ref)       
  High ARID1A 8(16) 42(84) 0,48 0.19 - 1.21 0.12 0.112 
                
Progression - NMI             
  Low ARID1A 2(12.5) 14(87.5) 1 (Ref)       
  High ARID1A 3(7.1) 39(92.9) 0,6 0.1 - 3.57 0.571 0.567 
                
Progression - Low Risk (NMI)           
  Low ARID1A 1(12.5) 7(87.5) 1 (Ref)       
  High ARID1A 1(3.2) 30(96.8) 0,29 0.02 - 4.64 0.381 0.351 
                
Progression - High Risk (NMI)           
  Low ARID1A 1(12.5) 7(87.5) 1 (Ref)       
  High ARID1A 2(18.2) 9(81.8) 1,37 0.12 - 15.17 0.795 0.794 
                
Progression - MI             
  Low ARID1A 8(44.4) 10(55.6) 1 (Ref)       
  High ARID1A 5(62.5) 3(37.5) 1,53 0.5 - 4.69 0.456 0.453 
Mortality - All             
  Low ARID1A 7(20.6) 27(79.4) 1 (Ref)       
  High ARID1A 7(14) 43(86) 0,58 0.2 - 1.65 0.307 0.301 
                
Mortality - MI             
  Low ARID1A 5(27.8) 13(72.2) 1 (Ref)       
  High ARID1A 5(62.5) 3(37.5) 2,24 0.65 - 7.75 0.203 0.191 
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Supplementary Table 11. Association between STAG2 expression and patient and tumor 
characteristics. 
  N STAG2 <50 STAG2 >50 P-value (*) 
    N(%) N(%)   
Gender    0.828 
Male 595 176 (89.3) 419 (88.4)  
Female 76 21 (10.7) 55 (11.6)  
Age    0.056 
<60 157 58 (29.7) 99 (21.2)  
61-70 264 74 (37.9) 190 (40.7)  
>70 241 63 (32.3) 178 (38.1)  
Area    0.769 
Barcelona 117 36 (18.5) 81 (17.3)  
Valles-Bages 117 38 (19.5) 79 (16.9)  
Alicante 54 17 (8.7) 37 (7.9)  
Tenerife 132 40 (20.5) 92 (19.7)  
Asturias 242 64 (32.8) 178 (38.1)  
Tumor number    0.606 
Solitary 431 133 (71.1) 298 (68.7)  
Multiple 190 54 (28.9) 136 (31.3)  
Tumor site    0.011 
1 site 387 130 (66.7) 257 (55.6)  
>1 site 270 65 (33.3) 205 (44.4)  
Tumor size    0.002 
<3cm 295 107 (54.3) 188 (39.7)  
>3cm 155 40 (20.3) 115 (24.3)  
Unknown 221 50 (25.4) 171 (36.1)  
Invasiveness    2.71x10-8 
NMIBC 480 171 (87.7) 309 (66.2)  
MIBC 182 24 (12.3) 158 (33.8)  
Risk group    4.29x10-11 
Low-risk 324 134 (68.7) 190 (40.7)  
High-risk 156 37 (19) 119 (25.5)  
Invasive 182 24 (12.3) 158 (33.8)  
TG category    2.20x10-16 
TaG1 156 83 (42.8) 73 (15.6)  
TaG2 167 50 (25.8) 117 (25.1)  
TaG3 35 21 (10.8) 14 (3)  
T1G2 6 3 (1.5) 3 (0.6)  
T1G3 115 13 (6.7) 102 (21.8)  
T2G2 6 2 (1) 4 (0.9)  
T2G3 86 8 (4.1) 78 (16.7)  
T3G2 5 3 (1.5) 2 (0.4)  
T3G3 43 2 (1) 41 (8.8)  
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T4G2 3 0 (0) 3 (0.6)  
T4G3 39 9 (4.6) 30 (6.4)  
T stage    5.72x10-15 
Ta 359 155 (79.5) 204 (43.7)  
T1 121 16 (8.2) 105 (22.5)  
T2 92 10 (5.1) 82 (17.6)  
T3 48 5 (2.6) 43 (9.2)  
T4 42 9 (4.6) 33 (7.1)  
Histological grade    1.96x10-15 
G1 156 83 (42.8) 73 (15.6)  
G2 187 58 (29.9) 129 (27.6)  
G3 318 53 (27.3) 265 (56.7)   
(*) P-value of the chi-squared test  
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Supplementary Table 12.  Association between ARID1A mutations and tumor/patient 
characteristics in all UBC studies. 
Compared categories 
Total number 
(mutated) 
P (Fisher´s exact 
test or Chi2 test) 
NMI 187 (27) = 14.4% 
0.02 
MI 258 (61) = 23.6% 
NMI-LR 120 (17) = 14.2% 
0.05 NMI-HR 67 (10) = 14.9% 
MI 258 (61) = 23.6% 
Non-aggressive 74 (12) = 16.2% 
0.4 
Aggressive 371 (76) = 20.5% 
Females 84 (20) = 23.8% 
0.2 
Males 362 (61) = 16.9% 
<60 89 (12) = 13.5% 
0.6 
>60 226 (36) = 15.9% 
Never smoked  119 (23) = 19.3% 
0.9 
Smoke(d)  210 (43) = 20.5% 
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Supplementary Table 13. Mutual exclusivity and co-occurrence analyses between ARID1A 
alterations and other genes in all UBC studies. 
 
  
KRAS 
    
  
Mutant Wild Type 
  
p left 1 
ARID1A 
Mutant 5 19 24 
 
p right 0.02 
Wild Type 6 119 125 
 
OR 5.2 
  
11 138 149 
   
      
  
  
FGFR3 
    
  
Mutant Wild Type 
 
 
p left 0.007 
ARID1A 
Mutant 10 98 108 
 
p right 1 
Wild Type 77 318 395 
 
OR 0.4 
  
87 416 503 
   
      
  
  
STAG2 
    
  
Mutant Wild Type 
  
p left 0.03 
ARID1A 
Mutant 6 85 91 
 
p right 1 
Wild Type 50 289 339 
 
OR 0.41 
  
56 374 430 
   
      
  
  
TP53 
    
  
Mutant Wild Type 
  
p left 0.0 
ARID1A 
Mutant 47 61 108 
 
p right 0.2 
Wild Type 148 247 395 
 
OR 1.3 
  
195 308 503 
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Supplementary Table 14. Association between STAG2 mutations and tumor/patient 
characteristics in all UBC studies. 
Compared 
categories 
Total number 
(mutated) 
P (Fisher´s exact 
test or Chi2 test) 
NMI 414 (109) = 26.3% 
<0.0001 
MI 348 (38) = 10.9% 
NMI-LR 228 (68) = 29.8% 
<0.0001 NMI-HR 166 (36) = 21.7% 
MI 348 (38) = 10.9% 
Non-aggressive 189 (56) = 29.6% 
<0.0001 
Aggressive 591 (93) = 15.7% 
Females 198 (44) = 22.2% 
0.01 
Males 545 (78) = 14.3% 
<60 87 (18) = 20.7% 
0.2 
>60 220 (32) = 14.6% 
Never smoked  156 (18) = 11.5% 
0.07 
Smoke(d)  242 (45) = 18.6% 
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Supplementary Table 15. Mutual exclusivity and co-occurrence analyses between STAG2 
alterations and other genes in all UBC studies. 
 
  
PIK3CA 
    
  
Mutant Wild Type 
  
p left 0.4 
STAG2 
Mutant 8 48 56 
 
p right 0.7 
Wild Type 63 311 374 
 
OR 0.8 
  
71 359 430 
   
      
  
  
KRAS 
    
  
Mutant Wild Type 
 
 
p left 0.0 
STAG2 
Mutant 1 13 14 
 
p right 1 
Wild Type 8 92 100 
 
OR 0.005 
  
9 105 114 
   
      
  
  
FGFR3 
    
  
Mutant Wild Type 
  
p left 1 
STAG2 
Mutant 23 33 56 
 
p right 0.0 
Wild Type 49 325 374 
 
OR 4.6 
  
72 358 430 
   
      
  
  
TP53 
    
  
Mutant Wild Type 
  
p left 0.2 
STAG2 
Mutant 16 29 45 
 
p right 0.9 
Wild Type 124 162 286 
 
OR 0.7 
  
140 191 331 
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